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Abstract 
 
Despite the fact that functional gastrointestinal disorders (FGID), such as 
irritable bowel syndrome, are common, our understanding of them is limited. 
The Joint Hypermobility Syndrome (JHS) is a common non-inflammatory 
connective tissue disorder which is thought to be associated with FGID 
although this has never been proven. Thus, further understanding of the link 
between  JHS and GI symptoms is warranted. 
 
Our aim was to fully characterise the gastrointestinal (GI) manifestations of 
JHS, to determine if there is a true association between GI symptoms in JHS 
and FGID, and to determine the factors that are involved in this association.  
 
Using a cross-sectional design I demonstrate in the first study that patients with 
a known diagnosis of JHS who are referred from rheumatologists to 
gastroenterologists have significantly increased gastro-oesophageal symptoms, 
alternating bowel habit, bloating and abdominal pain compared to other patients 
referred to the GI clinics. Autonomic factors, and to a lesser extent, somatic 
hypersensitivity factors appear to mediate the association between JHS and 
gastro-oesophageal symptoms. 
 
In the second study, I demonstrate that healthy university students with JHS are 
more likely to experience postprandial dyspeptic symptoms compared to those 
without JHS. Although autonomic and somatic symptoms are increased in JHS 
their presence does not seem to confound the association with GI symptoms in 
this group of healthy individuals.  
 
In a case-control study of patients attending secondary care GI clinics, I 
demonstrate that JHS is overrepresented in patients with FGID and reflux 
disease but not in those with organic disease. Furthermore, the association with 
FGID is specifically with postprandial distress syndrome and this association is 
dependent on autonomic factors. 
 
In the final chapter, I confirm that abnormalities in GI physiology are common in 
JHS patients with GI symptoms attending a physiology unit. 60% of JHS 
patients with reflux symptoms have non-erosive pathological acid reflux, 56% 
with dysphagia have oesophageal hypomotility, and 87% with dyspeptic 
symptoms have gastroparesis.  
 
My studies suggest that there is overlap between JHS, gastro-oeosphageal 
symptoms, FGID and GI dysmotility. Understanding the mechanisms underlying 
GI involvement in JHS may further our understanding of FGID. 
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Chapter 1 Introduction, literature review and aims 
Introduction, literature review and aims 
1.1 Functional Gastrointestinal Disorders 
 
Functional Gastrointestinal Disorders (FGID) are a common group of disorders 
causing chronic or recurrent gastrointestinal (GI) symptoms in the absence of 
any biochemical, anatomical, metabolic, radiological or histological 
abnormalities on conventional testing. They are often characterised by 
abnormal sensori-motor functioning of the GI tract. As a diagnostic biomarker 
for FGID does not exist, diagnosis is based on clinical criteria and recognition of 
a pattern of symptoms in the absence of structural or organic abnormalities that 
may account for those symptoms. The most widely recognised classification 
system for FGIDs is the ROME symptom-based classification system. The most 
recent version of this, ROME III, divides FGIDs into 45 subcategories (28 adult, 
17 paediatric). The adult subcategories are shown in Table 1.1.  
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Table 1.1: ROME III classification of Functional Gastrointestinal 
 Disorders in Adults (Drossman 2006) 	  
A. Functional Oesophageal Disorders: 
A1. Functional heartburn 
A2. Functional chest pain of presumed oesophageal origin 
A3. Functional dysphagia 
A4. Globus 
 
B. Functional Gastroduodenal Disorders: 
B1.Functional dyspepsia 
           B1a: Postprandial distress syndrome  
           B1b: Epigastric pain syndrome 
B2. Belching disorders 
 B2a: Aerophagia 
 B2b: Unspecified excessive belching 
B3. Nausea and Vomiting disorders 
 B3a: Chronic Idiopathic nausea 
 B3b: Functional vomiting 
 B3c: Cyclical vomiting syndrome 
B4. Rumination syndrome in adults 
 
C. Functional Bowel Disorders: 
C1. Irritable Bowel Syndrome 
C2. Functional Bloating 
C3. Functional Constipation 
C4. Functional Diarrhoea 
C5. Unspecified functional bowel disorder 
 
D. Functional abdominal pain syndrome 
 
E. Functional gallbladder and Sphincter of Oddi disorders: 
E1. Functional gallbladder disorder 
E2. Functional biliary Sphincter of Oddi disorder 
E3. Functional pancreatic Sphincter of Oddi disorder 
 
F. Functional anorectal disorders: 
F1. Functional faecal incontinence 
F2. Functional anorectal pain 
 F2a. Chronic proctalgia 
  F2a1. Levator Ani Syndrome 
  F2a2. Unspecified functional anorectal pain 
 F2b. Proctalgia fugax 
F3. Functional defecation disorders 
 F3a. Dyssynergic defecation 
 F3b. Inadequate defecatory propulsion 
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1.1.1 Epidemiology of Functional Gastrointestinal Disorders 
FGIDs are very common with a prevalence of up to 36% in the general 
population (Chang 2004). They are present worldwide, and show no 
geographical distribution. They are more commonly reported in females, and 
their prevalence decreases with age (Drossman, Li et al. 1993; Hungin, 
Whorwell et al. 2003).  FGIDs tend to cluster in families (Whorwell, McCallum et 
al. 1986), and it is common for patients with IBS to have a similarly affected 
parent or sibling.   
 
1.1.2 The burden of FGID 
FGIDs carry a substantial socio-economic burden to healthcare, the economy, 
and most importantly to patients. 
 
1.1.2.1 Healthcare burden 
These disorders generate a substantial workload in both primary care and 
secondary care. Up to 50% of patients in the community experiencing GI 
symptoms will consult their general practitioner (GP) (Wilson, Roberts et al. 
2004) and half the patients seen by GP’s for gut complaints end up with a 
diagnosis of a FGID (Thompson, Heaton et al. 2000). 17-30% of these will be 
referred to a secondary care gastroenterologist (Harvey, Salih et al. 1983; 
Wilson, Roberts et al. 2004). This equates to FGIDs accounting for 12% of the 
GP workload in primary care (Jones, Crowell et al. 2007) and 40% of the  
workload in secondary care gastroenterology clinics (Harvey, Salih et al. 1983).  
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1.1.2.2 Patient morbidity and quality of life 
FGIDs are chronic disorders - 8% of patients experience symptoms for more 
than 21 days a month (Hungin, Whorwell et al. 2003), and 95% of patients with 
IBS have persistent symptoms 5 years after initial symptom presentation (Kay, 
Jorgensen et al. 1994). 62% of patients do not respond completely to 
prescribed medication (Hungin, Whorwell et al. 2003), and in a proportion of 
patients, the unrelenting symptoms result in repeated outpatient visits and 
hospitalisations (Brun-Strang, Dapoigny et al. 2007).  All these factors 
contribute to the significant decrements in quality of life in patients with FGID 
(Hungin, Whorwell et al. 2003; Brun-Strang, Dapoigny et al. 2007). IBS restricts, 
or negatively affects, many aspects of patients’ lives including diet, leisure, 
travel, intimacy, with 50% of patients feeling unable to lead a normal life 
(Hungin, Whorwell et al. 2003).  The quality of life (QOL) in IBS sufferers is 
worse when compared to patients with other GI disorders such as gastro-
oesophageal reflux disease, inflammatory bowel disease and peptic ulcer 
disease, and compared to patients with chronic medical conditions such as 
Grade III congestive cardiac failure, chronic obstructive airways disease and 
osteoarthritis (Frank, Kleinman et al. 2002; Amouretti, Le Pen et al. 2006; 
Spiegel, Harris et al. 2009).  
 
1.1.2.3 Economic burden 
As a consequence of the above, IBS is associated with significant direct costs 
(use of health care resources) and indirect costs (work productivity). In the 
United States, an average of $1.7 billion to $10 billion (GBP 1 billion - 6 billion) 
is spent on IBS annually (Martin Mdel and Barron 2001; Martin, Barron et al. 
2001; Sandler, Everhart et al. 2002). In the US in 2002, estimates of the total 
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annual direct cost per patient for IBS ranged from US$348 (GBP 215) to 
US$8750 (GBP 5423) (Maxion-Bergemann, Thielecke et al. 2006). In Europe, 
the annual cost of an IBS patient was 756 Euros (GBP 625), and most of this 
was accounted for by investigations and hospitalizations, with the highest costs 
reported in patients with severe IBS symptoms, particularly those with 
abdominal pain (Brun-Strang, Dapoigny et al. 2007). Lack of response to IBS 
treatment also adds to the costs, and in a cross-sectional study from the UK, 
patients who did not respond to conventional treatments incurred annual costs 
of up to GBP 1400 (Creed, Ratcliffe et al. 2001). 
 
The average total number of days taken off work in the US due to IBS-related 
problems ranges from 8 to 21 (Jones, Crowell et al. 2007), and absence at work 
due to IBS is equivalent to that due to the common cold (Camilleri and Williams 
2000).  The total annual indirect cost per patient, attributable to both 
absenteeism (missed days of work) and presenteeism (impairment while at 
work) ranged from US$355 (GBP 220) to US$334,479 (GBP 207,332) (Fortea 
and Prior), with total costs to the economy reaching US$ 20 billion (GBP 12.4 
billion) (Martin Mdel and Barron 2001; Sandler, Everhart et al. 2002). 
 
These disorders are clearly a burden not only to patients, but also to healthcare 
systems and to the economy. Treatment of IBS symptoms improves quality of 
life, productivity, and reduces national healthcare expenditure (Akehurst, 
Brazier et al. 2002). However, this is not as easy in practice, as some of the 
symptoms associated with IBS are extra-intestinal and many are ‘unexplained’.   
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1.1.3 Associated features and disorders in FGID 
1.1.3.1 Extra-intestinal features of FGID 
Studies that have investigated the non-GI associations of FGID have 
predominantly been performed in patients with IBS. These patients have a 
significantly increased prevalence of lethargy, back pain, bad breath, menstrual 
disturbances, sleep disturbances and dyspareunia, compared to patients with 
organic GI disorders (Whorwell, McCallum et al. 1986; Maxton, Morris et al. 
1991; Hershfield 2005). IBS patients are also more likely to have urinary 
frequency, bladder dysfunction and detrusor instability compared to age and 
sex-matched controls (Whorwell, McCallum et al. 1986). 
 
There is an association between IBS and atopy. Patients with atopy are 3.1 
times more likely to satisfy criteria for IBS compared to a non-atopic control 
group, and patients with asthma have an increased prevalence of IBS 
compared to non-asthmatic controls (Panicker, Arifhodzic et al. 2010). 
 
IBS patients also have significant psychopathology. When compared with 
Inflammatory Bowel Disease (IBD) patients, IBS patients have significantly 
more lifetime diagnoses of major depression, somatisation disorder, generalized 
anxiety disorder, panic disorder, and phobic disorder (Walker, Roy-Byrne et al. 
1990). 
 
1.1.3.2 Association with medically unexplained disorders 
Considerable overlap is seen between FGID and medically ‘unexplained’ 
disorders, also known as functional somatic syndromes (White 2012). IBS is 
associated with migraines, tempero-mandibular joint (TMJ) disorder, interstitial 
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cystitis, painful bladder syndrome, chronic pelvic pain, vulvodynia, fibromyalgia 
(FM) and chronic fatigue syndrome (Schur, Afari et al. 2007).  
 
Fibromyalgia and IBS 
Fibromyalgia (FM) is a rheumatological condition characterized by chronic 
widespread pain and multiple tender points over the body. It is associated with 
somatic and psychological conditions, and is strongly associated with IBS.  A 
third of patients with FM have IBS and a third of patients with IBS have FM, and 
those with both disorders have a lower quality of life (Sperber, Atzmon et al. 
1999). Broadening this to FGIDs in general, the association is even stronger 
with 98% of FM patients satisfying criteria for an FGID, with IBS being the most 
common subtype (Almansa, Rey et al. 2009).  
 
IBS and unexplained urological conditions 
In a systematic review of 1038 publications investigating the association of 
various medically unexplained disorders, the most robust evidence for an 
overlap was between IBS and unexplained urological conditions such as 
interstitial cystitis, irritable bladder, and chronic pelvic pain, with up to 79% 
overlap between the two (Rodriguez, Afari et al. 2012).  
 
1.1.3.3 Common features in FGID and other functional somatic 
syndromes 
Functional somatic syndromes, such as IBS, FM and chronic pelvic pain 
(Creed, Guthrie et al. 2009), share common features such as pain, fatigue, 
disability out of proportion to physical examination findings, inconsistent 
laboratory abnormalities, and an association with stress and psychosocial 
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factors (Rodriguez, Afari et al. 2012) . Recent studies suggest that they all 
share a common patho-aetiology, which probably involves autonomic 
dysfunction, disturbances of the hypothalamic-pituitary adrenal axis, abnormal 
central processing of pain, immune mechanisms or a combination of these 
(Scully, McKernan et al. 2010; White 2012).  All of these factors have been 
researched thoroughly for FGID, albeit with no conclusive results. 
 
All the extra-intestinal and unexplained disorders associated with FGID 
contribute to the increasing healthcare utilisation and worsening quality of life of 
affected patients (Kindt, Van Oudenhove et al. 2011). Understanding the 
aetiology of these disorders is thus crucial not only to improve quality of life for 
its sufferers, but also to reduce the financial burden on the health system. 
 
1.1.4 Aetiology of FGID 
Over the past two decades, an increasing amount of research has been done to 
shed further light on our understanding of FGID and to discover an aetiology for 
these GI disorders. No single factor has been found to cause FGIDs but 
instead, various factors have been found to be associated with these functional 
disorders and they are thought to play an aetiological role.  
 
1.1.4.1 Psychopathology 
The old-fashioned view of FGIDs were that they were more a nuisance than a 
disorder, and that the symptoms were all ‘in the mind’, suggesting that they 
were more psychiatric in nature. FGIDs are not psychiatric conditions although 
stress and coexistent psychological morbidity can exacerbate the symptoms 
experienced (Drossman, Creed et al. 1999). FGID are associated with 
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psychopathology, such as anxiety and depression, and the somatisation 
disorder (Wessely, Nimnuan et al. 1999; Palsson and Drossman 2005). This 
refers to the presence of multiple vague and recurring somatic complaints that 
cannot be fully explained by any known general medical condition or the direct 
effect of a chemical substance, but which are not intentionally feigned or 
produced.  
 
‘Somatisation’ is the hallmark of the medically unexplained disorders, including 
FGID, and is increasingly thought to arise due to processes involving altered 
pain processing or autonomic dysfunction (White 2012).  
 
1.1.4.2 Autonomic dysfunction 
Dysfunction of the autonomic nervous system is associated with FGID (Farmer 
and Aziz 2009).  The specific type of central nervous system dysregulation has 
not yet been elucidated with respect to individual FGIDs, however increased 
sympathetic and decreased parasympathetic function have been associated 
with various functional GI disorders (Farmer and Aziz 2009).  In IBS patients 
increased sympathetic drive is associated with dysmotility in the upper GI tract 
(Mazur, Furgala et al. 2007), and vagal dysfunction has been demonstrated in 
response to rectal distension (Spaziani, Bayati et al. 2008). In functional 
dyspepsia, vagal dysfunction is thought to contribute to antral hypomotility and 
impaired gastric accommodation (Oustamanolakis and Tack 2012). Autonomic 
dysfunction is considered to be one mechanism by which visceral 
hypersensitivity arises (Farmer and Aziz 2009), though clear evidence for this is 
still lacking. 
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1.1.4.3 Visceral hypersensitivity 
Patients with IBS have visceral hypersensitivity, which refers to the fact that 
they have lower thresholds for visceral pain (Mertz, Naliboff et al. 1995). 
Clinically, this is manifest as reduced pain tolerance to endoscopic or digital 
rectal examinations. Visceral hypersensitivity is thought to occur due to 
sensitisation at both a peripheral and central level (Zhou and Verne 2011).  
 
Peripheral sensitisation 
Peripheral sensitisation occurs due to sensitisation of primary afferent nerves. It 
is unclear exactly why peripheral sensitisation occurs but recent work suggests 
that a variety of factors including low grade immune mechanisms, increased 
intestinal permeability or altered microbiota may be responsible (Piche, Barbara 
et al. 2009; Barbara, Cremon et al. 2011; Zhou and Verne 2011).  
 
Central sensitisation / hypervigilance 
Central sensitisation is due to altered pain processing at the level of spinal 
dorsal horn neurones and brain. It is exacerbated by stress and abnormal mood 
states due to descending pathways from the brain to the spinal cord and is 
considered aetiologically important in the development of visceral 
hypersensitivity in FGID (Palsson and Drossman 2005). It has been 
documented using brain imaging techniques and is manifest as altered central 
nervous system activation to stimuli in IBS patients compared to controls 
(Tillisch and Labus 2010).  
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1.1.4.4 Immune mechanisms 
Half of IBS patients have increased numbers of activated T lymphocytes and 
mast cells in the GI tract (Chadwick, Chen et al. 2002; Walker, Warwick et al. 
2011). IBS patients also have altered plasma cytokine profiles (Scully, 
McKernan et al. 2010), and altered expression of pathogen recognition 
receptors (toll-like receptors) compared to controls (Brint, MacSharry et al. 
2010; McKernan, Gaszner et al. 2011). All this points towards the presence of 
low-grade immune mechanisms in IBS. Further evidence for immune 
involvement comes from the fact that IBS can develop after an enteric infection 
i.e. post infectious IBS (PI-IBS) (Villani, Lemire et al. 2010).  
 
1.1.4.5 Increased intestinal permeability 
IBS patients have altered intestinal integrity and increased intestinal 
permeability (Dunlop, Hebden et al. 2006) and this is in part thought to be due 
to alterations in tight junction proteins (Piche, Barbara et al. 2009). 
 
1.1.4.6 Altered microbiota 
In IBS, small bowel bacterial overgrowth is associated with GI symptoms in at 
least a subset of patients (Pimentel, Chow et al. 2000; Stoicescu, Andrei et al. 
2013), and altered composition and biodiversity of the intestinal microbiota is 
also present ( Carroll, Ringel-Kulka et al. 2011). When either of these is altered 
e.g. by the use of probiotics or antibiotics, IBS symptoms improve  (Moayyedi, 
Ford et al. 2008; Pimentel, Lembo et al. 2011; Pimentel, Morales et al. 2011; 
Simren, Barbara et al. 2013). 
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1.1.4.7 Gastrointestinal dysmotility 
Dysmotility in the fore, mid and hindgut is associated with FGID. Gastroparesis 
is present in functional dyspepsia and contributes to postprandial symptoms 
(Sarnelli, Caenepeel et al. 2003; Haag, Talley et al. 2004). Small bowel 
dysmotility has been documented in patients with FGID, particularly those with 
more severe presentation and associated malnourishment (Cogliandro, 
Antonucci et al. 2011). Delayed colonic transit is present in about a third of 
patients with lower FGID (Manabe, Wong et al. 2010) and appears to be related 
to stool form and frequency, but not to symptoms of IBS (Deiteren, Camilleri et 
al. 2010; Tornblom, Van Oudenhove et al. 2012). In general, the presence of 
dysmotility in FGID is associated with poor nutritional status, and decrements to 
QOL (Cogliandro, Antonucci et al. 2011).  
 
1.1.4.8 Alterations in the Brain-Gut axis 
Evidence from brain imaging, pharmacology and neuroscience point towards 
the involvement of the brain-gut axis in the development of FGID (Fichna and 
Storr 2012).  The brain-gut axis consists of the enteric nervous system, the 
central nervous system, and the bi-directional interaction between the two, also 
involving the hypothalamic-pituitary axis. Dysfunction in the brain-gut axis, is 
thought to be responsible for the sensori-motor aspects of FGID i.e. visceral 
hypersensitivity and dysmotility (Fichna and Storr 2012), though the exact 
nature by which this occurs is still not clear. 
 
1.1.4.9 Diet 
Although true food allergies are uncommon in IBS, there is an increase in self-
reporting of food intolerances compared to the general population, and there is 
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a growing body of evidence that certain dietary constituents can exacerbate 
symptoms in IBS (Niec, Frankum et al. 1998; Eswaran, Tack et al. 2011). : 
Fermentable oligo- di- monosaccharides and polyols (FODMAPS) are short 
chain carbohydrates that are poorly absorbed in the intestine. Ingestion of 
FODMAPS leads to altered fluid content and bacterial fermentation in the colon, 
resulting in GI symptoms, particularly bloating, abdominal pain and altered 
bowel habit in susceptible individuals with FGID (Barrett and Gibson 2012). 
Lactose intolerance is increased in patients with IBS-D compared to controls 
(Yang, Deng et al. 2012). There is also an increasing body of work to suggest 
that non-coeliac gluten sensitivity is more common in IBS, particularly in 
patients with atopic symptoms (Aziz and Sanders 2012). In support of the 
concept that food intolerance is responsible for symptoms, elimination diets e.g. 
FODMAP diet, gluten-free and lactose-free diets, have been shown to improve 
symptoms in FGID (Eswaran, Tack et al. 2011).   
 
1.1.4.10 Genetics 
Twin studies have demonstrated that genes are important in the aetiology of 
IBS but that environmental factors have an even greater effect, which suggests 
that both nature and nurture are important (Levy, Jones et al. 2001). So far, 
studies suggest that polymorphisms in genes that encode proteins involved in 
neurohumoral mechanisms, epithelial cell barrier function and the innate 
immune response to enteric bacteria are associated with development of IBS 
(Camilleri, Atanasova et al. 2002; Kim, Camilleri et al. 2004; Villani, Lemire et al. 
2010; Zucchelli, Camilleri et al. 2011).  
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Neurohumoral genes 
IBS is associated with polymorphisms in the serotonin transporter gene 
(Camilleri and Katzka 2012) which leads to alterations in the concentration and 
signalling of serotonin (5-HT), a protein  responsible for GI secretion, motility 
and visceral perception (Gershon and Tack 2007).  In particular, the association 
appears to be between the homozygous short genotype (SS) of the serotonin 
reuptake transporter and IBS-D (Yeo, Boyd et al. 2004; Park, Choi et al. 2006).  
Polymorphisms in the Alpha-2-Adrenoceptor, which are involved in the 
maintenance of colonic tone and in sensation (Viramontes, Malcolm et al. 2001) 
are associated with IBS-C and with high somatic symptom scores (Kim, 
Camilleri et al. 2004), though the contribution of the genotype to the IBS 
phenotype is still unclear at this stage. 
 
Inflammatory / immune genes 
Polymorphisms in genes encoding IL-10, IL23, TNF-α and TNF superfamily 15 
(TNFSF15) have been associated with IBS, though the results are not always 
reproducible (Camilleri and Katzka 2012). Polymorphisms associated with Toll-
like receptor 9 (TLR-9) and IL-6 have been reported in association with PI-IBS 
(Villani, Lemire et al. 2010).  
 
Epithelial cell barrier function genes 
The cadherins are a group of transmembrane proteins that are involved in cell 
adhesion and barrier function. Polymorphisms in E-Cadherin 1 genes are 
associated with PI-IBS (Villani, Lemire et al. 2010).  
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Association with Crohn’s and Coeliac disease susceptibility genes 
 It is of interest that several of the above-mentioned gene polymorphisms, which 
are associated with IBS, are also associated with susceptibility to Crohn’s 
Disease or Coeliac Disease. This includes polymorphisms in TLR-9, IL-6, E-
Cadherin 1, and TNSF-15, and suggests a possible genetic overlap between 
IBS and these organic disorders (Wouters 2011).  
 
Although several genetic polymorphisms have been linked to FGID and these 
support molecular findings in FGID, no clear pattern of inheritance has 
emerged, so the exact role of genetics in IBS is unclear. It seems however, that 
a combination of genetic and environmental factors are important and that the 
genes confer susceptibility, whereas the environment influences the 
development or progression of FGID in a genetically susceptible individual, 
through any of the mechanisms described above.  
 
1.1.5 Biopsychosocial model for FGID 
The biopsychosocial model tries to combine all the above-mentioned 
associations into a single explanatory model (Drossman, Creed et al. 1999). It 
theorises that FGIDs are due to dysregulation of the brain-gut neuroenteric axis, 
which leads to altered sensory processing in the gut (hypersensitivity) and 
abnormal motility (dysmotility), both of which lead to the symptoms of FGID. 
According to the model, psychosocial factors such as early life events, coping 
strategies, life stresses and psychological states can influence this interaction 
between the brain and the gut and thus exacerbate symptoms. The model also 
recognises the influence of genetics on the presence of FGID namely that some 
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people are genetically predisposed to these disorders, and FGIDs tend to 
cluster in families (Drossman, Creed et al. 1999).  
 
 
 
 
Figure 1.1: Biopsychosocial model of IBS. 
This demonstrates the relationship between psychosocial and 
physiological factors, FGID symptoms and clinical outcome (Drossman, 
Creed et al. 1999). CNS: Central nervous system, ENS: Enteric nervous 
system 
 
This model is an effective framework to use when treating FGID as it focuses on 
the multimodal nature of the functional disorders and tackles all the different 
aspects. However, it is fairly generalised, it cannot explain why FGIDs develop 
in the first place, nor can it predict which individuals, or groups of individuals will 
develop FGIDs. Furthermore, none of these associative factors can fully explain 
the range of GI symptoms present in these heterogeneous conditions, nor why 
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individuals with FGID have an increased prevalence of other ‘unexplained’ 
disorders such as chronic fatigue syndrome, fibromyalgia and food intolerances, 
as described above.  
 
1.1.6 Limitations of FGID research 
Slow progress is being made in our understanding of the aetiology of FGID. 
This was initially thought to be due to the fact that the GI conditions being 
investigated were a heterogeneous group of conditions all lumped under the 
umbrella term ‘FGID’, not all of which may have identical aetiologies. Therefore, 
in orde to maintain homogeneity, the more recent studies have used the ROME 
classification systems to divide FGIDs into separate entities, and have tried to 
focus research on particular entities, mainly IBS and functional dyspepsia. 
However, once again this research has continued to yield solely associations 
with no all-encompassing aetiological explanation. This may be due to a 
general misguided approach to FGID and the erroneous categorisation of FGID 
into symptom-based subtypes.   
 
The problem with looking at individual ROME subtypes is that the classification 
provides a very arbitrary categorisation of these disorders. Patients who fulfil 
criteria for one subtype of FGID frequently fulfil criteria for several others (Talley 
2007) i.e. patients do not fall neatly into only one FGID subtype.  Dividing 
FGIDs into these symptom-based subtypes may be hampering our research 
into these disorders, and what may be needed is a more holistic view of these 
conditions and of their associated ‘unexplained’ multi-systemic phenomena.  
This may be achieved by looking at a potential aetiological factor that is 
ubiquitous throughout the body, including the GI tract, and which, when 
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abnormal, can lead to pathology that is associated with FGID and other 
disorders. The most obvious candidates are the major tissue types i.e. 
epithelium, muscle, nerves and connective tissue. Although research is ongoing 
into the first three potential aetiological candidates, almost none has looked at 
connective tissue. This is surprising because not only is connective tissue 
ubiquitous throughout the GI tract, but also GI symptoms are inextricably linked 
to connective tissue disorders. 
 
1.2 Connective tissue  
Connective tissue is one of the four major tissue types and functions to connect, 
support, bind and enclose the structures of the body, much like scaffolding. It is 
present in all parts of the body, including the skin, joints, internal organs and GI 
tract, albeit in different forms and quantities.  
 
1.2.1 Connective tissue components 
Connective tissue is made up of 3 main components: fibres, ground substance 
and cells. Abnormalities in any of the components can lead to disease. 
 
1) Fibres: Collagen is the main fibre and the main component of connective 
tissue. 29 different subtypes of collagen exist, but the most common is collagen 
I.  Collagen is mostly found in fibrous tissues such as tendon, ligament and 
skin, but is also abundant in cornea, cartilage, blood vessels, intervertebral 
discs and the GI tract. Elastin and fibrillin are other fibres that provide flexibility 
and stretch.  
2) Ground substance : This consists of glycoproteins and proteoglycans that 
form an amorphous gel-like material in which the connective tissue fibres are 
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contained. Tenascin is an important family of glycoproteins, and consists of 6 
members: Tenascin C, X, W, R, N and Y (Jakovcevski, Miljkovic et al. 2012).  
They have different distributions and functions, and as an example, Tenascin X 
(TNX) is expressed by neurones and glia, associates with collagen I, and 
interacts with the elastogenic pathways and matrix remodelling enzymes 
(Bristow, Carey et al. 2005). It is important in cell signalling, cell adhesion and 
the regulation of collagen deposition (Chiquet-Ehrismann and Tucker 2011).  
3) Cells: This includes fibroblasts, which synthesise the fibres and ground 
substance. 
 
Connective tissue is ubiquitous throughout the gastrointestinal (GI) tract, and 
alterations in connective tissue are associated with GI disease. 
 
1.2.2 Connective tissue and the GI tract in health  
In healthy individuals, connective tissue is present in all layers of the gut, albeit 
to different degrees (Figure 1.2). In the lamina propria and serosa it is most 
abundant and supports all the blood vessels and glands that are found in those 
layers. In the muscularis propria it forms connective tissue scaffolds which 
traverse the muscle layers and then enclose the myenteric plexi (Figure 1.3).  
Of the collagen subtypes, I, III, IV and V are the most common in the GI tract. 
Type IV is present in the subepithelial basement membrane and in the 
basement membrane surrounding smooth muscle cells. I III and V are mainly in 
the stomach and small intestine, so are thought to play a role in regulating 
permeability (Seki, Naito et al. 1998; Sato, Naito et al. 2007). As can be seen 
from the figures below (Figure 1.2, Figure 1.3) most of the connective tissue is 
in the deeper layers of the intestinal wall, which makes it difficult to study unless 
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full thickness specimens of bowel are obtained, which can only be done 
surgically or during post mortem. Consequently, very little research has 
examined the importance, functions and distribution of connective tissue in the 
GI tract in health, and even less so in disease.  
 
1.2.3 Connective tissue and the GI tract in GI disease 
Localised abnormalities in connective tissue have been described in association 
with GI pathology. In diverticular disease, there is increased elastin deposition 
in the taenia of the colon, and structural changes in the collagen of the smooth 
muscle (Whiteway and Morson 1985). Patients with hiatus hernias have 
fragmentation and distortion of elastin in their gastro-hepatic and phreno-
oesophageal ligaments (Curci, Melman et al. 2008).  Children with megacolon 
have atrophy of collagen in the tendinous connective tissue membrane of the 
myenteric plexus and muscularis propria (Figure 1.4), referred to as ‘atrophic 
desmosis’ (Meier-Ruge 1998). 
 
Thus it is clear that localised connective tissue abnormalities are associated 
with GI pathology. In addition, evidence exists for the association between 
generalised connective tissue disorders, both inflammatory and non-
inflammatory, and GI pathology.  
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Figure 1.2: Full thickness colon specimen, stained with Millers Elastic 
Vangieson.  
Collagen in red, muscle in yellow. Different layers of bowel annotated to 
right of vertical bars. 
 
 
 
Figure 1.3 Millers Elastic Vangieson staining of the colonic muscularis 
propria.  
Collagen scaffolds can be seen traversing the muscularis propria and 
then encapsulating the myenteric plexus. 
	   47	  
 
Figure 1.4: Atrophic desmosis of the colon. 
Full thickness colonic tissue, collagen stained in red, horizontal bar 
identifying muscularis propria (MP) layer. a- Normal colonic tissue, with 
collagen bands seen running through the muscularis propria. b-Tissue 
from megacolon. Absence of collagen scaffolds in the muscularis propria 
compared to normal colon - ‘atrophic desmosis’.  	  	  
1.2.3.1 GI pathology in inflammatory connective tissue disorders  
Scleroderma is an inflammatory connective tissue disorder characterised by 
autoimmune-mediated fibrosis in various organs. 90% of scleroderma patients 
have gastrointestinal involvement but only half are symptomatic. Typical 
symptoms include reflux, regurgitation, bloating and constipation (Figure 1.5) 
(Akesson and Wollheim 1989; Sallam, McNearney et al. 2006). GI symptoms 
are associated with pan-GI dysmotility – oesophageal hypomotility, 
gastroparesis, small bowel and anorectal dysmotility are all common in 
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scleroderma (Sallam, McNearney et al. 2006; Domsic, Fasanella et al. 2008; 
Gao, Liao et al. 2009).   
 
Gastrointestinal involvement is thought to occur in two stages – a neuropathic 
process followed by a myopathic one, and both are thought to be, in part, a 
consequence of fibrosis (Ebert 2008). Evidence for this comes from animal 
studies whereby increased collagen deposition and fibrosis in the gut was 
associated with diminished colonic contractility (Thoua, Derrett-Smith et al. 
2012). 
 
 
Figure 1.5: Barium swallow of scleroderma patient. 
A long oesophageal peptic stricture (arrow) is visible.  
 
1.2.3.2 GI pathology in non-inflammatory connective tissue disorders 
Non-inflammatory connective tissue disorders are generally rare, and so most 
evidence comes from small case series and individual case reports. Mega-
oesophagus, hernias and diverticular disease have been described in the 
Marfan Syndrome (Figure 1.6) (Eliashar, Sichel et al. 1998), and  intestinal 
perforation and ruptured viscera in Ehlers Danlos Syndrome (EDS) vascular 
	   49	  
type (Solomon, Abrams et al. 1996). The latter is part of the Ehlers-Danlos 
Group of disorders, which are characterised by tissue fragility, musculoskeletal 
symptoms and joint hypermobility.  
 
 
Figure 1.6: Barium enema of patient with the Marfan Syndrome, 
demonstrating large colonic diverticulae 
 
1.3 Joint hypermobility 
Joint hypermobility refers to the increased passive or active movement of a joint 
beyond its normal range (Figure 1.7).  It can be localised to one or few joints, or 
generalised, the latter referred to as generalised joint hypermobility (GJH). 
Artistic depictions of GJH date as far back as the 15th century, as can be seen 
in Figure 1.8. It is a relatively common finding, with a prevalence of 5-17% 
(Bulbena, Duro et al. 1992). This varies geographically and with gender and 
age  - it is more common in youth, in females and in non-whites (Rikken-
Bultman, Wellink et al. 1997; Ishaq, Sheikh et al. 2010; Castori, Sperduti et al. 
2012). It is a phenotypic trait or sign, and on its own does not signify the 
presence of disease i.e. it is not pathological. In fact, in some individuals e.g. 
ballerinas, gymnasts, musicians, it is considered an asset, and several studies 
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have confirmed a high prevalence of GJH in such populations (Kujala, Salminen 
et al. 1992; Decoster, Vailas et al. 1997; Day, Koutedakis et al. 2011). 
 
         
Figure 1.7: Joint hypermobility in the elbows (a), and fingers (b) 	  	  	  
 
Figure 1.8: ‘Saint Cyriaque’ by Matthias Grunewald (1460-1628).  
Hypermobility of the fingers can be seen. 	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1.3.1 Assessment of Generalised Joint Hypermobility 
1.3.1.1 Beighton score 
The Beighton score is the gold standard technique for diagnosing GJH. This 
scores the flexibility of 9 joints (back, elbows, little fingers, thumbs and knees) 
as shown in Figure 1.9 (Beighton 1988). The maximum score is 9 out of 9; 
higher scores represent greater degrees of joint hypermobility. A score of 4 or 
more out of 9 is considered diagnostic of GJH (Beighton, Solomon et al. 1973).  
 
1.3.1.2 5 point hypermobility questionnaire 
GJH can also be diagnosed using a validated 5-point questionnaire, which has 
84% sensitivity and 80% specificity when 2 or more questions are answered in 
the affirmative (Hakim and Grahame 2003) - Table 1.2. This questionnaire is 
particularly useful as a screening tool as it is easy and quick to complete. 
 
Table 1.2: Validated questionnaire for generalised joint hypermobility.  
Answering YES to 2 or more out of the 5 questions is 84% sensitive and 
80% specific for diagnosing GJH (Hakim and Grahame 2003).   	  
 
1. Can you now [or could you ever] place your hands flat on the floor without bending 
your knees?  
 
2.  Can you now [or could you ever] bend your thumb to touch your forearm?  
 
3.  As a child, did you amuse your friends by contorting your body into strange shapes 
or could you do the splits?  
 
4.  As a child or teenager, did your kneecap or shoulder dislocate on more than one 
occasion?  
 
5. Do you consider yourself ‘‘double-jointed’’?  
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Figure 1.9: Calculation of the Beighton score.  
A score of 4 or more is diagnostic of joint hypermobility (GJH). 
 
Ability to place hands flat on the floor without 
bending the knees – score 1 
 
 
Hyperextension of elbow beyond 10 °  
Score 1 for each elbow  
Maximum score: 2 
 
 
Passive extension of thumb to the forearm   
Score 1 for each thumb 
Maximum score: 2 
 
 
 
Hyperextension of knee by at least 10° - 
Score 1 for each knee 
Maximum score: 2 
 
 
Passive dorsiflexion of the little finger beyond 
90°  
Score 1 for each little finger 
Maximum score: 2 
 
	   53	  
 
1.3.2 Generalised Joint Hypermobility and connective tissue disorders 
On its own, GJH is only a sign and not pathological. However, it is the hallmark 
of several connective tissue disorders that are pathological. These are the 
hereditary disorders of connective tissue, a group of inherited disorders 
characterised by abnormalities in connective tissue matrix proteins.   Ehlers 
Danlos Syndrome and the Joint Hypermobility Syndrome are two examples of 
this. 
 
1.4 Ehlers-Danlos Syndrome  
The Ehlers Danlos Syndromes (EDS) are a heterogeneous group of inherited 
non-inflammatory connective tissue disorders which are thought to arise 
secondary to abnormalities in the synthesis and structure of collagen (Byers, 
Barsh et al. 1981).  The current Villefranche classification divides EDS into 6 
subtypes, based on the clinical phenotype and on the genetic and protein defect 
present, as shown in Table 1.3. All of the subtypes are characterised by varying 
degrees of tissue fragility, widespread musculoskeletal symptoms and joint 
hypermobility (Beighton, De Paepe et al. 1998) as shown in Figure 1.10 . 
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Table 1.3: Villefranche classification of Ehlers Danlos Syndromes 
(Beighton, De Paepe et al. 1998).  
AD: autosomal dominant, AR: autosomal recessive, COL5: collagen 5, 
COL3: collagen 3, COL1: collagen 1, TNX: Tenascin X. ADAMTS: 
metalloproteinase genes 
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Figure 1.10:  Common features of Ehlers Danlos Syndrome.  
a- Hypermobility of the finger joints , b- Atrophic papyraceous scarring 
over the knees, c- Hyperelasticity of the skin.  
 
 
1.4.1 Ehlers-Danlos Syndrome Hypermobility Type (EDS-HT)  
1.4.1.1 Characteristic features 
EDS Hypermobility Subtype (EDS-HT), formerly known as EDS Type III, is 
characterised by generalised joint hypermobility, easy bruising, poor wound 
healing and widespread musculoskeletal symptoms, predominantly pain 
(Beighton, De Paepe et al. 1998; Castori 2012). It is the most common of all the 
EDS subtypes, with a prevalence of around 1-5/10,000, and is more common in 
women than in men (De Paepe and Malfait 2012). It is present worldwide and 
cases have been documented in every continent (Beighton, Solomon et al. 
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1973; Bravo and Wolff 2006; Stoler and Oaklander 2006; Tofts, Elliott et al. 
2009; Castori, Camerota et al. 2010; Liu, Fuh et al. 2011; De Wandele, 
Rombaut et al. 2013). 
          
1.4.1.2 Aetiology 
EDS-HT is an inherited disorder, and displays an autosomal dominant pattern 
of inheritance (De Paepe and Malfait 2012). Unlike the other forms of EDS, the 
causative gene has not been located, and so its aetiology is as yet unknown. 
Light microscopic and ultrastructural examinations of skin from affected 
individuals reveal non-specific changes in collagen and elastin, which are non-
pathognomonic (Hausser and Anton-Lamprecht 1994; Hermanns-Le and 
Pierard 2007; Carlesimo, Cortesi et al. 2011; Hermanns-Le, Reginster et al. 
2012). 
 
Tenascin X deficiency  
An autosomal recessive form of EDS-HT also exists, and this is associated with 
haploinsufficiency of Tenascin X (TNX), a glycoprotein involved in cell adhesion 
and the regulation of collagen deposition (Burch, Gong et al. 1997). This defect 
is thought to be present in no more than 5% of patients with EDS-HT (Zweers, 
Hakim et al. 2004). Affected individuals have a similar phenotype with 
generalised joint hypermobility, joint dislocations, poor wound healing, easy 
bruising, and muscle weakness. They do not, however, have atrophic scarring 
(Lindor and Bristow 2005; Voermans, Altenburg et al. 2007; Hendriks, 
Voermans et al. 2011; Merke, Chen et al. 2013).  In these individuals, 
ultrastructural changes in the elastic fibres of the skin have been described 
(Zweers, Dean et al. 2005). In TNX-deficient patients with muscle weakness, 
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myopathic features are present in muscle biopsies. Tenascin-X null knockout 
mice recapitulate the skin and muscular findings of the human disease (Zweers, 
Schalkwijk et al. 2005; Voermans, Verrijp et al. 2011), confirming that TNX 
deficiency is responsible for the phenotype seen. 
 
1.4.1.3 Diagnosis 
As the aetiology of EDS-HT has not been characterised, there are no 
molecular, genetic or biochemical test available to diagnose it. Consequently, 
diagnosis is made using clinical criteria – the Villefranche diagnostic criteria for 
EDS-HT (Beighton, De Paepe et al. 1998) (Table 1.4). The presence of at least 
2 major criteria is required for diagnosis. 
 
As the clinical features of EDS-HT overlap substantially with the other subtypes 
(Table 1.3), diagnosis can be extremely difficult, and it is considered to be 
grossly underdiagnosed (Grahame 2008) . 
 
Table 1.4: Villefranche diagnostic criteria for the hypermobility type of 
Ehlers-Danlos Syndrome (Beighton 1988) 
 
Major criteria: 
 
1-Beighton score of ≥ 5 
2-Skin involvement: hyperextensibility or smooth velvety skin 
 
Minor criteria: 
 
1-Recurrent joint dislocations 
2-Chronic limb/joint pain 
3-Positive family history 
 
 
	   58	  
1.4.1.4 Comparison of EDS-HT to other subtypes 
It is clear that EDS-HT is quite different to the other subtypes for a number of 
reasons. It is more common than the other subtypes (De Paepe and Malfait 
2012)  (Table 1.3) , its aetiology has not been characterised, no diagnostic tests 
are available, and it is considered more benign. In fact, it seems to share more 
features in common with another hereditary disorder of connective tissue – the 
Joint Hypermobility Syndrome. 
 
1.5 Joint Hypermobility Syndrome  
The Joint hypermobility Syndrome (JHS) is an inherited non-inflammatory 
connective tissue disorder which was first described in 1967  (Kirk, Ansell et al. 
1967). It is defined as the presence of widespread musculoskeletal symptoms 
in patients with GJH, in the absence of systemic rheumatological disease (e.g. 
rheumatoid arthritis, scleroderma) or life-threatening complications (e.g. bowel 
perforations and cardiac valvular abnormalities) (Hakim and Grahame 2003). It 
is pathological, unlike isolated GJH.  
 
1.5.1 Epidemiology 
The exact prevalence of JHS has not been determined, partly as most 
individuals with JHS are undiagnosed (Adib, Davies et al. 2005), and therefore 
population studies underestimate its prevalence. Consequently, quoted 
prevalences in the literature are either mathematical estimates, or obtained 
from observational studies of JHS in specific populations. Mathematical 
estimates propose a prevalence of 0.75-2% (Hakim and Sahota 2006). 
Prevalences of 5% (Biro, Gewanter et al. 1983), 15% (Garcia Campayo, Asso 
et al. 2010), 30% (Baeza-Velasco, Gely-Nargeot et al. 2011), 34% (Liu, Fuh et 
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al. 2011) and 39% (Bravo and Wolff 2006; Baeza-Velasco, Gely-Nargeot et al. 
2011) , have been published in studies performed in USA, Spain, France, 
Taiwan and Chile respectively. The differences in prevalence reflect differences 
in the sampling population, and may not accurately reflect the true population 
prevalence. It does however, seem that the prevalence is geographically 
dependent.  JHS is more frequently reported in females (Hakim and Grahame 
2003) and tends to cluster in families (Finsterbush and Pogrund 1982).  
 
1.5.2 Classical features in JHS 
JHS is characterised by GJH, skin hyperelasticity and musculoskeletal 
symptoms. Skin tends to be thin and almost transluscent with visible capillaries 
and a bruising tendency (Castori, Camerota et al. 2010). Papyraceous scarring 
is common, as are excessive striae (Hakim and Sahota 2006) – Fig 1.11. The 
most common musculoskeletal complaint is arthralgia, but also includes 
recurrent dislocations, subluxations, and soft tissue injuries, all of which are 
thought to arise secondary to joint instability (Castori, Camerota et al. 2010). 
 
Patients also exhibit non-musculoskeletal features, probably a consequence of 
fragility and laxity in other organs and tissues.  Uterine and rectal prolapses, 
varicose veins, abdominal and inguinal hernias and myopia, and skeletal 
deformities such as scoliosis and the presence of a Marfanoid habitus (i.e. tall 
thin stature, long arms and fingers, high arched palate), have all been described 
in JHS and form part of the diagnostic criteria (Grahame, Bird et al. 2000).  
 
	   60	  
 
Figure 1.11: Cutaneous features of JHS 
 a – excessive striae , b – papyraceous scarring , c - bruising 	  
 
Although JHS shares several features to the EDS disorders, namely the 
presence of GJH and skin abnormalities,  presentation is not necessarily as 
pronounced, and life-threatening features are not present. As such it was 
previously known as the benign joint hypermobility syndrome. Recently, it has 
been recognised that the intensity and the burden of multiple different 
symptoms in JHS can, in fact, be quite debilitating to the patient (Adib, Davies 
et al. 2005). Studies confirm that quality of life is severely reduced in these 
patients (Rombaut, Malfait et al. ; Rombaut, Malfait et al. 2010) and pain seems 
to be an important predictor of poor quality of life (Castori, Camerota et al. 
2010). As such, the use of the prefix ‘benign’ from the Joint Hypermobility 
Syndrome is now omitted (Tofts, Elliott et al. 2009).  
 
1.5.3 Aetiology 
JHS is a hereditary disorder, and inheritance follows an autosomal dominant 
pattern (Hakim, Cherkas et al. 2004; Malfait, Hakim et al. 2006). The exact 
aetiology of JHS, and the causative gene, is however, undiscovered. As the 
phenotype is very similar to the other EDS disorders, the aetiology is thought to 
involve abnormal connective tissue which then causes multi-system 
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involvement. However, genetic studies to date have been unsuccessful at 
identifying a gene responsible for JHS. This probably reflects the heterogeneity 
of the disorder.  
 
Increased urinary excretion of collagen type I and III metabolites has been 
associated with the presence of JHS in patients with pelvic organ prolapses 
(Knuuti, Kauppila et al. 2010). However histological examination of skin from 
affected individuals do not reveal any pathognomonic abnormalities in 
connective tissue which can account for the disease (Hausser and Anton-
Lamprecht 1994). Interestingly, a recent family study of JHS and EDS patients 
has demonstrated that non-specific ultrastructural collagen and elastin 
abnormalities are present in skin from patients with JHS and in those with EDS-
HT.  These changes seemed to be preserved in families, regardless of whether 
the family members had the hypermobility phenotype, suggesting some genetic 
linkage. More importantly however, flower-like collagen fibrils were seen in all 
affected patients, regardless of whether they were diagnosed with JHS or EDS-
HT, and these changes were seen in a third of unaffected family members 
(Hermanns-Le, Reginster et al. 2012). This suggests that subtle collagen 
abnormalities are probably present in these individuals, but also that other (non-
collagen) factors must be involved, in order to explain how relatives with the 
same abnormalities did not have a hypermobile phenotype.  
 
1.5.4  Diagnosis  
As no biomarker exists for JHS, diagnosis is made using clinical criteria. The 
1998 Brighton classification system is the gold standard (Grahame, Bird et al. 
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2000) and incorporates most of the typical features of JHS described above 
(Table 1.5)  
 
Table 1.5: The 1998 Brighton classification—diagnostic criteria for the  
Joint Hypermobility Syndrome (Grahame, Bird et al. 2000) 
 
Major criteria  
 
1. A Beighton score of 4/9 or greater (either currently or historically) . 
 
2. Arthralgia for longer than 3 months in four or more joints.  
 
Minor criteria  
 
1. A Beighton score of 1,2, or 3/9 (0,1,2,or 3 if aged 50+).  
 
2. Arthralgia (for 3 months or longer) in one to 3 joints or back pain for (for 3 
months or longer), or spondylosis, sponylolysis/spondylolisthesis.  
 
3. Dislocation/subluxation in more than one joint, or in one joint on more than 
one occasion.  
 
4. Soft tissue rheumatism: three or more lesions (e.g. epicondylitis, 
tenosynovitis, bursitis).  
 
5. Marfanoid habitus (tall, slim, span/height ratio>1.03 upper: lower segment 
ratio <0.89, arachnodactyly).  
 
6. Abnormal skin: striae, hyperextensibility, thin skin, papyraceous scarring.  
 
7. Eye signs: drooping eyelids or myopia or antimongoloid slant.  
 
8. Varicose veins or hernia or uterine/rectal prolapse.  
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A diagnosis of JHS requires the presence of either: 
 - 2 major criteria, 
 - 1 major and 2 minor criteria 
 - 4 minor criteria, or 
 - 2 minor criteria and the presence of an unequivocally affected first-degree 
relative.  
 
JHS is excluded by the presence of the Marfan Syndrome or EDS, other than 
EDS-HT.  
 
As can be seen from Table 1.5 the diagnostic criteria incorporate the Beighton 
score. For major criteria a Beighton Score of 4 or more is required while for 
minor criteria, Beighton scores of less than 4 are acceptable. This may seem 
surprising, as this would suggest that individuals who are not hyperflexible may 
still satisfy criteria for JHS. The rationale behind such a design was to account 
for aging – older patients are less likely to have GJH, and so Beighton scores 
will decrease with age (Finsterbush and Pogrund 1982). However, in parallel 
with this, other complications such as soft tissue injuries and hernias (other 
minor criteria) will become more important (Castori, Sperduti et al. 2012). Thus 
the Brighton criteria are considered to take account of age and allow diagnosis 
of JHS independent of age (Grahame, Bird et al. 2000). 
 
Diagnosis of skin changes  
Skin changes in JHS appear under the minor criteria (Table 1.5), and include 
skin hyperextensibility, and papyraceous scarring (Figure 1.11). This requires 
an examination of the skin, and in particular a test of its ‘elasticity’. Historically 
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this was done by retracting the skin from the back of the hand or forearm, and 
performing a visual estimation of the degree of stretch. This is clearly 
subjective, so attempts to develop a more objective marker have been made. 
One technique uses a suction or cupping device, but this has not shown much 
reproducibility or validity (Remvig, Duhn et al. 2009; Remvig, Duhn et al. 2010). 
In a novel method called the skin stretch test, a lateral force is applied to the 
skin on the back of the hand to calculate the percentage increase in stretch. 
This is then divided by the thickness of the skin to give a corrected skin 
extensibility score (CSES) (Farmer, Douthwaite et al. 2010) (Figure 1.12).The 
CSES  was shown to correlate very well with the Beighton score in healthy 
individuals, and a cut-off  of 18 percent per mm, had a 72% sensitivity and 75% 
specificity for predicting GJH in healthy individuals (Farmer, Douthwaite et al. 
2010). This test has been validated in healthy volunteers but not in individuals 
with JHS. 
 
Most of the Brighton criteria are subtle and relatively subjective and so it is 
unsurprising that the exact prevalence of JHS has not been well documented, 
nor indeed that the condition is grossly underdiagnosed and patients can seek 
help for their symptoms for over a decade before a diagnosis is reached 
(Simpson 2006). The Brighton classification exemplifies the fact that JHS  
phenotypes can be heterogeneous as a diagnosis of JHS can be achieved by 
differing combinations of the Brighton criteria. For example, a young patient with 
a Beighton score of 8 out of 9, a Marfanoid habitus and multiple spontaneous 
dislocations, fulfils the criteria for JHS, as does an older patient with a Beighton 
score of 2 out of 9, varicose veins, multiple soft tissue injuries and the presence 
of generalised arthralgia, despite the fact that their presentations are quite 
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different (Table 1.5). This is a consequence of the Brighton classification which 
was designed as such to account for the multisystem nature of the disorder and 
the changing presentation with increasing age.  
 
 
Figure 1.12: Skin stretch test 
 a) 2 dots are placed on the back of the hand, 1cm apart b) the distance 
between the dots is measured c) a lateral force is applied to the skin and 
the percentage increase in stretch is measured; d) this is then  divided by 
the thickness of the skin to give a corrected skin extensibility score 
(CSES) (Farmer, Douthwaite et al. 2010) 
 
From  Table 1.4 and Table 1.5, it can be seen that the Brighton classification for 
JHS is very similar to the Villefranche classification for EDS-HT. In fact both 
EDS-HT and JHS are thought to be part of the same disorder and the two terms 
are now used interchangeably (Tinkle, Bird et al. 2009) . For the purpose of this 
thesis, the term JHS will be used to describe both JHS and EDS-HT. The term 
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‘hypermobility’ will be used to describe any disorder which is characterised by 
joint hypermobility, and will therefore include GJH, EDS-HT and JHS. 
 
1.5.5 Extra-articular associations of JHS 
Since the Brighton classification was formulated  over 14 years ago, it has 
become apparent that the effect of JHS is much more widespread than 
originally suspected. Epidemiology studies have revealed that several disorders 
and extra-articular symptoms are associated with JHS, all of which contribute to 
morbidity and further decrease quality of life in affected patients (Verbraecken, 
Declerck et al. 2001; Hakim and Grahame 2004; Voermans, Knoop et al. 2009). 
 
1.5.5.1 Neurological 
Autonomic dysfunction –Postural Orthostatic Tachycardia Syndrome 
The association between JHS and autonomic dysfunction was recognised over 
10 years ago. Up to 78% of patients with JHS have autonomic symptoms  
(Rombaut, Malfait et al. 2011), particularly orthostatic symptoms (Gazit, Nahir et 
al. 2003) and these are associated with demonstrable changes in autonomic 
parameters (Gazit, Nahir et al. 2003).  More recently, this association has been 
refined and it appears that most JHS patients with autonomic dysfunction suffer 
with the Postural Orthostatic Tachycardia Syndrome (PoTS) (Bohora 2010; 
Kanjwal, Saeed et al. 2010). Patients with PoTS have symptoms of dizziness, 
palpitations, pre-syncope and syncope, and these symptoms can be 
exacerbated by prolonged standing, exertion, alcohol, heat and sometimes 
ingestion of carbohydrates (Mathias, Low et al. 2011). It is present in a large 
proportion of patients with JHS and is diagnosed by the presence of a rise in 
pulse rate by more than 30, or an increase in pulse to greater than 120 bpm , 
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within 10 minutes of moving from a recumbent to a standing position, without 
accompanying orthostatic hypotension. It is often accompanied by visible 
venous pooling in the lower limbs or blotching of the skin. It is not considered an 
autonomic failure, as specific sympathetic and parasympathetic tests appear to 
be normal. In PoTS, a rise in noradrenaline levels (NA) is common but baseline 
catecholamine levels are normal. The exact mechanism by which this occurs in 
unknown, but it is thought to involve a failure of normal vasoregulatory 
mechanisms and therefore an uneven redistribution of circulatory blood volume, 
with various precipitants (Mathias, Low et al. 2011).  
 
Neuromuscular 
Muscle weakness can be a major cause of disability in JHS (Rombaut, Malfait 
et al. 2010), and several patients have severe limitations in their mobility, to the 
point at which they are wheelchair-bound. Muscle weakness in JHS is due to 
impaired muscle function rather than a reduction in muscle mass (Rombaut, 
Malfait et al. 2012). Affected individuals appear to have proprioceptive problems 
mainly involving the large joints and this seems to improve with training (Eyigor, 
Ozdedeli et al. 2008; Rombaut, De Paepe et al. 2009). They also have 
increased passive muscle tension and stiffness (Rombaut, Malfait et al. 2012), 
confirming that hypermobility extends beyond the joints, and also affects the 
muscles and tendons (Voermans, van Alfen et al. 2009).  
 
Fatigue 
Fatigue is a frequent JHS symptom and significantly contributes to disability 
(Voermans, Knoop et al. 2009). Fatigue is strongly correlated with both the self- 
report of muscle weakness and objective assessment of weakness (Voermans, 
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Knoop et al. 2011).  Both pain and fatigue are important predictors of muscle 
weakness, suggesting that they co-occur. This is typical for presentation of the 
chronic fatigue syndrome, and in fact studies have documented a strong 
association between hypermobility conditions and chronic fatigue syndrome in 
both children and adults (Barron, Cohen et al. 2002; Nijs, Aerts et al. 2006).  
 
Migraine 
Females  with JHS have an increased prevalence of migraines (Bendik, Tinkle 
et al. 2011).   
 
1.5.5.2 Uro-gynaecological 
Urological 
Urinary symptoms are common in JHS. Even in nulliparous women and 
children, urinary stress incontinence, detrusor instability and recurrent urinary 
tract infections occur more frequently compared to controls (de Kort, Verhulst et 
al. 2003; Manning, Korda et al. 2003; Arunkalaivanan, Morrison et al. 2009).  
 
Gynaecological 
There is an increased prevalence of obstetric complications with a higher risk of 
premature rupture of the membranes, early delivery, bleeding and perineal 
trauma (Dutta, Wilson et al. 2011; Molloholli 2011). Later complications include 
poor wound healing, urine and faecal incontinence and uterine prolapse 
(Molloholli 2011). Prolapse appears to be the most clinically relevant 
complication and is associated with episiotomy (Castori, Morlino et al. 2012). 
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Dysmenorrhoea and menorrhagia is present in over half of patients with 
established JHS; irregular menses and vulvodynia is present in over a third 
(Castori, Morlino et al. 2012). 
 
1.5.5.3 Chronic pain 
Pain is a common finding in JHS (Voermans and Knoop 2010; Voermans, 
Knoop et al. 2011), and in fact, joint pain is an important component of the 
Brighton classification (Table 1.5). However, in addition to arthralgia, individuals 
with JHS experience widespread pain, which is often  recurrent, chronic, and 
significantly impairs quality of life (Castori, Morlino et al. 2012). As testament to 
this, opiates and antidepressants are common prescriptions in these 
individuals. In a recent study of JHS patients in a genetics clinic setting, 37% 
were on opiates, and 20% were on antidepressants (Rombaut, Malfait et al. 
2011).  Interestingly, it has been observed that  patients with JHS (or EDS-HT) 
have far more pain than those with classical EDS despite the fact that the latter 
subtypes have far more dramatic joint involvement (Castori 2012). This would 
suggest that pain is not solely due to joint damage, but rather that altered pain 
mechanisms are involved. This is supported by the fact that these patients 
suffer with chronic pain syndromes, such as fibromyalgia and chronic regional 
pain syndrome (Ofluoglu, Gunduz et al. 2006; Stoler and Oaklander 2006), and 
that neuropathic pain is common (Voermans, Knoop et al. 2011).  
 
Fibromyalgia (FM) 
The prevalence of FM in JHS is high and is present in almost 50% of adults with 
JHS (Sendur, Gurer et al. 2007) . Equally, the prevalence of JHS in FM is also 
high.  64% of adults with FM have JHS (Ofluoglu, Gunduz et al. 2006),  and in 
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children with FM the prevalence of JHS ranges from 40% (Siegel, Janeway et 
al. 1998) to 81% (Gedalia, Press et al. 1993). Adolescents with JHS and FM 
have significantly more pain sensitivity i.e. more tender points and lower 
threshold for pain, but no differences in the self reporting of pain (Ting, Hashkes 
et al. 2012). This supports the notion that pain processing may be altered in 
JHS. 
 
Complex regional pain syndrome 
Complex regional pain syndrome (CRPS), formerly known as reflex sympathetic 
dystrophy , is a chronic systemic disorder characterised by limb pain, swelling, 
and vasoregulatory changes, often visible in the skin. Dysregulation of the 
autonomic and central nervous system, causing central and peripheral 
sensitisation, is thought to be involved, as are immune mechanisms (Goebel). 
Interestingly, recent literature has found a possible association between both 
JHS and EDS (including classical EDS), and CRPS, although the exact 
mechanism is still unknown (Stoler and Oaklander 2006).  
 
It would thus appear that a significant proportion of patients with JHS have a 
chronic pain syndrome which probably includes different types of pain including 
nociceptive pain (arthralgias), neuropathic pain (e.g. chronic regional pain 
syndrome), and functional somatic pain (e.g. fibromyalgia), and is accompanied 
by fatigue . A clear explanation for several of these pain syndromes, and for the 
accompanying fatigue, is not available, although it is thought that both 
peripheral and central hypersensitivity are likely to be involved (Castori, Morlino 
et al. 2012). The lack of understanding of the cause of pain adds to the difficulty 
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in treatment, thus causing further disability and impairing quality of life 
(Voermans and Knoop 2010). 
 
1.5.5.4 Psychopathology 
JHS individuals have high levels of emotional and psychological distress, and a 
higher number of somatic symptoms. Individuals with JHS are almost 16 times 
over-represented in those with panic disorders (Garcia Campayo, Asso et al. 
2010). JHS patients who are pain-free have a higher frequency and intensity of 
somatic symptoms (somatosensory amplification), and higher anxiety scores 
compared to a control group (Ercolani, Galvani et al. 2008; Garcia-Campayo, 
Asso et al. 2010), suggesting that the psychopathology is not secondary to 
pain. Population studies have demonstrated that in previously undiagnosed 
JHS (i.e. non-patients), high levels of somatosensory amplification and anxiety 
are present in both males and females, and that females had higher levels of 
depression compared to controls (Baeza-Velasco, Gely-Nargeot et al. 2011). 
 
The association between JHS and anxiety is robust  - it has been replicated, it 
is present in non-patients and the prevalence of anxiety has been shown to 
increase with time (Garcia-Campayo, Asso et al. 2010). In a longitudinal study 
with a 15 year follow up, the relative risk of developing anxiety in patients with, 
compared to without, JHS  was 22.3 (Bulbena, Gago et al. 2011) , suggesting 
that JHS is a risk factor for anxiety disorders. The mechanism for this is 
unknown but is thought to be either due to alterations in linked genes which 
predispose to both GJH and anxiety disorders (Gratacos, Nadal et al. 2001) , or 
due to altered autonomic processing centrally (Gazit, Nahir et al. 2003). One 
MRI study has reported increased amygdala volumes in patients with JHS – this 
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brain region is responsible for emotional processing of pain (Eccles, Beacher et 
al. 2012). This has not been replicated so firm conclusions cannot yet be drawn 
from this.  
 
From the evidence it is clear that higher levels of psychological distress are 
present in JHS, both in patients and in healthy non-patients.  
 
1.5.5.5 Cardio-respiratory 
Individuals with JHS tend to suffer with palpitations (Gazit, Nahir et al. 2003), 
and there is an increased incidence of  JHS in individuals with mitral valve 
prolapse (Yazici, Ataoglu et al. 2004). 
 
There is an increased prevalence of asthma and atopy in JHS and this is 
associated with physiological evidence of increased lung volumes, impaired gas 
exchange and an increased tendency of both the lower and upper airways to 
collapse (Morgan, Pearson et al. 2007) . 
 
1.5.5.6 Orthopaedic  
Early osteoarthritis is frequently encountered in JHS, and is thought to be a 
consequence of the excessive and unusual strain put on the joints while they 
are hyperextended (Dolan, Hart et al. 2003). JHS is also associated with 
osteopenia and osteoporosis, though the exact mechanism by which this occurs 
is not clear (Dolan, Arden et al. 1998; Gulbahar, Sahin et al. 2006). 
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1.5.5.7 Dental  
Tempero-mandibular joint dysfunction  is present in over 70% of JHS patients 
(Hirsch, John et al. 2008) which results in repeated jaw clicking, locking, and 
pain and is thought to be due to increased tempero-mandibular joint  mobility.  
 
1.5.5.8 Bleeding disorders 
Clinically, patients with JHS tend to have a bleeding or bruising tendency, but 
clotting parameters are generally normal. In a haematology ‘bleeding disorder’ 
clinic, the prevalence of JHM in patients with a bleeding disorder was 23% 
compared to a prevalence of 2% in a control population with no bleeding 
disorder. 77% of the patients with JHM also had JHS (Jackson, Odiaman et al. 
2012).  
 
1.5.5.9 Ocular 
Ocular features in JHS include xerophthalmia, steeper corneas, pathologic 
myopia, and vitreous abnormalities, as well as a higher rate of minor lens 
opacities (Gharbiya, Moramarco et al. 2012). Blue sclera, are also relatively 
common and are thought to be due to the visible uveal vessels through the 
thinner sclera (Bravo and Wolff 2006).  
 
1.5.6 Functional somatic symptoms, JHS and FGID 
It is clear that JHS is a systemic disease with widespread organ involvement. 
Furthermore, it is associated with several medically unexplained disorders, the 
so called functional somatic syndromes e.g. FM, chronic fatigue syndrome, 
chronic regional pain syndrome, TMJ dysfunction and migraines (Castori, 
Celletti et al. 2011), all of which are also linked with FGID.  
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Several of these somatic symptoms were described in a study investigating 
possible autonomic-induced symptoms in JHS. It was found that apart from joint 
pain and fatigue, the most common symptoms in JHS patients were insomnia, 
syncope, migraines, psychopathology and gastrointestinal symptoms (Hakim 
and Grahame 2004). From the link between functional somatic symptoms and 
both JHS and FGID independently, it would be assumed that an association 
exists between FGID and JHS. As yet, there is no direct evidence for this. 
However, there is an increasing body of work that supports an association 
between joint hypermobility, anatomical and physiological GI abnormalities and 
GI symptoms. 
 
1.6 Joint Hypermobility and the GI tract 
1.6.1 Joint Hypermobility and abnormal GI anatomy 
Joint Hypermobility is associated with several anatomical abnormalities in both 
the upper and lower GI tract. In a study of 100 patients attending an endoscopy 
unit, the prevalence of GJH in patients with hiatus hernias (22%) was 
significantly increased compared to age and sex-matched controls without 
hernias (6%, p<0.001)  (Al-Rawi, Al-Dubaikel et al. 2004).  
 
In patients with constipation and symptoms of rectal evacuatory dysfunction 
those with GJH had an increased prevalence of  rectal morphological anomalies 
compared to those without GJH (Mohammed, Lunniss et al. 2010), most 
commonly large functional rectoceles (24%) and external compression of the 
anterior rectal wall (11%). Lower GI symptoms frequently overlap with urinary 
symptoms, and a study of patients with lower urinary tract dysfunction similarly 
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demonstrated that patients with JHS were significantly more likely to have 
symptoms of rectal evacuatory dysfunction and evidence of rectal 
morphological anomalies e.g. rectal prolapses, compared to those without JHS 
(Manning, Korda et al. 2003) .  
 
Case reports of patients with JHS or EDS-HT describe further anatomical 
abnormalities in small numbers of patients, including diverticular disease (Lindor 
and Bristow 2005), and viscerotopsis of the bowel  (Reinstein, Pimentel et al. 
2012). The latter is rare and refers to the downward displacement of abdominal 
organs below their natural position. It can cause kinking of blood vessels and 
nerves and thereby cause symptoms, which can be severe. In one case 
described, the patient presented with a 4 year history of abdominal distension 
and bloating that interfered with her eating and activities of daily living. 
 
1.6.2 Joint hypermobility  and abnormal GI physiology 
Physiologically, there is an association between GJH and constipation (Reilly, 
Chase et al. 2008; Manning, Korda et al. 2003; Al-Rawi, Al-Dubaikel et al. 2004) 
In young boys, a higher prevalence of GJH was demonstrated in those with 
slow transit constipation compared to those without (Reilly, Chase et al. 2008) . 
Adults appear to have a different pattern of constipation, and in a study of 
adults referred for lower GI physiology testing for functional constipation, those 
with GJH had more severe constipation, greater abdominal pain, increased 
laxative use and need for manual evacuation. However, there was no increase 
in slow transit constipation, but instead a higher prevalence of rectal evacuatory 
dysfunction was observed in these patients  (Mohammed, Lunniss et al. 2010). 
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1.6.3 Association between JHS and GI symptoms 
The association between JHS and GI symptoms was first described 8 years ago 
by Hakim and Grahame (Hakim and Grahame 2004). They found that JHS 
patients attending a hypermobility clinic had significantly more GI symptoms 
compared to age and sex matched controls (37% vs 11%) (Figure 1.13). The 
most common GI symptoms were nausea, abdominal pain, constipation and 
diarrhoea. It was felt that dysautonomia was one mechanism by which this may 
occur (Gazit, Nahir et al. 2003; Hakim and Grahame 2004), and since then it 
has been shown that POTS is associated with GI symptoms such as nausea, 
reflux, bloating, constipation and diarrhoea (Mathias, Low et al. 2011). Thus it 
would appear that JHS, autonomic symptoms and GI symptoms are indeed 
linked, though the exact mechanism for the association is unknown. 
 
Since that landmark study, other studies worldwide in specialist hospital settings  
have confirmed that GI symptoms are common in patients with an existing 
diagnosis of JHS. In a study of 21 JHS patients attending a genetics clinic in 
Italy, 87% of patients were found to have GI symptoms, most commonly 
dyspepsia (67%), gastro-oesophageal reflux (57%), recurrent abdominal pain 
(62%), alternating constipation and diarrhoea (33%) and abdominal hernias 
(5%) (Castori, Camerota et al. 2010). Furthermore, it was observed that the 
incidence of GI symptoms increased with age, and that older JHS patients were 
more likely to have GI symptoms than their younger counterparts (Castori, 
Sperduti et al. 2012).  
 
Another study demonstrated not only that GI symptoms such as constipation, 
diarrhoea, bloating and swallowing problems are present in JHS, but that these 
	   77	  
GI symptoms are also associated with clusters of other extra-articular 
symptoms, in particular cognitive problems, insomnia, postural dizziness and 
syncope (Rombaut, Malfait et al. 2011), supporting previous findings.  
Furthermore, there was large heterogeneity in presentation and with cluster 
analysis it was demonstrated that 2 main clusters of symptoms, and therefore 
patients, were present. Musculoskeletal symptoms were prominent in both 
clusters but GI symptoms were particularly prominent in the group which also 
had high levels of fatigue, cutaneous changes, orthostatic, immune, 
urogynecologic, visual and respiratory problems (De Wandele, Rombaut et al. 
2013).   
 
 
Figure 1.13: Extra-articular symptoms in JHS  
(Hakim and Grahame 2004) 
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Thus the association between GI symptoms and JHS in specialist hospital 
settings seems to be consistent. Furthermore there appears to be clustering of 
JHS and GI symptoms with several other symptoms, including musculoskeletal 
pain, fatigue, autonomic symptoms and urological symptoms, to varying 
degrees.  
 
From a gastroenterology point of view, GI symptoms can be due to organic 
disorders or functional disorders. There is literature, albeit limited, that 
associates JHS with both  types of disorder. 
 
1.6.4  Joint hypermobility and organic GI disorders 
Only 2 published studies exist which demonstrate a possible association 
between hypermobility and organic disorders, and these were done in patients 
with inflammatory bowel disease (IBD) and coeliac disease. The first compared 
69 patients with IBD to 67 age and sex-matched controls. A significantly higher 
prevalence of GJH was found in patients with Crohn’s disease (70%) compared 
to controls (25%) and to patients with Ulcerative colitis (36%), (Vounotrypidis, 
Efremidou et al. 2009), suggesting a possible association between GJH and 
Crohn’s Disease though this has not yet been replicated. Additionally, only GJH 
was assessed, so it is questionable whether the findings can be generalised to 
JHS. 
 
The other study assessed 31 JHS patients for celiac disease. 5 (16%) had a 
confirmed diagnosis based on both serological and histological testing (Danese, 
Castori et al. 2011), which was significantly higher than the estimated 
population prevalence (1%). However, the patients were a highly selected 
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group of patients attending specialist clinics and therefore these findings are not 
necessarily generalisable to the majority of patients with JHS, most of whom 
remain undiagnosed.  
 
1.6.5 Joint hypermobility and functional GI disorders 
The only direct evidence for an association between FGID and hypermobility 
comes from a single retrospective observational study in tertiary 
gastroenterology setting (Zarate, Farmer et al. 2009). In this study, the validated 
5-point hypermobility questionnaire was used to screen for GJH in 129 
consecutive patients attending a neurogastroenterology clinic. The prevalence 
of GJH in these clinic patients was 49%, three times higher than the prevalence 
in healthy controls (17%). Those with GJH were more likely to have GI 
symptoms without a known underlying structural, biochemical, metabolic or 
autoimmune cause compared to those without GJH i.e. the symptoms were 
more likely to be unexplained.  A subgroup of these patients were assessed 
further by a rheumatologist, and found to have JHS. The patients with JHS 
tended to have motility problems in their gut on physiological testing, e.g. small 
bowel dysmotility, delayed gastric emptying and delayed colonic transit. This 
study confirmed that in a tertiary neurogastroenterology setting, GJH was 
strongly associated with unexplained GI symptoms, or FGID, and that GI 
dysmotility was common in patients with GI symptoms and JHS, suggesting that 
these patients may have a neuromuscular basis for their symptoms.  
 
These may represent a unique group of patients in FGID clinics, who are more 
likely to have unexplained symptoms and underlying dysmotility. Abnormal 
connective tissue may be contribute to GI pathology in this group,  
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Although no large observational studies have been published that definitely 
confirm an association between JHS and FGID, smaller studies have 
demonstrated not only that IBS symptoms are common in JHS (Hakim and 
Grahame 2004; Castori, Camerota et al. 2010; De Wandele, Rombaut et al. 
2013), but that JHS patients with GI symptoms often have a pre-existing 
diagnosis of IBS (Manning, Korda et al. 2003; Castori, Camerota et al. 2010).    
 
Further support for the association between JHS and FGID comes from the fact 
that both disorders share several features, in particular an association with 
several medically-unexplained disorders, also known as functional somatic 
syndromes – Table 1.6. In fact, it has been speculated that that the same 
underlying process, involving a combination of somatic hypersensitivity, chronic 
pain, and dysautonomia, underlies all the functional somatic syndromes and 
that JHS is the common link (Castori, Celletti et al. 2011).  
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Table 1.6: Similarities between JHS and FGID.  
Asterisks mark disorders that are considered functional somatic 
syndromes. 	  
 
 
JHS FGID 
 
DEMOGRAPHICS 
 
Population prevalence 
 
5-17% 
 
2.5-13% 
 
Gender 
 
More common in 
females 
 
More common in 
females 
 
Age 
 
 
Incidence decreases 
with age 
 
Incidence decreases 
with age 
 
SYMPTOMS 
 
Chronic pain 
 
Yes 
 
Yes 
 
Hypersensitivity 
 
Somatic 
 
Visceral 
 
DIAGNOSIS 
 
Validated biomarker 
 
No 
 
No 
 
Criteria based diagnosis 
 
Yes 
 
Yes 
 
DISEASE ASSOCIATIONS 
 
Fibromyalgia* Yes 
 
Yes 
Chronic fatigue syndrome* Yes 
 
Yes 
Anxiety Yes 
 
Yes 
Depression Yes 
 
Yes 
Migraine* Yes 
 
Yes 
TMJ disorder* Yes 
 
Yes 
Pelvic/bladder pain* Yes 
 
Yes 
Insomnia Yes 
 
Yes 
Allergies/Atopy Yes 
 
Yes 
Autonomic dysfunction Yes 
 
Yes 
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1.7 Limitations and Knowledge gaps 
Despite the lack of direct evidence, the existence of this growing body of work is 
suggestive of an association between JHS and GI symptoms. Moreover, it 
leads us to think that there might be an overlap between FGID and JHS, and 
that they share a common aetiology which may explain a subgroup of patients 
with FGID. This would have important prognostic and aetiological implications, 
and could potentially lead to a paradigm shift in the way we approach FGID. 
However, before such a novel concept is proposed, and a detailed analysis of 
connective tissue in the GI tract of these individuals is begun, it is imperative to 
conclusively confirm that an association between GI symptoms, FGID and JHS 
exists, to characterise it fully, and to tease out the various factors which might 
be involved in this association. This has not yet been done, and the studies 
described above all have their limitations which restricts the conclusions that 
can be drawn from them. 
 
1.7.1 Limitations of currently performed research studies 
The main limitation of the above studies is the selection bias. The JHS patients 
studied were those seeking specialist care in rheumatology or genetics clinics, 
which are often tertiary care settings (Hakim and Grahame 2004; Castori, 
Camerota et al. 2010; Rombaut, Malfait et al. 2011; De Wandele, Rombaut et 
al. 2013). Given that JHS is underdiagnosed, this population is unlikely to 
represent the majority of JHS patients, but instead more likely to represent the 
most severe cases at the tip of the iceberg with refractory symptoms. Secondly, 
several of the studies were small, with not more than 40 JHS patients (Reilly, 
Chase et al. 2008; Castori, Camerota et al. 2010). In view of the fact that JHS is 
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actually quite common and heterogeneous, this is a very limited sample, and 
again may not reflect the general population of JHS patients. Thirdly, there is 
huge variation in the type of controls used in the study – in the majority of 
studies these were healthy patients (Hakim and Grahame 2004), but in some 
studies, there were no controls at all (Castori, Camerota et al. 2010; Rombaut, 
Malfait et al. 2011; De Wandele, Rombaut et al. 2013). GI symptoms are very 
common in the general population, therefore it is difficult, in the absence of a 
suitable control group, to comment on whether the prevalence of GI symptoms 
is disproportionately high. Furthermore, it is interesting that no studies of GI 
symptoms in JHS have been performed in a gastroenterology setting. In view of 
the high incidence of GI symptoms reported in JHS, it would be expected that 
some of these patients would end up in a gastroenterology clinic, yet this has 
not been reported, nor has a comparison of symptoms in JHS been made with 
a GI control population. The only studies that have been performed in a GI 
setting were those relating to GI physiology and anatomy (Al-Rawi, Al-Dubaikel 
et al. 2004; Zarate, Farmer et al. 2009; Mohammed, Lunniss et al. 2010), but 
these looked at patients with GJH rather than JHS. Even with the GJH patients, 
methods of diagnosing hypermobility varied amongst the studies – some used 
the Beighton score (Al-Rawi, Al-Dubaikel et al. 2004; Reilly, Chase et al. 2008) 
which is the gold standard, and others used the hypermobility questionnaire, 
which is just a screening tool (Zarate, Farmer et al. 2009; Mohammed, Lunniss 
et al. 2010). Thus the definitions for hypermobility and the methods for 
diagnosing it were not standardised, making comparisons, and conclusions, 
difficult. Lastly, and very importantly, GI symptoms are influenced by a number 
of factors including, psychopathology, hypersensitivity, opiates and autonomic 
dysfunction, all of which are common in JHS. None of the studies controlled for 
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these variables and so it is impossible to know whether these were confounding 
the association seen between GI symptoms and JHS.  
 
1.7.2 Knowledge gaps 
Data on the relationship between JHS and both GI symptoms and GI disorders 
in patients not referred to tertiary centres are lacking and similarly, no 
population based data in JHS non-patients is available. In addition, the 
comparison of GI symptom prevalence with a GI control group and the effect of 
confounding factors such as psychopathology, autonomic dysfunction and 
hypersensitivity has not been ascertained. Lastly, the physiological mechanisms 
for the increased symptoms in these individuals is unknown.  
 
1.8  Aims 
The general aim of the studies is to address the above knowledge gaps - to fully 
characterise the range and prevalence of GI symptoms in patients and non-
patients with JHS , to determine the influence of various confounding factors on 
these symptoms, to investigate the physiological mechanisms for the most 
common symptoms and to determine if a true association exists between JHS 
and FGID. 
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1.8.1 Specific aims 
1. To characterise the GI presentation in patients with an established 
diagnosis of JHS and known GI symptoms, and to compare this to 
patients without JHS attending GI clinics. Specifically: 
a. To determine the range and prevalence of GI symptoms in 
patients referred to gastroenterology clinics with a known 
diagnosis of JHS. 
b. To compare the prevalence of individual GI symptoms to that in  
patients without JHS, also attending GI clinics. 
c. To determine whether there is a high prevalence of FGID in JHS 
patients.  
d. To determine what associated extra-intestinal factors are 
confounders, and the effect of these on GI symptoms in JHS. 
e. To determine the increased burden of GI symptoms on quality of 
life in JHS patients. 
 
2. To determine if there is an association between JHS and GI symptoms in 
a population based sample of non-patients. Specifically: 
a. To determine and compare the range and prevalence of GI 
symptoms in university students with and without JHS. 
b. To determine which associated factors confound the association 
between JHS and GI symptoms, and whether these are the same 
as those present in patients  
c. To determine the effect of JHS on quality of life in non-patients. 
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3. To determine if there is an association between JHS and GI disorders in 
secondary care. Specifically: 
a. To determine and compare the prevalence of JHS in GI patients 
with organic GI disorders, FGID and in a non-GI control group, 
and therefore to determine if JHS is associated with FGID. 
b. To determine whether JHS is associated with particular subtypes 
of FGID or organic disease.   
c. To determine whether the association between JHS and GI 
disorders is dependent on autonomic, somatisation, psychological, 
or chronic pain factors.   
d. To determine if the added presence of JHS is clinically significant 
in patients with GI disorders and whether it is associated with 
altered quality of life or comorbidity. 
  
4. To determine whether physiological abnormalities are present in JHS 
patients with upper GI symptoms. Specifically: 
a. To determine whether dysphagia is associated with oesophageal 
dysmotility. 
b. To determine whether reflux symptoms are caused by true reflux, 
or functional heartburn. 
c. To determine whether gastroparesis is present in patients with 
dyspepsia. 
d. To determine whether gastro-oesophageal compliance is 
increased in JHS patients. 
 
	   87	  
1.9 Hypothesis 
Individuals with JHS have a generalised connective tissue disorder which not 
only affects the skin and joints leading to musculoskeletal features, but also 
affects the GI tract and everything within it including the sensory and autonomic 
nerves. This will lead to altered compliance and altered autonomic and sensory 
function. Autonomic dysfunction will lead to altered motility, sensory dysfunction 
will lead to hypersensitivity and both these will contribute to the generation of GI 
symptoms and disorders. Thus it is expected that JHS patients with GI 
symptoms will have increase autonomic symptoms and hypersensitivity, and 
altered compliance of the GI tract. All these abnormalities are genetically 
determined and therefore will be present at an early age, even before 
individuals present as patients. Hence the following is expected: 
 
1. JHS patients will have a high prevalence of GI symptoms as well as 
autonomic and somatic symptoms.  Autonomic and somatic factors  will 
be involved in the association between JHS and GI symptoms. 
2. A  high prevalence of GI symptoms will be present in young JHS non-
patients, and again this will be associated with the presence of 
autonomic and somatic symptoms.  
3. There will be an association between JHS and FGID but not with organic 
GI disorders. In particular,  ROME III categories of FGID which are 
characterised by hypersensitivity will be most associated with JHS. 
4. Physiological abnormalities, particularly altered sensori-motor function, 
will be present in symptomatic JHS patients. JHS patients will also have 
altered compliance of GI tissue, and this will contribute to symptom 
presentation.  
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Chapter 2 Characterisation of Gastrointestinal Symptoms in the Joint Hypermobility Syndrome 
Characterisation of Gastrointestinal Symptoms in the 
Joint Hypermobility Syndrome 
2.1 Introduction 
As described in the introduction, several preliminary studies have demonstrated 
that GI symptoms occur in patients with JHS (Castori, Camerota et al. 2010) 
and that symptoms such as constipation, diarrhoea abdominal pain and nausea 
are more common than in the general population (Hakim and Grahame 2004). 
However, a GI control group was not used in any of these studies, therefore it is 
not known if the prevalence and range of GI symptoms in JHS patients is any 
different from patients with other GI disorders. In addition, it is unknown whether 
GI symptoms in JHS patients are due to primarily an organic or functional 
cause.  Furthermore, several factors known to be associated with GI symptoms 
such as autonomic dysfunction and psychopathology are also present in JHS 
patients (Table 1.5) but it is not yet known whether these factors are 
responsible for the association between JHS and GI symptoms. Lastly, it has 
been demonstrated that in patients with JHS, the presence of musculoskeletal 
symptoms, particularly pain, is associated with decreased QOL. The added 
effect of GI symptoms on QOL has never been studied in these patients. 
	  
2.2 Aims 
The primary aims of the study were (1) To determine the range and prevalence 
of GI symptoms in patients referred to gastroenterology clinics with a known 
diagnosis of JHS in comparison to patients referred with GI symptoms, but 
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without JHS; (2) to compare the prevalence of FGID in patients with JHS 
compared to those without JHS; (3) to determine what associated extra-
intestinal factors are confounders of the association between GI symptoms and 
JHS; and (4) to compare the quality of life in patients with a combination of both 
JHS and GI symptoms to those with GI symptoms but without JHS.  	  
2.3 Hypothesis 
It was hypothesised that in a GI clinic, patients with JHS compared to patients 
without JHS will have a higher prevalence of GI symptoms, extra-intestinal 
symptoms, and FGID, and a reduced quality of life. Furthermore, GI symptoms 
in JHS patients would be influenced by psychopathology, opiate use, autonomic 
and hypersensitivity factors i.e. those were confounding factors. 
 
2.4 Materials and Methods  
2.4.1 Study design 
This study was part of a much larger study that was designed to address the 
aims in this Chapter as well those in Chapter 4 – see Figure 2.1 for details. 
Consecutive ‘new’ patients attending general gastroenterology clinics for their 
first visit between April 2010 and April 2012 participated in studies described in 
Chapter 2 and 4. All patients completed a set of validated questionnaires, and 
were assessed for hypermobility and fibromyalgia status (see below) before 
their initial clinical consult with the attending gastroenterologist.  The GI 
diagnosis that the patients were eventually given could be obtained from the 
medical notes. 
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Figure 2.1 Overall study design for Chapter 2. 
 GI symptoms were compared in patients with a pre-existing diagnosis of 
JHS (JHS-Rh) and those in whom JHS had been excluded (Non-JHS-G).  
 
For the study described in this Chapter, two groups of patients were selected 
and compared: those with a previous rheumatology diagnosis of JHS (JHS-Rh), 
and those in whom JHS was excluded (Non-JHS-G) - Figure 2.1. These two 
groups were compared with respect to the presence of GI and extra-articular 
symptoms and disorders, and quality of life. 
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2.4.2 Patients 
Eligibility criteria 
Consecutive patients aged 16-70, who had GI symptoms and were newly 
referred to gastroenterology clinics at Barts and the London NHS Trust and Mile 
End Hospital between April 2010 and April 2012 were eligible to take part. 
Patients who were illiterate or who could not speak English were excluded as 
the study relied heavily on questionnaires. Patients who were asymptomatic 
e.g. those attending for routine bowel cancer screening, and patients with 
predominantly hepatology problems were also excluded. 
 
Patients were assessed for eligibility and recruited after informed written 
consent. Patients who had previously seen a rheumatologist and had an 
established diagnosis of JHS formed the JHS-Rh group. Patients who did not 
fulfill the Brighton diagnostic criteria for JHS formed the Non-JHS-G group.  
	  
2.4.3 Questionnaires 
Subjects completed validated questionnaires to systematically assess for GI 
symptoms, psychopathology, autonomic symptoms, somatic symptoms and 
quality of life. Demographic information and medication histories were also 
collected via standardized case report forms. Questionnaires once completed 
were placed in a sealed envelope to ensure blinding of the researchers to 
questionnaire responses.  
 
GI symptom assessment: The Bowel Disease Questionnaire (BDQ) (Talley, 
Phillips et al. 1990) is a validated instrument used to obtain a detailed 
assessment of the frequency and severity of both functional and organic GI 
symptoms experienced over the past 6 months and to collect medical history 
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data. For this study, GI symptoms were considered to be present if they 
occurred at least once a week. 
 
Autonomic symptom assessment: The Composite Autonomic Symptom Scale 
(COMPASS questionnaire) is a validated questionnaire that provides a score of 
autonomic dysfunction, with higher scores representing a higher number of 
autonomic symptoms. Scores correlate well with objective measures of 
autonomic dysfunction (Suarez, Opfer-Gehrking et al. 1999).  Scores are 
provided for various autonomic domains; for this study, scores relating to 
orthostatic, urinary, vasomotor and syncope domains were used. The scores 
are converted into a percentage of the maximum possible score for each 
domain where higher scores represent greater autonomic dysfunction. The 
maximum score is 100% (Suarez, Opfer-Gehrking et al. 1999). 
 
Psychological assessment: The psychological profile of each patient was 
assessed using the validated SCL-90 questionnaire (Derogatis, Rickels et al. 
1976). This is a 90-item self-report questionnaire that provides an assessment 
of the psychological symptom pattern and severity in various dimensions 
including anxiety and depression. The individual raw scores for anxiety and 
depression were used. Scores range from 0.005-4.05 with higher scores 
representing increased severity of symptoms. 
 
Somatic symptoms: The validated Patient Health Questionnaire 15 (PHQ 15) 
assesses the presence, type and severity of somatic symptoms and serves as a 
screening tool for somatosensory amplification (Kroenke, Spitzer et al. 2002). It 
consists of 15 symptoms, each of which can be scored 0 (not bothered by 
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symptom), 1 (bothered a little by symptom) or 2 (bothered a lot by symptom). A 
total score is calculated which can range from 0 to 30, with higher scores 
indicating a higher number of somatic symptoms. Three of the questions relate 
to GI symptoms: 1 relates to indigestion type symptoms, 1 related to bowel 
disturbance and 1 relates to abdominal pain. As we were interested in the non-
GI somatic symptoms, The PHQ15 score was recalculated (PHQ15 adj) without 
these three questions resulting in a score ranging from 0 to 24.   
 
Quality of life assessment: Health-related quality of life (QOL) was evaluated 
using the SF-36, a generic QOL tool that includes eight multi-item scales. The 
SF-36 evaluates the extent to which an individual’s health limits their physical, 
emotional, or social functioning (McHorney, Ware et al. 1993). Each scale is 
scored from 0 to 100, with higher scores indicating better health-related QOL. 
	  
	  
2.4.4 Examination and structured interview 
Structured interviews and examinations were performed by me, following a 
period of formal training from hypermobility specialists. All assessments were 
conducted blind to the results of the questionnaires.  
 
2.4.4.1 Assessment for JHS 
Diagnosis of JHS was made using the Brighton criteria (Grahame, Bird et al. 
2000), which requires the presence of a combination of major and minor 
features as described in the introduction (Table 1.5). This was assessed using a 
combination of structured interview and examination. Examination was required 
to calculate the Beighton score (Figure 1.9) and to assess for scoliosis, skin 
signs and Marfanoid habitus. 
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Beighton score: 
This is an established measure of generalised joint hypermobility based on the 
flexibility of 9 joints - back, thumbs, little fingers, knees, elbows. This was 
calculated as described in the introduction (Figure 1.9). A score of 4 or more out 
of 9 is considered indicative of generalised joint hypermobility and is a major 
criteria, whereas a score of 1-3 out of 9 satisfies a minor criteria (Table 1.5).  
 
Assessment of scoliosis 
A scoliometer was used to assess for the presence of scoliosis. The subject 
was asked to flex their back forward and the scoliometer (Figure 2.2) was 
placed at 3 different points on the back (upper, mid and lower). The angle of the 
spine was measured at each of the points and the difference between the 
largest and smallest values was calculated to give the angle of scoliosis. A 
scoliosis > 5 degrees was considered pathological.  
 
 
Figure 2.2: Assessment of scoliosis using a scoliometer. 	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Assessment of Marfanoid Habitus 
A Marfanoid Habitus was confirmed if the student had an arm span/height ratio 
>1.03 or if they had arachnodactyly. The latter was assessed using the wrist 
sign and the Steinberg sign as shown in Figure 2.3.  
 
 
Figure 2.3: Features of arachnodactyly.  
A- Wrist sign: the ability of the thumb and little finger to overlap while 
encircling the contralateral wrist. B-Steinberg sign:  the ability of the 
thumb to protrude beyond the lateral aspect of the ipsilateral palm when 
the remaining 4 digits are clenched over it  
 
Assessment of skin  
Skin was examined for the presence of papyraceous or keloid scars, for soft 
velvety texture and for the degree of stretchiness of the skin, all of which are 
associated with hypermobility. Assessment of skin stretchiness was first 
performed on the medial aspect of the forearm by pinching and stretching the 
skin (Figure 2.4).  
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Figure 2.4: Assessment of skin hyperextensibility. 
Skin is pinched and pulled at the medial aspect of the forearm. 	  	  
2.4.4.2 Skin stretch test 
A skin stretch test, which gave a corrected skin extensibility score (CSES), was 
also performed to provide an objective measure of skin stretch (Farmer, 
Douthwaite et al. 2010), as illustrated in the introduction (Figure 1.12) . Skin 
extensibility was measured by placing 2 dots on the dorsum of the left hand 
between the 2nd and 3rd metacarpals, approximately 10mm apart, and the 
distance between them was measured using an electronic caliper (+/- 0.01mm) 
A lateral force was applied to the dots, perpendicular to the metacarpals, until 
the skin was fully taut and the increase in distance between the dots was noted 
and transformed into a percentage increment. Skin fold thickness was 
measured using a Harpenden calliper. A corrected skin extensibility score 
(CSES) was calculated by dividing the percentage increment by skin thickness 
in mm (skin fold/2).  
 
2.4.4.3 Assessment for fibromyalgia 
Assessment of fibromyalgia was made using both the 1990 Wolfe criteria, which 
are considered the gold standard (Wolfe, Smythe et al. 1990), and the revised 
	   97	  
2010 ACR criteria (Wolfe 2010). The 1990 criteria requires the presence of 
more than 11 tender points out of a total 18 tested, in the presence of chronic 
widespread pain - Figure 2.5. The revised (2010) criteria requires the presence 
of insomnia and memory changes in addition to the presence of chronic 
widespread pain, and does not require a tender point assessment. Patients 
were considered to have fibromyalgia if they satisfied the 1990 or 2010 criteria.  
 
 
 
Figure 2.5: Location of 18 fibromyalgia tender points  	  	  
2.4.5 Data analysis and Statistics 
Data were described in terms of means and confidence intervals (normal ordinal 
data), medians and IQR (non-normal ordinal data) and proportions and 
confidence intervals (categorical data). Comparisons between patients with and 
without JHS were performed using the t-test (normal ordinal data), Mann 
Whitney U-test (non-normal ordinal data) and chi-squared test (categorical 
data). The associations of particular GI symptoms with JHS were investigated 
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using odds ratios adjusted for age and gender. Multivariate logistic regression 
analyses, adjusting for other factors which were significantly different in the 
groups (possible confounders) were performed to further investigate the effect 
of these factors on the association between GI symptoms and JHS. Due to 
multiple comparisons, only results of univariate comparisons with a p value < 
0.01 were interpreted as being significant. Stata IC/12.0 (StataCorp, College 
Station, Texas, USA) was used to carry out data management and statistical 
analysis in this chapter and in the other three results chapters in this thesis. 
 
The study was approved by the East London and City Research Ethic 
Committee: REC Ref: 09/H0704/72. 
 
2.5 Results 
2.5.1 Patients 
2445 new patients scheduled to attend GI clinics were sent letters a few weeks 
prior to their appointment, inviting them to participate - Figure 2.6.  273 
cancelled their appointments or did not attend, and 304 could not speak 
English, leaving 1868 potential subjects. Of these, 778 patients consented to 
take part, giving a response rate of 42%. Out of the 778, 146 did not complete 
their questionnaires, 21 did not undergo a full examination and 15 did not meet 
the inclusion criteria, leaving 596 patients who were included in the study. Of 
these 596, 44 were referred from rheumatology clinics with a known diagnosis 
of JHS (JHS-Rh), and 372 did not have JHS (Non-JHS-G). To simplify the 
group labels in the remainder of the chapter, the JHS-Rh patients will be 
referred to as JHS patients, and the Non-JHS-G will be referred to as Non-JHS 
patients. 
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Figure 2.6: Flowchart of patients recruited.  
JHS-Rh: patients referred from rheumatology clinics with an established 
diagnosis of JHS. JHS-G: patients who had been diagnosed with JHS by 
the research team. Non-JHS-G: patients in whom JHS had been excluded. 
In this study, only JHS-Rh and Non-JHS-G (bold arrows) were included. 	  	  	  
2.5.2 Demographics and hypermobility features  
JHS patients were significantly younger (34.7 ± 10.9 vs 44.2 ± 13.6, p<0.001) 
and more likely to be female (95.5% vs 54.6%, p<0.001). The JHS group had 
significantly more hypermobility features including a higher median Beighton 
score, and a higher incidence of polyarthralgia, dislocations, soft tissue injuries, 
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Marfanoid habitus, skin signs, varicose veins and organ prolapses (all p<0.001) 
- 
Table 2.1.  
 
2.5.3 Gastrointestinal symptoms in JHS vs Non-JHS  
The most common symptoms experienced weekly in JHS were bloating (89%), 
early satiety (79%), abdominal pain (66%), alternating bowel habit (66%) and 
postprandial fullness (61%). The prevalence of individual GI symptoms 
experienced at least weekly were compared in JHS and non-JHS, and adjusted 
for age and gender using an adjusted odds ratio (ORadj). The only lower GI 
symptoms which were significantly more common in JHS than in Non-JHS was 
alternating bowel habit (ORadj: 4.3, CI: 2.08-8.92) and faecal urgency 
(ORadj:2.2, CI: 1.09-4.20) - Table 2.2. 
 
Several upper GI symptoms were significantly more prevalent in JHS including 
abdominal pain (ORadj:4.7, CI: 2.3-9.6), globus (ORadj:3.6, CI: 1.8-7.2), 
dysphagia (ORadj: 3.8, CI: 1.7-8.4), regurgitation (ORadj: 3.0, CI: 1.4-6.6), 
postprandial fullness (ORadj: 3.1, CI: 1.5-6.1), early satiety (ORadj: 4.1, CI: 1.8-
9.0) and bloating (ORadj:6.0, CI: 2.3-16.0) - Table 2.3.   
 
2.5.4 Functional gastrointestinal disorders in JHS and non-JHS patients 
40 out of the 44 JHS patients (91%) were given a diagnosis of FGID, and this 
was significantly higher than in Non-JHS patients (45%, OR: 2.9, CI: 1.7-4.9, 
p<0.001).  
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Table 2.1: Comparison of features of Brighton criteria between patients 
with and without JHS.  
Values represent proportion of patients with each features. Interquartile 
ranges/confidence intervals are given in brackets. All features, apart from 
back pain, scoliosis, eye problems and hernias were significantly more 
common in JHS patients.  	  
 
 
NON - JHS 
(n=372) 
JHS 
(n=44) 
p 
 
Median beighton score 
(IQR) 
 
 
1 
(0-2) 
 
5.5 
(4-6) 
 
<0.001 
Arthralgia> 4 joints 
(CI) 
 
15.0 
(11.6-19.1) 
95.5 
(84.5-99.4) 
<0.001 
Back pain 
(CI) 
 
27.7 
(23.2-32.5) 
20.5 
(9.8-35.3) 
0.31 
Spondylosis etc 
(CI) 
 
9.1 
(6.4-12.5) 
18.2 
(8.2-13.7) 
0.06 
Dislocations/subluxations 
(CI) 
 
10.8 
(7.8-14.3) 
77.3 
(62.2-88.5) 
<0.001 
Soft tissue injury 
(CI) 
 
14.2 
(10.9-18.2) 
65.9 
(50.1-79.5) 
<0.001 
 Marfanoid habitus 
(CI) 
 
1.3 
(0.4-3.1) 
13.6 
(51.7-27.4) 
<0.001 
Skin signs 
(CI) 
 
27.7 
(23.2-32.5) 
81.8 
(67.3-91.8) 
<0.001 
Eye signs 
(CI) 
 
11.3 
(8.3-15.0) 
18.2 
(8.2-32.7) 
0.18 
Varicose veins 
(CI) 
 
10.5 
(7.6-14.0) 
31.8 
(18.6-47.6) 
<0.001 
Hernias 
(CI) 
 
7.5 
(5.1-10.7) 
6.8 
(1.4-18.7) 
0.87 
Organ prolapse 
(CI) 
 
1.9 
(0.8-13.8) 
13.6 
(5.2-27.3) 
<0.001 
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Table 2.2: Comparison of Lower GI symptoms in JHS and Non-JHS 
patients.   
Values in first 2 columns represent the percentage of patients who 
experience symptoms at least once a week. The third column represents 
the odds ratio for an association between JHS and each symptom, 
adjusted for age and gender. Confidence intervals are in brackets. 	  
 Non-JHS 
(n=372) 
 
JHS 
(n=44) 
ORadj(age,gender) 
(CI) 
p 
 
Alternating bowel 
habit 
 
 
30.4 
(25.6-35.6) 
 
 
65.8 
(49.4-79.9) 
 
4.30 
(2.08-8.92) 
 
<0.001 
 
Less than 3 bowel 
movements/week 
 
 
16.9 
(13.2-21.2) 
 
36.4 
(22.4-52.2) 
 
1.77 
(0.86-3.60) 
 
0.12 
 
More than 3 bowel 
movements/day 
 
34.3 
(29.3-39.5) 
 
 
31.8 
(18.6-47.6) 
 
0.92 
(0.45-1.87) 
 
0.82 
 
Faecal urgency 
 
 
28.5 
(23.9-33.5) 
 
 
50 
(34.6-65.4) 
 
2.15 
(1.09-4.20) 
 
0.03 
 
Straining 
 
29.6 
(24.9-34.7) 
 
44.2 
(29.1-60.1) 
 
1.53 
(0.77-3.02) 
 
 
0.22 
 
Incomplete 
evacuation 
 
 
41.2 
(36.0-46.5) 
 
61.4 
(45.5-75.6) 
 
1.67 
(0.85-3.29) 
 
0.14 
 
Blocked sensation 
 
22.7 
(18.4-27.4) 
 
34.9 
(21.0-50.9) 
 
1.58 
(0.77-3.24) 
 
 
0.21 
 
Digitation 
 
11.3 
(8.2-15.0) 
 
 
22.7 
(11.5-37.8) 
 
1.75 
(0.76-4.0) 
 
0.19 
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Table 2.3: Comparison of Upper GI symptoms in JHS and Non-JHS 
patients.  
Values given are percentage of patients who experience symptoms at 
least once a week.  
 Non-JHS 
(n=372) 
 
JHS 
(n=44) 
ORadj(age,gender) 
(CI) 
p 
 
Abdominal pain 
> 5 years  
 
31.4 
(26.2-37.0) 
 
 
65.9 
(50.1-79.5) 
 
4.69 
(2.29-9.58) 
 
<0.001 
Globus 
 
19.1 
(15.1-23.6) 
 
47.7 
(32.5-63.3) 
3.57 
(1.78-7.17) 
<0.001 
Retrosternal 
chest pain 
 
24.2 
(19.8-28.9) 
 
40.9 
(26.3-56.8) 
 
1.91 
(0.96-3.80) 
0.06 
Heartburn 
 
23.5 
(19.2-28.3) 
 
25 
(13.2-40.3) 
1.18 
(0.55-2.55) 
0.67 
Waterbrash  
 
18.5 
(14.5-22.9) 
 
29.5 
(16.8-45.2) 
1.95 
(0.92-4.14) 
0.08 
Dysphagia  
 
10.6 
(7.5-14.3) 
 
31.8 
(18.6-47.6) 
3.82 
(1.73-8.4) 
0.001 
Early satiety  
 
42.8 
(37.7-48.0) 
 
79.1 
(64.0-90.0) 
3.06 
(1.84-8.96) 
0.001 
Postprandial 
fullness 
 
27.1 
(22.6-32.1) 
 
61.4 
(45.5-75.6) 
2.14 
(1.54-6.07) 
0.001 
Epigastric pain 
 
28.4 
(23.9-33.4) 
 
51.2 
(35.5-66.7) 
2.14 
(1.09-4.22) 
0.03 
Nausea 
 
22.4 
(18.2-27.0) 
 
46.5 
(31.2-62.3) 
2.00 
(1.01-3.97) 
0.05 
Vomiting 
 
9.6 
(6.7-13.2) 
 
14.0 
(5.3-27.9) 
1.14 
(0.43-3.05) 
0.79 
Regurgitation  
 
11.4 
(8.3-15.2) 
 
33.3 
(19.6-49.5) 
3.05 
(1.4-6.6) 
0.005 
Belching 
 
33.2 
(28.3-38.4) 
 
46.3 
(30.6-62.6) 
1.80 
(0.90-3.61) 
0.10 
Bloating  
 
47.9 
(42.6-53.2) 
 
88.6 
(75.4-96.2) 
6.03 
(2.27-16.0) 
<0.001 
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2.5.5 Extra-intestinal factors in JHS and non-JHS patients - Table 2.4 
 Psychopathology 
Anxiety and depression scores were significantly higher in JHS compared to 
Non-JHS (p<0.001). 
 
Autonomic symptoms 
JHS patients had significantly higher autonomic scores for urinary symptoms 
(30 vs 0, p<0.001), orthostatic intolerance (68.75 vs 25, p<0.001), and 
vasomotor symptoms ( 56.7 vs 0, p<0.001) but not for reflex syncope (0 vs 0, 
p=0.19). The highest scores were in the orthostatic domain. 
 
Somatic symptoms 
JHS patients had significantly more somatic symptoms than did the Non-JHS 
patients as evidenced by higher median PHQ15adj scores (13.5 vs 6, p<0.001). 
 
Fibromyalgia 
57% of JHS patients satisfied either the 1990 or 2010 ACR fibromyalgia criteria, 
compared to 5% of the Non-JHS patients (p<0.001). In line with this, the JHS 
patients had significantly more chronic widespread pain (59% vs 10%, 
p<0.001), memory problems (50% vs 15%, p<0.001), insomnia (67% vs 28%, 
p<0.001) and a higher median number of tender points (8.5 vs 0, p<0.001). 	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Table 2.4: Autonomic scores, somatic symptoms scores and fibromyalgia 
features in JHS and Non-JHS patients.  
CWP: Chronic widespread pain. Values given are medians and 
interquartile ranges, or proportions and 95% confidence intervals 	  
 NON-JHS 
(n=372) 
JHS 
(n=44) 
p 
 
PSYCHOPATHOLOGY- SCL90 
 Median anxiety score 
(IQR) 
 
0.30 
(0.005-0.805) 
0.80 
(0.405-1.95) 
<0.001 
Median depression score 
(IQR) 
 
0.62 
(0.24-1.31) 
1.005 
(0.62-2.04) 
<0.001 
 
AUTONOMIC SYMPTOMS – COMPASS QUESTIONNAIRE 
Urinary  
(IQR) 
 
0 
(0-20) 
30 
(10-45) 
<0.001 
Orthostatic intolerance  
(IQR) 
 
25 
(0-43.75) 
68.75 
(56.25-81.25) 
<0.001 
Reflex Syncope 
(IQR) 
 
0 
(0-0) 
0 
(0-0) 
0.19 
Vasomotor  
(IQR) 
 
0 
(0-0) 
56.7 
(37.8-63) 
<0.001 
 
SOMATIC SYMPTOMS – PHQ15 without GI questions 
Median PHQ15adj score 
 
6 
(3-9) 
13.5 
(10.5-16) 
<0.001 
 
FIBROMYALGIA 
% with Fibromyalgia  
(CI) 
 
4.6 
(2.7-7.2) 
56.8 
(41.0-71.7) 
<0.001 
Median tender points  
(IQR) 
 
0 
(0-2) 
8.5 
(2-13) 
<0.001 
% CWP  
(CI) 
 
10.5 
(7.6-14.1) 
59.1 
(43.2-73.7) 
<0.001 
% with Insomnia  
(CI) 
 
28.5  
22.9-34.8) 
66.7  
(43.0-85.4) 
<0.001 
% with Memory problems  
(CI) 
 
14.7  
(10.5-19.9) 
50.0  
(27.2-72.8) 
<0.001 
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Table 2.5: Medication use in JHS and Non-JHS patients.  
Values given represent the percentage of patients who were on each class 
of medication. Confidence intervals are shown in brackets. JHS patients 
were more likely to be on opiates, NSAIDs, antidepressants and 
neuromodulators. PPI: Proton Pump inhibitors 	  
Class of medication 
 
NON-JHS 
(n=372) 
 
JHS 
(n=44) 
p 
 
Opiates  
(CI) 
 
 
8.6 
(5.6-11.9) 
 
29.6 
(16.8-45.2) 
 
<0.001 
Antidepressants  
(CI) 
 
7.0 
(4.6-10.1) 
25.0 
(13.2-40.0) 
<0.001 
NSAIDS 
(CI) 
 
5.6 
(2.5-7.5) 
20.4 
(9.8-5.3) 
<0.001 
Anxiolytics 
(CI) 
 
1.1 
(0.3-2.7) 
2.3 
(0-12.0) 
0.84 
Neuromodulators 
(CI) 
 
1.6 
(0.6-3.5) 
6.8 
(1.4-18.6) 
0.02 
Antispasmodics 
(CI) 
 
5.6 
(3.5-8.5) 
4.6 
(0.6-15.5) 
0.76 
Prokinetics 
(CI) 
 
7.5 
(5.1-10.7) 
6.8 
(1.4-18.7) 
0.87 
PPI 
(CI) 
 
26.3 
(5.1-10.7) 
22.7 
(11.5-37.8) 
0.60 
Steroids 
(CI) 
 
2.3 
(0-12.0) 
2.4 
(0.2-2.8) 
0.95 
Bisphosphonates 
(CI) 
 
0 
(0-8.0) 
1.1 
(0-1.7) 
0.49 
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Medication use - Table 2.5 
JHS patients were significantly more likely to be on analgesics including opiates 
(30% vs 9%, p<0.001) and NSAIDS (20% vs 5%, p<0.001), and were 
significantly more likely to be on antidepressants (25% vs 7%, p<0.001). A 
higher proportion of JHS patients were on neuromodulators such as pregabalin 
(7% vs 2%, p=0.02), but this was not significant by the statistical parameters set 
a priori for this study. There was no difference in the use of PPI’s, prokinetics 
(e.g. domperidone), anxiolytics (e.g. diazepam), antisapasmodics (e.g. 
mebeverine), steroids or bisphosphonates - Table 2.5.  
	  
2.5.6 Factors mediating association between JHS and GI symptoms  
Based on univariate analyses, several factors were significantly associated with 
JHS and were thus potential confounders. These included orthostatic, urinary 
and vasomotor autonomic factors, fibromyalgia, anxiety, depression, 
somatosensory factors (PHQ15adj), analgesic and antidepressant use. These 
factors were evaluated using multiple logistic regression analyses in a stepwise 
fashion by adding them to a model containing JHS phenotype, age and gender 
as fixed variables, and GI symptoms associated with JHS  (from Table 2.2 and 
Table 2.3) as dependent variables. 
	  
Anxiety, depression and antidepressant use did not have a significant effect on 
the odds ratios and were therefore not confounders. Fibromyalgia, opiate and 
NSAID use, somatic symptom scores and autonomic scores had an effect on 
the odds ratios for at least some of the symptoms, and were therefore either 
partly or wholly mediating the association between JHS and the GI symptoms – 
Table 2.6. 
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Table 2.6: Influence of medication, fibromyalgia, somatic symptoms, and 
autonomic symptoms on the association between JHS and GI symptoms.  
Values given are odds ratios adjusted for various factors. Confidence 
intervals are shown in brackets. Asterisks mark GI symptoms where the 
association between JHS and the symptom remains significant even after 
the addition of the above factors. A:Age, G:Gender, M:Opiate and NSAID 
Medication, FM: Fibromylagia, Aut: Autonomics, PHQ: Adjusted PHQ15 
score (PHQ15adj). All: Fibromyalgia, autonomics, PHQ15adj 	  	  
Symptom 
 
ORadj 
(A,G) 
ORadj 
(A,G,Med) 
ORadj 
(A,G,FM) 
ORadj 
(A,G,Aut) 
ORadj 
(A,G,PHQ) 
ORadj 
(All) 
 
Alternating 
bowel habit * 
 
 
 
4.3 
(2.1-8.9) 
 
 
3.6 
(1.7-7.6) 
 
5.9 
(2.4-14.7) 
 
2.69 
(1.2-6.2) 
 
3.6 
(1.7-7.6) 
 
3.9 
(1.5-10.2) 
Abdominal 
pain > 5 yrs * 
 
 
4.7 
(2.3-9.6) 
 
4.8 
(2.25-10.2) 
4.2 
(1.9-9.4) 
3.7 
(1.6-8.6) 
4.7 
(2.2-10.2) 
4.3 
(1.7-10.4) 
Globus 
 
 
 
3.6 
(1.8-7.2) 
 
2.3 
(1.1-5.0) 
2.9 
(1.3-6.5) 
1.5 
(0.7-3.6) 
1.8 
(0.8-3.9) 
1.4 
(0.6-3.6) 
Dysphagia 
 
 
 
3.8 
(1.7-8.4) 
 
2.2 
(0.9-5.3) 
2.3 
(0.9-5.9) 
1.3 
(0.5-3.5) 
1.6 
(0.7-3.8) 
1.2 
(0.4-3.2) 
Regurgitation 
 
 
 
3.0 
(1.4-6.6) 
 
2.4 
(1.0-5.7) 
2.4 
(0.9-6.1) 
1.3 
(0.5-3.5) 
1.6 
(0.7-3.9) 
1.1 
(0.4-3.2) 
Early satiety 
 
 
 
4.1 
(1.8-9.0) 
 
3.8 
(1.7-8.7) 
2.7 
(1.1-6.4) 
2.1 
(0.8-5.2) 
2.3 
(1.0-5.2) 
1.6 
(0.6-4.2) 
Postprandial 
fullness 
 
 
3.1 
(1.5-6.1) 
 
2.3 
(1.1-4.8) 
1.8 
(0.8-4.1) 
1.3 
(0.6-3.1) 
1.4 
(0.6-3.0) 
1.0 
(0.4-2.5) 
Bloating * 
 
 
 
6.0 
(2.3-16.0) 
 
5.3 
(2.0-14.4) 
5.1 
(1.8-14.6) 
3.2 
(1.1-9.5) 
4.4 
(1.6-12.1) 
3.2 
(1.1-10.0) 
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Opiate and NSAID use had no significant effect on the multivariate model, and 
only weakened the association between JHS and GI symptoms but did not 
abolish it. In contrast, autonomic and somatic symptom scores had a dramatic 
effect on the association between JHS and GI symptoms, reducing the odds 
ratios considerably, and resulting in a loss of significance of association 
between JHS and most symptoms except for alternating bowel habit, abdominal 
pain and bloating - Table 2.6.  The presence of fibromyalgia did not have as 
marked an effect as did autonomic and somatic factors -  its largest effect was 
on symptoms of  postprandial fullness, regurgitation and dysphagia, and for 
these symptoms it reduced the odds ratios considerably.  
 
Thus there was a differential effect of the extra-intestinal factors on different 
groups of symptoms. The association between JHS and alternating bowel habit, 
bloating and abdominal pain was independent of all the above factors. In 
contrast, the association between JHS and gastro-oesophageal symptoms 
seemed to be dependent on the various extra-intestinal factors, particularly the 
autonomic and somatosensory amplification factors. 
 
Out of all the autonomic domains, only the orthostatic and urinary domains were 
significantly associated with symptoms. Orthostatic scores were independently 
associated with globus, dysphagia, early satiety, postprandial fullness and 
bloating.  For each of these symptoms, the odds of having the symptom 
increased by 1.01 for each 1-point increase in orthostatic score (OR: 1.01, CI: 
1.001-1.02). Urinary scores were independently associated with regurgitation, 
dysphagia and globus, with a 0.02 increase in the odds of the symptom per 1-
point increase in urinary score (OR: 1.02, CI: 1.01-1.03). The syncope and 
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vasomotor domains were not independently associated with any of the GI 
symptoms.  
	  
2.5.7 Quality of Life  
Quality of life scores in JHS were very low, particularly for all the physical 
domains (all with median scores less than 25), social functioning (score: 25) 
and pain (score: 23). These were significantly lower than in the non-JHS 
patients (all p<0.001). There was no difference in HRQOL scores for the 
emotional domains - Table 2.7.  
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Table 2.7: Quality of life scores in JHS and Non-JHS patients. 
Values given are the median quality of life scores, and corresponding 
interquartile ranges, for each of the 8 domains of the SF36. JHS patients 
had significantly worse quality of life on all but the emotional domains. 
	  
QUALITY OF LIFE 
SF36 
 
NON-JHS 
(n=372) 
JHS 
(n=44) 
p 
 
General health 
(IQR) 
 
 
50 
(30-65) 
 
22.5 
(15-40) 
 
<0.001 
Pain  
(IQR) 
 
57 
(32-80) 
22 
(0-32) 
<0.001 
 Energy/fatigue  
(IQR) 
 
50 
(30-65) 
25 
(10-45) 
<0.001 
Physical functioning  
(IQR) 
 
85 
(55-100) 
22.5 
(10-50) 
<0.001 
Role-limiting physical  
(IQR) 
 
75 
(0-100) 
0 
(0-0) 
<0.001 
 Social functioning  
(IQR) 
 
62 
(37-100) 
25 
(0-43.5) 
<0.001 
 Emotional wellbeing 
(IQR) 
 
72 
(52-84) 
64 
(44-80) 
0.13 
Role-limiting 
emotional 
(IQR) 
 
100 
(33-100) 
83 
(33-100) 
0.55 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	   112	  
2.6 Discussion 
2.6.1.1 Summary of findings 
This is the first comparative study of GI symptoms in patients with and without 
JHS in a gastroenterology setting. The main findings are: (1) JHS is significantly 
associated with abdominal pain, alternating bowel habit, globus, dysphagia, 
regurgitation, postprandial symptoms, and bloating even when correcting for 
differences in age and gender; (2) JHS patients have a significantly higher 
prevalence of FGID compared to patients without JHS; (3) JHS is significantly 
associated with autonomic symptoms, measures of somatic pain, 
psychopathology and increased analgesic and antidepressant use; (4) the 
association of JHS with upper GI symptoms is accounted for by autonomic 
symptoms and measures of somatic sensitivity (PHQ15adj and fibromyalgia); 
however alternating bowel habit, abdominal pain and bloating are not 
significantly influenced by any of the extra-intestinal factors; (5) quality of life in 
all but the emotional domains is markedly reduced in JHS patients. 
 
2.6.1.2 Comparison with previous studies 
The hypermobility features in our JHS group ( 
Table 2.1) are very similar to those reported previously (Celletti, Castori et al. 
2011), suggesting that the JHS patients in our study are typical of those seen in 
specialist centres, thus enabling comparisons with other studies. The 
observation of high levels of abdominal pain, alternating bowel habit, bloating 
and dysphagia is consistent with previous studies of similar patients in non-GI 
settings (Hakim and Grahame 2004; Castori, Camerota et al. 2010; Rombaut, 
Malfait et al. 2011). However, with the presence of a GI control group in our 
study, it can be further concluded that not only are these symptoms common in 
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the JHS group, but they are more frequently reported than in other GI patients. 
High levels of nausea in JHS were previously reported in comparison with 
healthy controls (Hakim and Grahame 2004), but this was not replicated here. 
This may be due to the fact that nausea is a common symptom in a GI clinic, 
and therefore differences would not necessarily be found in comparison with a 
GI control group. The association demonstrated with globus is, to our 
knowledge, a newly reported one. In the absence of comprehensive GI 
questionnaires, this is not a symptom that would necessarily be elicited by non-
GI specialists, which may explain this seemingly new finding. However these 
observations are not unfounded - laryngo-pharyngeal problems have been 
documented previously (Rombaut, Malfait et al. 2011), and features of ‘globus’ 
may have been observed in these patients. Lastly, the findings in this study add 
specificity to those suggesting a high prevalence of gastro-oesophageal reflux 
and dyspepsia in JHS (Castori, Camerota et al. 2010). Gastro-oesophageal 
reflux symptoms include heartburn, waterbrash and regurgitation and the 
results in this chapter demonstrate that it is only regurgitation that is significantly 
increased. Likewise, the term ‘dyspepsia’ describes both epigastric pain and 
postprandial distress type symptoms (early satiety and postprandial fullness), 
but it is only the latter which was observed to be overrepresented in this study.  
 
Interestingly an association between JHS and FGID was present, and 91% of 
the JHS patients were eventually given a functional, as opposed to organic, GI 
diagnosis. The presence of FGID in JHS has only previously been documented 
as an observation in JHS patients attending urology, neurogastroenterology and 
genetics clinics, but has never been compared to a suitable control group 
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(Manning, Korda et al. 2003; Zarate, Farmer et al. 2009; Castori, Camerota et 
al. 2010). Therefore the association documented here is a new finding.  
 
The presence of associated extra-intestinal factors cannot be ignored, as they 
are implicated in the development of gastrointestinal symptoms, particularly in 
the case of FGID. In accord with previous studies there was a significant 
association between JHS and autonomic symptoms (Gazit, Nahir et al. 2003; 
Rombaut, Malfait et al. 2011), fibromyalgia (Ofluoglu, Gunduz et al. 2006), 
somatosensory amplification, anxiety and depression (Baeza-Velasco, Gely-
Nargeot et al. 2011; Baeza-Velasco, Gely-Nargeot et al. 2011) and with opiate 
and antidepressant use (Rombaut, Malfait et al. 2011). Orthostatic symptom 
scores were particularly high in JHS and this may be due to underlying PoTS in 
these patients (Mathias, Low et al. 2011).  
 
In order to determine the effects of these extra-intestinal factors on the 
association between JHS and GI symptoms, they were added stepwise to a 
logistic regression model. Interestingly, the presence of psychopathology and 
medication use did not significantly confound the association between JHS and 
symptoms, suggesting that GI symptoms in JHS are not secondary to those 
factors. In contrast, autonomic scores and somatic hypersensitivity (fibromylagia 
presence and increasing PHQ15adj scores) were important confounders, 
particularly for the postprandial and oesophageal symptoms, as their inclusion 
into the regression model completely abolished the independent association 
originally observed between GI symptoms and JHS. This would suggest that 
presence of upper GI symptoms in JHS are dependent on the presence of 
autonomic and somatic symptoms.  
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Out of all the factors, the addition of the autonomic scores caused the greatest 
reduction in the strength of the association between JHS and all the GI 
symptoms, suggesting that this factor was the most important confounder - 
Table 2.6. Of all the autonomic domains, the orthostatic domain appeared to be 
most important not only because scores were higher than in any other domain 
but also because orthostatic factors mediated the association with wide-ranging 
upper GI symptoms (globus, dysphagia, early satiety, postprandial fullness and 
bloating). 
 
Although is difficult at present to propose a mechanistic explanation for the 
association between orthostatic autonomic symptoms and gastro-oesophageal 
symptoms, this finding is supported by several observations in the literature. 
Firstly, it has been observed that patients with PoTS, regardless of the 
presence of JHS, frequently have GI symptoms including nausea, reflux, 
alternating bowel habit and bloating (Mathias, Low et al. 2011). Secondly, in a 
study using electrogastrograms in PoTS patients compared to healthy controls, 
PoTS patients had increased variability of the gastric pacemaker rhythm pre 
and postprandially, and in those with known GI symptoms, the postprandial 
changes were more marked (Seligman, Low et al. 2012). Hence there is 
evidence that orthostatic intolerance, as seen in PoTS, is associated with 
postprandial and other GI symptoms. 
 
It is interesting that the association between JHS and abdominal pain, 
alternating bowel habit and bloating remained significant even after the addition 
of all the extra-intestinal factors to the regression model. This suggests that the 
mechanism for these symptoms involves factors other than just autonomic 
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dysfunction and hypersensitivity. Possibilities include altered compliance of the 
viscera, which is known to be associated with functional dyspepsia, a functional 
GI disorder associated with symptoms of abdominal pain and bloating 
(Oustamanolakis and Tack 2012). Another possibility is intestinal dysbiosis. The 
latter is particularly plausible as small bowel bacterial overgrowth is known to be 
associated with symptoms of abdominal pain, altered bowel habit and bloating 
in GI patients (Simren, Barbara et al. 2013) but has not yet been investigated in 
JHS.  
 
Putting all this together it would appear that the upper and lower GI symptoms 
arise by different mechanisms in JHS patients, and that autonomic factors are 
involved in the association of JHS with all the observed GI symptoms. For the 
gastro-oesophageal symptoms, autonomic factors interact with somatic factors 
to mediate the symptom association seen in JHS. This concept is not novel –
several published studies have demonstrated that the somatic hypersensitivity 
seen in fibromyalgia, IBS and other functional somatic syndromes is associated 
with abnormal autonomic function (Scully, McKernan et al. 2010; da Cunha 
Ribeiro, Roschel et al. 2011; White 2012).  
 
Finally, quality of life in JHS was significantly worse in the physical, social, but 
not the emotional, domains. This is expected as the JHS patients had 
significantly more musculoskeletal symptoms than did the non-JHS patients ( 
Table 2.1). However, what is interesting is that the QOL scores in this JHS 
group presenting to GI clinics, were worse than that reported in a previous 
study of JHS patients with predominantly musculoskeletal complaints 
(Rombaut, Malfait et al. 2010). This suggests that the presence of GI and other 
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associated symptoms in JHS causes further deterioration in quality of life and 
further impairs physical and social functioning.  
 
2.6.1.3 Limitations 
The current study was not without its limitations. Firstly, it is not unforeseeable 
that selection bias may have occurred and that JHS patients with more severe 
GI symptoms would have been more likely to take part, thus exaggerating the 
observed differences seen. However, our interest lay more in the pattern of 
symptoms and in the influence of various factors, which would have been less 
affected by selection bias. Secondly, as it was a questionnaire study it was 
prone to recall bias, and so patients with multiple symptoms may have been 
more enthusiastic in responding positively to the questions. However, if this 
were truly the case, we would have observed an increase in all reported GI 
symptoms and not only a particular selection, which turned out to be compatible 
with several previous findings.   
 
The main limitation however, was that the JHS patients included in this study 
were an extremely selected group of patients. Not only had they presented to 
tertiary rheumatology clinics, but they were further referred for GI assessment. 
According to a previous study, 37% of JHS patients attending rheumatology 
clinics have significant GI symptoms (Hakim and Grahame 2004).  Hence the 
JHS patients in our study represent a small subset of the patients who present 
to hypermobility clinics, which are not necessarily representative of the majority 
of JHS individuals anyway as most JHS individuals remain undiagnosed and do 
not even see a rheumatologist (Grahame 2008).This is evident from Figure 2.6 
which demonstrates that 180 other patients in that cohort satisfied the 
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diagnostic criteria for JHS but had not seen a rheumatologist nor had they been 
previously diagnosed with JHS.  
 
Although it would appear that we selected a very biased group of JHS patients 
for this study, these were exactly the type of patients we were interested in 
investigating for a number of reasons. Firstly, these were the type of patients 
who were the subject of previous studies, and we were interested to find out 
how valid previous findings were and how they compared to a GI population 
without JHS. Secondly, these patients represent those at the more severe end 
of the scale with greatest comorbidity and lowest quality of life (Rombaut, 
Malfait et al. 2010; Voermans and Knoop 2010; Rombaut, Malfait et al. 2012) 
and so they are clinically the most important. Lastly, these are the patients who 
will ultimately be referred to gastroenterology services and present in clinics and 
so from a gastroenterology point of view they are an important group to study.  
 
With all these points in mind however, it should be remembered that because 
the JHS patients were highly selected, these results are only applicable to a 
small subset of JHS patients and it is impossible draw any firm conclusions from 
them. To determine if the concept of an association between JHS and GI 
symptoms and functional GI disorders is true and not just a by-product of 
severe selection and response bias we would need to demonstrate that it is 
present in other groups of JHS individuals, ideally in unselected individuals who 
are unaware of their JHS status. Firstly, to prove that GI symptoms are truly 
associated with JHS we would need to demonstrate the same GI symptom 
association in healthy subjects with JHS.  This is the subject of chapter 3. 
Secondly, we would need to demonstrate that in an unselected group of GI 
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patients who are unaware of their JHS status, there exists an association 
between JHS and FGID – this is the subject of chapter 4. Finally, in order to 
confirm the importance of autonomic and somatic factors in the GI association 
of JHS, we would need to demonstrate that these factors are common in 
previously undiagnosed JHS patients, and that they are involved in the GI 
association observed in JHS  - this is also the subject of chapter 4.   
 
2.6.1.4 Clinical implications 
With increasing knowledge and recognition of JHS, more of these patients will 
be referred to gastroenterology clinics. These will be the patients with 
widespread GI and extra-intestinal symptoms, including chronic pain and 
functional somatic syndromes, and those in whom quality of life is dismal 
despite their young age and seeming normality. It is important to elicit these 
extra-intestinal symptoms as they have an important impact on GI symptoms 
and may influence efficacy of treatments. In the absence of evidence on the 
best treatment approach for these patients, a holistic approach involving pain 
specialists, rheumatologists, autonomic neurologists, and the prescription of 
neruomodulators, does not seem unreasonable.  
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Chapter 3 Association of  Gastrointestinal Symptoms with the Joint Hypermobility  Syndrome in Healthy Subjects 
Association of Gastrointestinal Symptoms with the 
Joint Hypermobility Syndrome in Healthy Subjects 
3.1 Introduction 
GI symptoms are present in 37-86% of JHS patients attending rheumatology 
and genetics clinics (Hakim and Grahame 2004; Castori, Camerota et al. 2010; 
Rombaut, Malfait et al. 2011), and are increased compared to healthy controls 
(Hakim and Grahame 2004). This association has been refined further in 
Chapter 2 where GI symptoms were characterised in patients with JHS and it 
was demonstrated that symptoms  of alternating bowel habit, abdominal pain, 
bloating, postprandial discomfort, globus, dysphagia and regurgitation were 
over-represented in JHS patients, and were increased compared to non-
hypermobile GI controls. Furthermore the combination of GI symptoms and JHS 
was associated with a worse quality of life compared to patients with GI 
symptoms but without JHS.  
 
In addition, it was demonstrated that autonomic factors, anxiety, depression , 
somatosensory amplification, chronic pain, fibromyalgia and opiate use were 
overrepresented in the JHS patients studied, as reported in other studies of 
JHS patients (Gazit, Nahir et al. 2003; Ofluoglu, Gunduz et al. 2006; Baeza-
Velasco, Gely-Nargeot et al. 2011; Castori, Celletti et al. 2011; Rombaut, Malfait 
et al. 2011; Castori, Morlino et al. 2012). Both autonomic and somatic factors, 
but not psychopathology or opiate use, mediated the association between JHS 
and the upper GI symptoms, supporting current opinion that autonomic and 
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somatic factors are involved in the generation of extra-articular symptoms in 
JHS patients (Gazit, Nahir et al. 2003; Hakim and Grahame 2004; Castori, 
Celletti et al. 2011). 
 
The observations relating to JHS in Chapter 2 and in previously published 
studies were all based on highly selected and highly symptomatic subjects, 
attending tertiary or specialist clinics, and probably represented a very extreme 
end of the JHS spectrum. This limits the ability to generalise these findings to 
the JHS population as a whole and therefore restricts the conclusions that can 
be drawn from them. A population based study of non-patients would address 
all these issues. 
 
Population based studies are free from biases present in patients studies, as 
they involve relatively healthy people who are not seeking medical attention. 
Thus conclusions drawn are more representative of the general population, and 
allow an estimation of the population prevalence of various factors. Such 
population studies of GI symptoms in JHS are lacking. 
 
3.2 Aims 
The aim of this study was to reproduce the patient study described in Chapter 
2, but this time in a population of healthy individuals, to determine how 
generalisable our earlier findings were. Specifically, (1) to determine and 
compare the prevalence of individual GI symptoms and other associated factors 
in a population of healthy subjects with and without JHS; (2) to determine what 
factors were predictive of GI symptom presence in JHS in this population (3) to 
determine the influence of possible confounders on the association between 
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JHS and GI symptoms; and (4) to examine the effect of JHS on quality of life in 
non-patients.  
 
3.3 Hypothesis 
We hypothesised that GI and other extra-articular symptoms would be present 
in JHS non-patients, albeit at a lower prevalence than that quoted in previous 
studies of JHS patients. Furthermore, we expected upper GI symptoms to be 
associated with autonomic and hypersensitivity factors (as shown in the patient 
study in Chapter 2). We also hypothesised that subjects with JHS would have a 
worse quality of life than those without JHS.  
 
3.4 Materials and methods 
3.4.1 Study design 
A cross sectional study in Queen Mary University Students was performed. The 
first part of the study involved the completion of the validated hypermobility 
screening questionnaire online (Hakim and Grahame 2003). Those who 
screened positive (score ≥ 2 out of 5) and negative (score 0 out of 5) were 
further invited to the second part of the study where they were assessed for 
JHS and fibromyalgia and then completed a set of validated questionnaires as 
described below. Comparisons were made between students with and without 
confirmed JHS. 
 
3.4.2 Subjects 
All 12,000 students at QMUL were invited to participate in the first part of the 
study via a university-wide email that contained a link to an online hypermobility 
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questionnaire and an attachment containing the information sheet for the study. 
Those that screened positive and negative and who had supplied their contact 
details were further invited to the second part of the study if they were between 
the ages of 16 and 35, and had a sufficient understanding of written English to 
be able to answer the questionnaires. Written consent was taken from all the 
subjects. The study was approved by Queen Mary Research Ethics Committee, 
Ref: QMREC2011/42. 
 
3.4.3 Questionnaires 
Hypermobility Screening Questionnaire 
For the first part of the study, subjects completed the validated hypermobility 
questionnaire online . Answering in the affirmative to at least 2 of the 5 
questions was considered a positive screen, as recommended for that 
questionnaire (Hakim and Grahame 2003). For the purposes of the study, a 
score of 0 was considered a negative screen.  
 
For the second part of the study, subjects completed validated questionnaires 
to systematically assess for GI symptoms, psychopathology, autonomic 
symptoms, somatic symptoms and quality of life. Demographic information and 
medication histories were also collected via standardized forms. Subjects were 
asked to provide details of past medical history – specifically they were asked 
whether they had ever consulted their GP or attended a hospital for GI 
problems, and whether they had been given a diagnosis of IBS.  
 
 
 
	   124	  
GI symptom assessment:  
The Bowel Disease Questionnaire (BDQ) (Talley, Phillips et al. 1990) was used  
to obtain a detailed assessment of GI symptoms experienced over the past 6 
months, as described in Chapter 2. For this study, GI symptoms were 
considered to be present if they were experienced at least a few times per 
month.  
 
Autonomic symptom assessment:  
The validated Composite Autonomic Symptom Scale (COMPASS 
questionnaire), as described in Chapter 2, was used to obtain a detailed 
assessment of autonomic symptoms (Suarez, Opfer-Gehrking et al. 1999).  
Scores are provided for various autonomic domains including constipation, 
gastrointestinal, diarrhoea, urinary, vasomotor, syncope, pupillary, 
secretomotor, sleep, psychosomatic and erectile dysfunction. A composite 
score for all autonomic symptoms can also be calculated.  For this study, the 
composite score and the score for all the individual domains except for erectile 
dysfunction were used. 
 
Psychological assessment:  
The Hospital Anxiety and Depression Scale (HADS)  (Zigmond and Snaith 
1983) is used to determine the levels of anxiety or depression a person is 
experiencing. It consists of 14 items – 7 relating to anxiety and 7 to depression. 
Each question can be scored from 0-3, thus scores for each of anxiety or 
depression can range from 0-21, with higher scores indicating a higher severity 
of symptoms.  Scores of 11 or more out of 21 are considered indicative of the 
presence of anxiety or depression. 
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Somatic symptoms: 
The validated Patient Health Questionnaire 15 (PHQ 15), which was described 
in detail in Chapter 2, was used to assess for somatosensory amplification 
(Kroenke, Spitzer et al. 2002). All 15 items were used, giving a total score 
between 0 and 30, with higher scores indicating a higher number of somatic 
symptoms.  	  
Quality of life assessment:  
Health-related QOL was evaluated using the SF-36, as described in Chapter 2 
(McHorney, Ware et al. 1993).  
 
3.4.4 Examination and structured interview 
This was performed after written consent was taken and before questionnaires 
were completed so that the assessment of JHS and fibromyalgia was performed 
blinded to the subjects’ symptoms. 
 
Assessment of JHS 
Diagnosis of JHS was made using the Brighton criteria (Grahame, Bird et al. 
2000), as described in Chapter 2.   
 
Skin stretch test 
Skin was examined for texture, striae, scarring  and for the degree of 
stretchiness of the skin, as described in Chapter 2.  
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Assessment for fibromyalgia 
This was performed as described in Chapter 2. Subjects were considered to 
have fibromyalgia if they satisfied the 1990 or 2010 ACR criteria (Wolfe, Smythe 
et al. 1990; Wolfe 2010). 
 
3.4.5 Blinding 
To ensure blinding of the students to their JHS status, they were not informed of 
their hypermobility status until after they had completed the questionnaires. 
They were also blinded to the exact aim of the study and told that the study was 
being performed to determine if there was a link between skin and joint 
characteristics and the presence of GI and other symptoms – they were not 
informed what those skin and joint characteristics were. This reduced the 
likelihood of response bias in answering the questionnaires.  To ensure blinding 
of the researcher to the presence of GI symptoms in the students, the 
assessment for JHS and fibromyalgia was performed before students 
completed the questionnaires. Once completed, questionnaires were placed in 
a sealed envelope and then handed to a research assistant for transcription 
onto an electronic database. A unique ID code was used to match examination 
findings with questionnaire responses on the database and prevented 
recognition of individual students therefore reducing bias when analysing the 
results.   
 
3.4.6 Data analysis and Statistics 
Univariate analysis 
Data were described in terms of means and confidence intervals (normal ordinal 
data), medians and IQR (non-normal ordinal data) and proportions and 
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confidence intervals (categorical data). Comparisons of GI and associated 
factors in students with and without JHS were performed using the t-test 
(normal ordinal data), Mann Whitney U-test (non-normal ordinal data), chi 
squared test (categorical data) or Fisher’s exact test (categorical data if 
proportions were less than 5%).  
 
Identification of factors independently associated with GI symptoms 
To determine which factors (independent of JHS) predicted GI symptoms, a 
multivariate stepwise logistic regression analyses was performed with the GI 
symptom of interest as the dependent variable, and JHS status and all other 
measured factors as the independent variables. This produced a regression 
model of best fit, which included all those factors that were independently 
associated with the GI symptom of interest , at a significance level of <0.05.  
 
Effect of possible confounding factors on the regression model of best fit 
Possible confounders were identified as those factors that were associated with 
both JHS and GI symptoms, in this study, or in Chapter 2. To determine the 
effect of these factors on the association between JHS and individual GI 
symptoms, a stepwise logistic regression analysis was performed. The initial 
regression model contained JHS, age and gender as fixed variables, as well as 
any other factors which were present in the regression model of best fit and 
therefore independently associated with the GI symptom of interest. Factors 
identified as potential confounders were added individually to the initial model 
and the effect on the odds ratio between JHS and GI symptoms was observed. 
Factors which decreased the odds ratio considerably, were considered to 
confound or mediate the association between JHS and GI symptoms.  
	   128	  
3.5 Results 
3.5.1 Subjects 
All 12,000 students at Queen Mary University London were invited, via email, to 
complete the online hypermobility screening questionnaire (Figure 3.1). 1998 
students completed the questionnaire but only 1576 supplied their contact 
details. Of the 1576, 497 had negative screens (score=0/5), 575 had positive 
screens (score ≥ 2/5), and 504 scored 1/5. Of the 575 positive screens, 125 
consented to attend the second part of the study; on assessment only 74 of 
these had JHS (screen positive and JHS positive). Of the 497 negative screens, 
98 consented to attend the second part of the study; on assessment 88 were 
confirmed not to have JHS (screen negative, JHS negative) (Figure 3.1). Thus  
73 JHS students and 89 non-JHS students were finally included in the study.  
 
3.5.2 Demographics and hypermobility features  
There were no significant gender differences in the 2 groups - Table 3.1. JHS 
students were significantly younger (21.6 vs 22.8, p=0.048) and had a lower 
BMI (22.0 vs 23.4, p=0.05). The JHS students were also more likely to be White 
(69% vs 52%, p=0.02), and more likely to drink alcohol (86% vs 72%, p=0.02) – 
Table 3.1. Students with JHS had a higher median Beighton score (5 vs 1, 
p<0.001) - Figure 3.2. They also had a significantly higher incidence of other 
hypermobility features including polyarthralgia, scoliosis, dislocations, soft 
tissue injuries, Marfanoid habitus, skin signs, and affected first degree relative 
(all p<0.005) - Table 3.2. JHS students also had higher skin extensibility scores 
(Median CSES: 15 vs 11, p<0.001)  - Figure 3.3. 
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Figure 3.1: Flowchart of subject selection for Chapter 3. 
Of the 1576 students who completed the screening questionnaire and 
supplied their contact details, 497 had negative screens and 575 had 
positive screens. 98/497 negative screens and 118/575 positive screens 
attended the second part of the study. After examination, 88 students 
without JHS and 74 students with JHS were included.   	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Figure 3.2:  Beighton scores in students with and without JHS.  
The dotted line represents a score of 4 out of 9 which is the cut-off for 
GJH. 
 
 
 
 
Figure 3.3:  Skin extensibility (CSES) in students with and without JHS. 
The dotted line represents a CSES of 18 which has the highest sensitivity 
and specificity for discriminating between those with GJH 
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Table 3.1 Comparison of demographic features in students with and 
without JHS.  
Values given are percentages of students and the 95% confidence 
intervals for each group. BMI: Body Mass Index 	  
 No JHS 
(n=88) 
JHS 
(n=74) 
p 
 
Female (%) 
(CI) 
 
 
53.4 
(42.8-62.0) 
 
64.9 
(53.7-76.0) 
 
0.14 
Mean age  
(CI) 
 
22.8  
(22.0-23.7) 
21.6  
(20.7-22.5) 
0.05 
BMI  
(CI) 
 
23.4  
(22.3-24.5) 
22.04  
(21.3-22.8) 
0.05 
 
Ethnicity 
 
Asian (%) 
(CI) 
 
28.4 
(18.8-38.0) 
16.4 
(7.7-25.1) 
0.07 
Black (%) 
(CI) 
 
3.4 
(0.5-7.3) 
1.4 
(0-4.1) 
0.4 
White (%) 
(CI) 
 
52.3 
(41.6-62.9) 
68.9 
(59.1-80.6) 
0.02 
Chinese (%) 
(CI) 
 
6.8 
(1.4-12.2) 
2.7 
(1.1-6.6) 
0.24 
Mixed (%) 
(CI) 
 
4.6 
(0.1-9.0) 
8.1 
(1.8-14.7) 
0.34 
Other (%) 
(CI) 
4.5 
(0.1-9.0) 
 
1.4 
(0-4.1) 
0.25 
 
Social History 
 
Smoker (%) 
(CI) 
 
13.6 
(6.3-20.9) 
13.5 
(5.5-21.5) 
0.98 
Alcohol use (%) 
(CI) 
 
71.6 
(62.0-81.2) 
86.5 
(78.5-94.4) 
0.02 
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Table 3.2: Comparison of features of Brighton classification in students 
with and without JHS.  
Values given are the percentages of students who had each feature. 	  
 No JHS  
(n=88) 
JHS 
(n=74) 
p 
 
Median Beighton score 
 (IQR) 
 
 
1  
(0-2) 
 
5  
(4-5) 
 
<0.001 
  JHM (Beighton ≥ 4)  
(CI) 
 
7.9 
(2.2-13.7) 
82.4 
(73.6-91.3) 
<0.001 
Arthralgia ≥ 4 joints 
(CI) 
 
2.3 
(0-5.4) 
18.9 
(9.8-28.0) 
<0.001 
Arhralgia 1-3 joints 
(CI) 
 
13.6 
(6.3-20.9) 
29.7 
(19.1-40.4) 
0.012 
Back pain 
(CI) 
 
7.9 
(2.2-13.7) 
18.9 
(10.9-29.6) 
0.004 
Spondylosis, scoliosis 
(CI) 
 
4.6 
(0.1-9.0) 
18.9 
(9.8-28.0) 
0.004 
Dislocation,subluxation 
(CI) 
 
7.9 
(2.2-13.7) 
52.7 
(41.1-64.3) 
<0.001 
Soft tissue problems 
(CI) 
 
4.6 
(0.1-9.0) 
33.8 
(22.8-44.8) 
<0.001 
Marfanoid habitus 
(CI) 
 
11.4 
(4.6-18.1) 
29.7 
(19.1-40.4) 
0.003 
Skin changes 
(CI) 
 
36.4 
(26.1-46.6) 
64.9 
(53.7-76.0) 
<0.001 
Eye signs 
(CI) 
 
29.6 
(19.8-39.3) 
37.8 
(26.5-49.2) 
0.3 
Varicose veins 
(CI) 
 
1.1 
(0-3.4) 
4.1 
(0-8.6) 
0.33 
Hernia 
(CI) 
 
4.6 
(0.1-9.0) 
4.1 
(0.5-8.6) 
1.0 
Organ prolapse 
(CI) 
 
0 
(0-0) 
0 
(0-0) 
- 
Affected first degree relative 
(CI) 
 
1.1 
(1.1-3.4) 
25.7 
(15.5-38.9) 
<0.001 
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3.5.3 GI symptoms in students with and without JHS 
52.7% of the JHS students experienced at least 3 GI symptoms more than once 
a month, and this was significantly increased compared to the non-JHS 
students (29.5%, p=0.003). To determine which symptoms were particularly 
different in the groups, the prevalence of individual lower and upper GI 
symptoms which were experienced more than once per month were compared - 
Table 3.3 and Table 3.4. There was no significant difference in the prevalence 
of any of the lower GI symptoms, however the prevalence of proctalgia was 
twice as high in the JHS group (14% vs 7%, p=0.19) - Table 3.3. There was no 
significant difference in bowel habit, though constipation was over twice as 
common in the JHS group (8% vs 3%, p=0.2) - Table 3.3. The most prevalent 
upper GI symptoms in JHS were abdominal pain (43%), postprandial fullness 
(34%), early satiety (32%) and bloating (26%). However, only postprandial 
fullness and early satiety showed a significant increase when compared with 
non-JHS students (postprandial fullness: 16%, p=0.01.; early satiety:  17%, 
p=0.03) - Table 3.4. 
 
There was no difference in the proportion of JHS and non-JHS students who 
had seen their GP for GI problems (25.6% vs 26.4%, p=0.9), been to hospital 
for GI problems (9.5% vs 4.5%, p=0.2), or been diagnosed with IBS (5.4% vs 
10.3%, p=0.3). 
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Table 3.3: Comparison of lower GI symptoms in students with and without 
JHS.  
Values given are percentages of students in each group who experience 
the symptom at least ‘often’.  
 No JHS  
(n=88) 
JHS 
(n=74) 
p 
 
Constipation  
(CI) 
 
 
3.4 
(0-7.3) 
 
8.1 
(1.7-14.4) 
 
0.30 
Diarrhoea 
(CI) 
 
1.1 
(0-3.4) 
1.4 
(1.3-4.0) 
1.0 
Alternating bowel habit 
(CI) 
 
11.5 
(4.6-18.3) 
12.2 
(4.5-19.8) 
0.90 
Lumpy stool 
(CI) 
 
19.8 
(11.1-28.3) 
21.6 
(12.0-31.2) 
0.77 
Watery stool 
(CI) 
 
2.3 
(0.9-5.5) 
6.8 
(0.9-12.6) 
0.25 
Straining 
(CI) 
 
17.2 
(9.1-21.3) 
14.8 
(6.6-23.2) 
0.68 
Incomplete evacuation 
(CI) 
 
23.0 
(14.0-32.0) 
24.3 
(14.3-24.3) 
0.84 
Blocked sensation in rectum 
(CI) 
 
9.2 
(3.0-15.4) 
8.1 
(1.7-14.4) 
0.81 
Poor relaxation of sphincter 
(CI) 
 
3.5 
(0.5-7.4) 
8.2 
(1.8-14.7) 
0.85 
Manual manoeuvres for 
rectal evacuation 
(CI) 
 
2.3 
(0.9-5.5) 
0 
(0-0) 
0.50 
Faecal incontinence 
(CI) 
 
3.5 
(0.5-17.4) 
2.7 
(1.1-6.4) 
1.0 
Faecal urgency 
(CI) 
 
10.3 
(3.8-16.9) 
6.8 
(0.9-12.6) 
0.58 
Anal pain (proctalgia) 
(CI) 
 
6.9 
(1.5-12.3) 
13.7 
(5.6-21.8) 
0.19 
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Table 3.4 : Comparison of upper GI symptoms (from BDQ) in students with 
and without JHS.  
Values given are percentages of students in each group who experience 
the symptom at least ‘2-3 times per month’. 
 No JHS  
(n=88) 
JHS 
(n=74) 
p 
 
Abdominal pain 
(CI) 
 
 
34.1 
(23.8-44.4) 
 
42.6 
(30.6-54.7) 
 
0.28 
Globus 
(CI) 
 
6.8 
(1.4-12.2) 
6.8 
(0.9-12.8) 
1.0 
Retrosternal chest pain 
(CI) 
 
16.1 
(8.2-24.0) 
12.3 
(4.6-20.0) 
0.50 
Heartburn 
(CI) 
 
11.4 
(4.6-18.1) 
13.5 
(5.5-21.5) 
0.68 
Waterbrash 
(CI) 
 
10.3 
(3.8-16.9) 
13.5 
(5.5-21.5) 
0.54 
Dysphagia 
(CI) 
 
3.5 
(0-7.5) 
2.7 
(1.1-6.6) 
1.0 
Epigastric discomfort 
(CI) 
 
5.7 
(0.8-10.7) 
12.2 
(4.5-19.8) 
0.17 
Postprandial fullness 
(CI) 
 
15.9 
(8.1-23.7) 
34.4 
(21.6-43.3) 
0.01 
Early satiety 
(CI) 
 
17.0 
(9.0-25.0) 
31.5 
(20.6-42.4) 
0.03 
Nausea 
(CI) 
 
11.4 
(4.6-18.1) 
16.2 
(7.6-24.8) 
0.37 
Vomiting 
(CI) 
 
1.1 
(1.1-3.4) 
2.7 
(1.1-6.6) 
0.59 
Regurgitation 
(CI) 
 
2.3 
(0-5.4) 
5.5 
(0.1-10.8) 
0.41 
Belching 
(CI) 
 
11.4 
(4.6-18.1) 
16.4 
(7.7-25.1) 
0.35 
Bloating 
(CI) 
 
22.7 
(13.8-31.7) 
26.4 
(16.0-36.8) 
0.59 
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3.5.4 Comparison of extra-intestinal features: psychopathology, somatic 
symptoms and fibromyalgia  
JHS students did not have increased anxiety or depression - Table 3.5. They 
did however, have increased somatic sensitivity as manifest by increased 
scores on the PHQ15 (7 vs 4, p=0.03).  
 
The number of positive tender points in both groups ranged from 0-11 out of a 
maximum 20, and had a very skewed distribution towards the lower scores with 
a median score of 1 in students with JHS  (IQR: 0-4), and 0 in students without 
JHS (IQR: 0-1). This was significant using the Mann-Whitney U test (p=0.004), 
however analysing the number of tender points as a continuous variable did not 
give a very good idea of the real spread of positive tender points in the 2 
groups. To enable this, the number of tender points was converted into a 
categorical variable and the number of students with 0 tender points, 1-4 
positive tender points, 5-8 positive tender points and 9-11 tender points was 
compared in each group.  JHS students were significantly more likely to have 
positive tender points (54.1 vs 31.8, p=0.004) - Figure 3.4. 
 
There was no difference in the prevalence of chronic widespread pain, 
insomnia, memory problems, all of which were features of the revised 
classification for fibromyalgia - Table 3.5. Only 1 student (JHS) was diagnosed 
with fibromyalgia but this was not significant.  
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Table 3.5: Comparison of psychopathology, fibromyalgia and 
somatosensory amplification in students with and without JHS.  
For categorical variables, values given are proportions for that group 	  
 No JHS  
(n=88) 
JHS 
(n=74) 
p 
 
PSYCHOPATHOLOGY (HADS) 
 
Anxiety score  
(CI) 
 
6.49  
(0.43) 
6.50  
(0.44) 
0.98 
Depression score  
(CI) 
 
2.42  
(0.27) 
2.51  
(0.28) 
0.69 
 
FIBROMYALGIA 
 
Chronic widespread pain 
(CI) 
 
2.3 
(0-5.4) 
1.4 
(1.3-4.0) 
1.0 
Insomnia 
(CI) 
 
14.8 
(7.2-22.3) 
24.3 
(14.3-34.3) 
0.12 
Memory problems 
(CI) 
 
8.0 
(2.2-13.7) 
4.0 
(0.5-8.6) 
0.35 
Positive tender points  
(CI) 
 
31.8 
(22.3-42.6) 
54.1 
(42.1-65.7) 
0.004 
% with fibromyalgia 
(1990/2010) 
(CI) 
 
0 
(0-0) 
1.3 
(1.3-4.0) 
0.46 
SOMATIC SYMPTOMS (PHQ15) 
 
PHQ15 
 (IQR) 
 
4  
(3-8.5) 
7  
(4-9) 
 
0.04 
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Figure 3.4:  Number of positive tender points in students with and without 
JHS.  
Students with JHS were significantly less likely to have no positive tender 
points 
 
 
3.5.5 Comparison of extra-intestinal features: autonomic symptoms  
Overall autonomic scores were higher in the JHS students (14.4 ± 1.0 vs 9.7 ± 
0.8, p<0.001). When the scores were broken up into the individual domains, 
differences were only seen in the orthostatic domain (31.3 ± 2.5 vs 21.3 ± 2.0, 
p=0.002) and diarrhoea domain (15.9 ± 2.5 vs 7.5 ± 1.5, p=0.003) - Figure 3.5. 
There was no difference in vasomotor scores (10.3 ± 2.5 vs 5.8 ± 1.8, p=0.1), 
secretomotor scores (13.5 ± 1.4 vs 12.1 ± 1.4, p=0.5), gastrointestinal scores 
(7.4 ± 1.6 vs 4.0 ± 1.0, p=0.06), constipation scores (9.3 ± 1.6 vs 8.1 ± 1.6, 
p=0.6), urinary scores (6.5 ± 1.5 vs 4.0 ± 1.0, p=0.2), pupillary scores (13.9 ± 
2.1 vs 10.3 ± 1.9, p=0.2), sleep scores (7.0 ± 1.0 vs 4.9 ± 1.0, p=0.1) or 
syncope scores (1.9 ± 0.7 vs 1.1 ± 0.5, p=0.4).   Psychosomatic scores were 
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not increased in the JHS students compared to the non-JHS students (0.12 ± 
0.12 vs 0.93 ± 0.93, p=0.43). 
 
 
Figure 3.5: Comparison of autonomic scores (from COMPASS) in students 
with and without JHS.  
Asterisks represent significant comparisons (p<0.05). 
 
3.5.6 Medication use and past medical history 
Past medical histories included asthma, migraines, eczema, irritable bowel 
syndrome, hay fever, diabetes, dental problems, polycystic ovary syndrome, 
renal problems, orthopaedic problems, and musculoskeletal problems e.g. 
muscle sprains. Apart from musculoskeletal problems, which were significantly 
increased in JHS (13.7% vs 4.5%, p=0.02), there were no significant differences 
in the prevalence of medical problems in the 2 groups. 
	   140	  
Nor were there any differences in medication use in the 2 groups. Medications 
included antidepressants, simple analgesics, bronchodilators, antibiotics, 
antispasmodics, antihistamines, the oral contraceptive pill and proton pump 
inhibitors. No students were taking opiates.  
 
3.5.7 Factors predicting GI symptoms  
To determine whether JHS was independently associated with GI symptoms, a 
multivariate logistic regression analysis was performed with the symptom of 
interest as the dependent variable, JHS, age and gender as fixed independent 
variables and all other measured factors (autonomic scores, number of tender 
points, PHQ15 scores, anxiety and depression levels) as covariates.  
 
The logistic regression analysis was first run for GI symptom presence (at least 
3 GI symptoms over the past 3 months) as the dependent variable. In this 
model, the presence of JHS was independently associated with GI symptom 
presence (OR: 2.71, CI: 1.11-6.58, p=0.03) even after adjusting for all the other 
variables. In addition, anxiety levels (p<0.001), autonomic scores (p=0.004) and 
number of tender points (p=0.05) were independently associated with GI 
symptom presence. Hence JHS, as well as autonomic and anxiety scores and 
number of tender points, were all independent predictors of GI symptoms. 
 
To look specifically at postprandial fullness and early satiety, which were earlier 
shown to be significantly associated with JHS, a similar logistic regression 
analysis was run with either postprandial fullness or early satiety as the 
dependent variable. This time, only JHS and anxiety scores were significantly 
associated with both symptoms. Hence JHS is an independent predictor of both 
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postprandial fullness (p=0.04) and early satiety (p=0.046), even after adjusting 
for all other factors.  
 
3.5.8 Effect of autonomic and somatic factors on the association between 
JHS and postprandial symptoms. 
Autonomic symptoms and somatic hypersensitivity (PHQ15 scores and 
fibromyalgia) have previously been shown to confound the association between 
JHS and postprandial symptoms in patients (Chapter 2). To determine whether 
this was also the case in non-patients, a logistic regression analysis was 
performed as described in the methods section. This was run twice – once for 
early satiety and once for postprandial fullness. The regression model 
contained as independent variables those factors that were independently 
associated with postprandial symptoms (i.e. JHS and anxiety) as well as age 
and gender; and as dependent variables, either postprandial fullness or early 
satiety. Autonomic scores, tender points (as a surrogate for fibromyalgia) and 
PHQ15 scores were added stepwise to this model, and the effect on the 
association between JHS and postprandial symptoms (adjusted odds ratio) was 
observed (Table 3.6) 
 
None of the factors had a substantial effect on the association between JHS 
and postprandial symptoms, as manifest by an adjusted odds ratio which did 
not change significantly from that of the initial model. PHQ15 scores had 
practically no effect on the JHS-postprandial symptom association. The number 
of positive tender points, reduced the strength of the association between JHS 
and early satiety only, but this effect was small - Table 3.6. 
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Table 3.6: Effect of orthostatic symptoms, number of tender points, 
PHQ15 scores on the association between JHS and GI symptoms.  
Results of the multivariate logistic regression analysis: Values given are 
odds ratios for the association between JHS and symptoms, adjusted for 
various factors. Confidence intervals are given in brackets. Anx: anxiety 
scores, ortho: orthostatic autonomic scores. Tenderpt: number of positive 
tender points.  	  
 Postprandial 
fullness 
 
Early satiety 
 
ORadj (age, gender, anx) 
 
2.79  
(1.19-6.54) 
 
2.21 
(1.00-4.86) 
 
ORadj (age, gender, anx, autonomic) 2.55 
(1.05-6.18) 
2.42 
(1.06-5.53) 
 
ORadj (age, gender, anx, ortho) 2.49 
(1.04-5.96) 
2.48 
(1.09-5.63) 
 
ORadj (age, gender,anx, PHQ15) 2.83 
(1.20-6.69) 
2.26 
(1.02-5.01) 
 
ORadj (age, gender, anx, tenderpt) 2.74 
(1.16-6.47) 
2.10 
(0.95-4.70) 
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3.5.9 Quality of life in JHS and non JHS 
All 74 JHS students were initially compared to all 88 Non-JHS students. Those 
with JHS had lower QOL scores on the pain component of the SF36 (80 vs 90, 
p=0.03). There were no other differences in the scores on any of the physical, 
emotional or social domains. 
 
When comparisons were made between students who had more than 3 GI 
symptoms, Non-JHS students had significantly worse scores for energy and 
fatigue (45 vs 55, p=0.005) and for general health (40 vs 70, p=0.004) - Table 
3.7 .  
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Table 3.7: Median SF36 scores in JHS and non-JHS students who had GI 
symptoms 	  	  
SF36 domain 
 
No JHS 
(n=26) 
JHS 
(n=39) 
p 
 
General health 
(IQR) 
 
 
40 
(35-65) 
 
70 
(45-85) 
 
0.004 
Physical function 
(IQR) 
 
95 
(85-100) 
100 
(95-100) 
0.06 
Role limiting physical 
(IQR) 
 
100 
(75-100) 
100 
(50-100) 
0.88 
Emotional well-being 
(IQR) 
 
60 
(48-72) 
68 
(52-76) 
0.35 
Role limiting emotional 
(IQR) 
 
66 
(0-100) 
100 
(0-100) 
0.24 
Energy and fatigue 
(IQR) 
 
45 
(30-60) 
55 
(45-70) 
0.005 
Pain 
(IQR) 
 
73.5 
(67-90) 
77 
(57-90) 
0.99 
Social function 
(IQR) 
 
75 
(62-100) 
75 
(62-100) 
0.42 
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3.6 Discussion 
3.6.1 Summary of results 
We have demonstrated that 53% of young JHS non-patients experience 3 or 
more GI symptoms more than once a month, and that abdominal pain, bloating, 
postprandial fullness and early satiety are the most commonly experienced 
symptoms.  When compared to students without JHS, those with JHS had 
significantly more GI symptoms, and more extra-intestinal features, as manifest 
by higher autonomic scores, somatic symptom scores and greater number of 
positive tender points.  There was a significant and independent association 
between JHS and dyspeptic symptoms (early satiety and postprandial fullness), 
which was not related to autonomic, somatic or psychological factors. Quality of 
life scores in JHS non-patients were generally high, and moreover, JHS 
students with GI symptoms had higher quality of life scores than did their non-
JHS counterparts.  
 
3.6.2 Comparison with previous studies 
The prevalence of GI symptoms in the non-JHS students was comparable to 
previous population studies (Stanghellini 1999; Bytzer, Talley et al. 2001) 
suggesting that our students were typical non-patients. The prevalence of GI 
symptoms in our JHS group was twice as high, and was within the range 
quoted in JHS patient studies (37-86%) (Hakim and Grahame 2004; Castori, 
Camerota et al. 2010; Rombaut, Malfait et al. 2011). This large range quoted 
previously is most likely due to the fact that each of the studies used different 
methods to obtain GI symptom information. Some used information obtained on 
medical interview (Rombaut, Malfait et al. 2011), some used non-validated 
questionnaires (Hakim and Grahame 2004), and others used non-GI specific 
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validated questionnaires  (Castori, Camerota et al. 2010). The frequency with 
which GI symptoms were experienced, and the time frame within which they 
were experienced, were not clearly specified in the above studies, and this is 
likely to account for the variability in quoted prevalence. For example, the 
prevalence of GI symptoms would clearly be much higher if ‘symptom presence’ 
referred to the presence of at least one GI symptom experienced at least once 
a month, than if it referred to the presence of at least 4 symptoms experienced 
daily.  In our study, the BDQ was used which allows the subject to specify the 
frequency with which the symptoms occurred over the past 3 months. In view of 
the fact that our subjects were young and non-patients, GI symptom presence 
was defined as the presence of at least 3 symptoms experienced more than 
once a month. Despite this conservative definition, we observed a significantly 
increased prevalence of GI symptoms in JHS compared to non-JHS, echoing 
the results found in rheumatology patients (Hakim and Grahame 2004), and in 
our study in GI patients (Chapter 2), suggesting that the presence of JHS is 
associated with increased GI symptoms, in any setting.  
 
To further characterise this association, the prevalence of individual symptoms 
was compared in the 2 groups. Only postprandial fullness and early satiety, 
which are considered dyspeptic symptoms, were significantly increased in the 
JHS students, and were twice as high as the quoted population prevalence (12-
16%) of these symptoms (Tougas, Chen et al. 1999; Sobieraj, Coleman et al. 
2011). This association of JHS with postprandial (dyspeptic) symptoms was 
previously described in JHS patients attending genetics clinics (Castori, 
Camerota et al. 2010), as well as JHS patients referred from rheumatology to GI 
	   147	  
clinics (Chapter 2). Thus with respect to postprandial symptoms, findings in 
non-patients mimic those in patients.  
 
For non-dyspeptic symptoms, our findings differed to those in patient studies. 
Constipation and proctalgia were twice as high in JHS compared to non-JHS 
students, but the comparisons were not significant. Other symptoms which have 
previously been shown to be associated with JHS in patient studies e.g. 
alternating bowel habit, bloating, abdominal pain, reflux and dysphagia, (Hakim 
and Grahame 2004; Castori, Camerota et al. 2010) and in Chapter 2 of this 
thesis did not show a similar association in our non-patients. There are two 
possible explanations for this. Firstly, subjects in this study were much younger 
than those in patient studies and it is believed that GI and non-GI symptoms 
increase with age (Castori, Sperduti et al. 2012). In the absence of a 
longitudinal study, it is impossible to determine whether JHS students who are 
asymptomatic, will go on to develop GI symptoms, nor indeed whether those 
with postprandial symptoms, will further develop the other symptoms seen 
commonly in JHS patients.  Secondly, patient studies are biased, as they 
include patients who present to specialty clinics and who thus have a more 
pronounced hypermobility presentation, as well as associated comorbidity, both 
of which might contribute to the increased range of GI symptoms in patients 
with JHS. In this way, patient studies may represent findings at the more severe 
end of the JHS spectrum, whereas non-patient studies provide evidence for the 
milder end. Thus it would appear that postprandial symptoms, but not other 
symptoms, are significantly increased in mild asymptomatic JHS individuals 
who have no knowledge of their hypermobility status, and that other symptoms 
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become more important as JHS progresses and the individual turns into a 
patient with other associated comorbidities.  
 
With regards to extra-intestinal features, there was an increased incidence of 
autonomic symptoms in the JHS group, and this was mainly due to increased 
orthostatic symptoms, consistent with previous JHS patient studies (Gazit, Nahir 
et al. 2003; Mathias, Low et al. 2011). This supports the growing literature in 
patients on the association between JHS, orthostatic symptoms and PoTS 
(Gazit, Nahir et al. 2003; Kanjwal, Saeed et al. 2010; Mathias, Low et al. 2011), 
but to our knowledge, this is the first description of such an association in non-
patients. The presence of increased autonomic symptoms in young JHS 
individuals who are attending university, and who are healthy and highly 
functioning, would suggest that the autonomic features are not secondary to 
deconditioning (De Wandele, Rombaut et al. 2013). Instead, it suggests that 
orthostatic symptoms may inherently be associated with JHS from an early age, 
slowly increasing over time, until they cause decompensation and the eventual 
syndrome of POTS.  
 
In addition to autonomic symptoms, JHS students had a greater number of 
somatic symptoms. PHQ15 scores, which are thought to represent 
somatosensory amplification, were higher in the JHS students, and this 
supports a previous study in French undergraduate students (Baeza-Velasco, 
Gely-Nargeot et al. 2011). These findings are also in line with the observation 
that JHS patients have an increased incidence of functional somatic syndromes 
(Castori, Celletti et al. 2011; Castori 2012) including fibromyalgia. Although only 
one JHS student fulfilled the criteria for fibromyalgia, there was a higher 
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proportion of students with positive tender points in the JHS group, which 
provides objective evidence of somatic hypersensitivity in this group.  
 
Interestingly, anxiety and depression scores were not increased in JHS 
students. This is in contrast to longitudinal studies which showed that JHS is a 
predictor of future anxiety (Bulbena, Gago et al. 2011) and that there is an 
association between JHS and anxiety even in non-patients (Baeza-Velasco, 
Gely-Nargeot et al. 2011). Once again, this can be explained by age differences 
in the 2 studies. In the longitudinal study, the association was only manifest in 
the follow-up period, when the JHS individuals were in their mid-thirties. The 
students in our study were substantially younger, with a mean age of 22, and 
anxiety may not have yet developed.  
 
The increased number of somatic symptoms and tender points in JHS students 
in spite of the absence of anxiety and depression, would suggest that 
somatosensory amplification is not a consequence of psychopathology and 
somatisation (Rief and Isaac 2007). Instead, it might be secondary to altered 
sensory or pain processing in JHS, which leads to the development of several 
functional somatic syndromes e.g. chronic fatigue syndrome, fibromyalgia, 
pelvic pain, irritable bowel syndrome (Castori, Celletti et al. 2011). Furthermore, 
the increase in tender points in the absence of all the other features of 
fibromyalgia would suggest that as was postulated for the other symptoms, 
these somatic features may increase over time and ultimately lead to overt 
syndromes such as fibromyalgia, which have been associated with JHS in a 
relatively older cohort.   
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Previous studies performed in JHS patients have demonstrated that the 
presence of GI symptoms is associated with multiple somatic and autonomic 
symptoms (Castori, Celletti et al. 2011) and it has been hypothesised that an 
underlying dysautonomia leads to visceral and somatic hypersensitivity which 
then results in GI and unexplained somatic symptoms (Castori, Celletti et al. 
2011). Other hypotheses, based on patient studies, have suggested that the GI 
symptoms are either due to deconditioning (due to physical inactivity), opiate 
use, or genetic factors (De Wandele, Rombaut et al. 2013). We were able to 
address some of these hypotheses with our non-patient study. As none of the 
students were on opiates, and all were healthy and active with no evidence or 
cause for deconditioning, we could rule out those 2 factors as an explanation for 
the observed increase in JHS symptoms.  
 
The autonomic/hypersensitivity theory was not as clear-cut. Students with JHS 
had increased autonomic and somatic symptoms as well as GI symptoms so it 
was more difficult to tease these factors apart. Our study in GI patients (chapter 
2) demonstrated that postprandial symptoms, were mediated by a combination 
of autonomic and somatic factors, and that those factors accounted for most of 
the association between JHS and symptoms.  This was not the case in this 
student study. Interestingly, JHS was independently associated with 
postprandial symptoms, and was not substantially affected by autonomic or 
somatic symptoms (PHQ15), nor by the number of positive tender points. Thus 
in young JHS students, as compared to older JHS patients, the presence of 
JHS is independently associated with postprandial symptoms, and autonomic 
and somatic factors have no effect on this. 
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Lastly, the effects of these increased symptoms on quality of life were 
examined. Interestingly, JHS students had very good quality of life scores, 
which were much higher than scores published for patients (Castori, Camerota 
et al. 2010; Rombaut, Malfait et al. 2010), and which did not differ to scores in 
non-JHS students except for the ‘pain’ component. The latter is to be expected, 
as JHS students had more arthralgia (Table 3.2). To examine the effect of GI 
symptoms on quality of life, quality of life scores were compared in JHS and 
non-JHS students who had GI symptoms. Surprisingly, JHS students had better 
quality of life scores for general health and energy and fatigue, and were 
comparable to the non-JHS students for all other quality of life measures. This 
is in complete contrast to findings in JHS patients in Chapter 2 and in the 
literature whereby the combination of JHS and multiple extra-articular 
symptoms is associated with severe impairments in quality of life, (Castori, 
Camerota et al. 2010; Rombaut, Malfait et al. 2010) and would suggest that at 
an early stage, the increase in all symptoms does not affect quality of life, and 
that JHS patients cope relatively well. However, over time, the increased 
burden of multiple symptoms, possibly leads to increased pain, reducing 
physical and social functioning and resulting in impaired general health.  
 
Putting this all together it would seem that in younger healthy JHS individuals 
who are non-patients, JHS is independently associated with dyspepsia, 
autonomic and somatic symptoms, but none of these are pathological, nor do 
they affect general health, social or physical functioning. With time, the number 
of autonomic and somatic symptoms increase (Castori, Sperduti et al. 2012), 
and the combination of these factors may lead to an increased range and 
prevalence of GI symptoms, as seen in Chapter 2. The presence of all these 
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comorbid symptoms significantly affects quality of life and affects physical and 
social functioning, motivating them to seek specialist help, by which time they 
have multiple associated symptoms, widespread organ involvement and very 
poor health.  
 
3.6.3 Limitations 
The study was not without limitations. Firstly, the required sample size was not 
achieved, due to a lower than expected response rate, and so the study was 
underpowered. Despite this, several significant differences in the groups were 
observed, which were supportive of previous studies. However it is possible that 
several of the symptoms which showed a non-significant trend e.g. constipation 
and proctalgia, would in fact show a significant difference, had the required 
sample size been recruited.  
 
Secondly, multiple comparisons were performed in our study, which increases 
the chances that significant results were obtained by chance. However in view 
of the fact that the significant findings in our study supported previous studies, 
this explanation for our significant results is less likely. 
 
Thirdly, the study was questionnaire-based and so it was subject to recall bias. 
However, most questions related to symptoms which were being experienced in 
the previous few months, making this less likely. An additional problem faced 
with questionnaires, is that symptoms picked up are not always equivalent to 
measureable pathology. As an example, autonomic symptoms are relatively 
non-specific, and so a high autonomic score is not equivalent to autonomic 
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dysfunction. To reduce the chances of this we used questionnaires which had 
previously been validated.  
 
Fourthly, the possibility of response bias cannot be ignored. The information 
sheet sent out to the students during the first part of the study, explained that 
the aim was to investigate GI symptoms in certain populations of students. It is 
therefore likely that students with GI symptoms were more likely to take part in 
the study. However, if this were the case, it would have applied to both the JHS 
and non-JHS group and would not have accounted for the differences seen 
between them.  
 
Lastly, our study was cross-sectional and was performed in young students, 
and therefore not necessarily representative of the entire population. Hence the 
extrapolation of our findings to different groups of healthy JHS individuals must 
be done with caution.  
 
3.6.4  Implications for future research 
Symptoms of postprandial fullness and early satiety are typical of functional 
dyspepsia and are thought to be secondary to abnormal sensation, motility or 
accommodation of the stomach, which can arise for a variety of reasons 
including autonomic dysfunction, hypersensitivity, somatisation, medication use, 
or gastric compliance (Oustamanolakis and Tack 2012). Our findings would 
suggest that in JHS non-patients these symptoms are not due to abnormal 
autonomic function, medication or somatisation, which leaves the possibility of 
altered biomechanics and/or motility. All these factors need to be investigated 
with physiological testing in the future.  
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Furthermore, the understanding of how symptoms progress over time, what 
other factors precipitate the worsening of symptoms and which factors predict 
the development of GI disorders (as opposed to symptoms) in these young 
individuals require longitudinal studies. This has yet to be done.   
 
3.6.5 Clinical implications  
This study demonstrates that despite the increased prevalence of autonomic, 
somatic and GI symptoms in young JHS individuals, their quality of life is 
preserved. This is clearly not the case when they eventually present to doctors 
as patients, by which point they have widespread organ involvement, multiple 
complications and poor quality of life. Hence earlier identification and 
management of JHS may retard the progression of GI and associated 
symptoms, and improve quality of life. As these individuals will initially present 
to primary care it is important for GP’s to consider the diagnosis of JHS in 
young patients with postprandial symptoms, widespread musculoskeletal 
problems and hypermobile joints.  
 
3.7 Conclusion 
Over 50% of students with JHS experience GI symptoms regularly and there 
exists an association between JHS and GI symptoms in this young and healthy 
JHS population. This association is independent of autonomic and somatic 
factors which confound the association in patient studies suggesting that other 
factors present in JHS are involved. Although these JHS individuals have 
increased GI, autonomic and somatic symptoms, quality of life remains good at 
this early stage. 
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Chapter 4 nvestigating the association between the Joint Hypermobility Syndrome and Gastrointestinal Disorders 
Investigating the Association between the Joint 
Hypermobility Syndrome and Gastrointestinal 
Disorders 
4.1 Introduction 
The JHS literature provides consistent evidence that JHS patients attending 
specialist clinics have a high prevalence of GI symptoms (Hakim and Grahame 
2004; Castori, Camerota et al. 2010; Rombaut, Malfait et al. 2011) which are 
predominantly ‘functional’ in nature e.g. globus, bloating, postprandial fullness 
and early satiety, and the studies described in Chapters 2 and 3 support this 
link. I have confirmed not only that GI symptoms occur in JHS patients 
presenting to rheumatology clinics, (Chapter 2), but that they also occur in 
healthy students with JHS who are non-patients (Chapter 3).  Moreover, in the 
student study, the presence of JHS was an independent predictor for 
postprandial symptoms, suggesting that the JHS phenotype is a risk factor for 
these functional symptoms.  
 
However, no large epidemiology studies have been performed to determine 
whether JHS is associated with GI disorders, as opposed to only GI symptoms, 
and specifically to determine whether there exists an association between JHS 
and FGID.  The available evidence is mixed. Evidence from case series, and 
small observational studies demonstrate that hypermobility in the form of either 
JHS or generalised joint hypermobility (GJH), is associated with wide-ranging 
GI disorders, with very little consistency between the studies.  
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In case series a high prevalence of IBS, gastritis, gastro-oesophageal reflux 
disease (GORD), diverticular disease and celiac disease have been reported in 
patients with JHS (Castori, Camerota et al. 2010; Danese, Castori et al. 2011; 
Castori, Sperduti et al. 2012). In case control studies of patients with lower 
urinary tract symptoms, those with JHS were more likely to report a previous 
diagnosis of IBS (Manning, Korda et al. 2003). In an observational study of 
patients attending a neurogastroenterology clinic, those with JHS had a high 
incidence of GI dysmotility (Zarate, Farmer et al. 2009). 
 
Other studies have used the presence of GJH as a surrogate for JHS. Case 
control studies that used the Beighton score to define GJH found an association 
with slow transit constipation (Reilly, Chase et al. 2008), and Crohn’s Disease, 
but not Ulcerative Colitis (Vounotrypidis, Efremidou et al. 2009). Case control 
studies that used the screening questionnaire to define GJH demonstrated an 
association with unexplained GI disorders (Zarate, Farmer et al. 2009) and with 
rectal evacuatory dysfunction (Mohammed, Lunniss et al. 2010). 
 
Hence it is clear that the available literature does not provide consistent 
evidence for an association between JHS and any type or group of GI 
disorders. Furthermore, the above studies all have several important limitations 
and should be interpreted with caution. These limitations include selection bias 
(Manning, Korda et al. 2003; Zarate, Farmer et al. 2009; Castori, Camerota et 
al. 2010), small size (Castori, Camerota et al. 2010), unblinded studies 
(Vounotrypidis, Efremidou et al. 2009), lack of control groups for comparison 
(Castori, Camerota et al. 2010), differing definitions of hypermobility with lack of 
distinction between JHS and GJH (Vounotrypidis, Efremidou et al. 2009; Zarate, 
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Farmer et al. 2009; Mohammed, Lunniss et al. 2010) and finally, differing 
methods of assessing for hypermobility, including the use of a screening 
questionnaire (Zarate, Farmer et al. 2009; Mohammed, Lunniss et al. 2010), 
measurement of the Beighton score, (Vounotrypidis, Efremidou et al. 2009) , or 
the Brighton criteria and/or the Villefranche criteria (Castori, Camerota et al. 
2010).  
 
In our study of GI symptoms in JHS (Chapter 2) we provided preliminary 
evidence for an association between JHS and FGID, and demonstrated that 
91% of JHS patients referred from hypermobility clinics to GI clinics had FGID.  
We also demonstrated that autonomic and somatic factors were involved in the 
association of JHS with GI symptoms. However, even this study was biased, as 
JHS patients were highly selected from rheumatology clinics and both patients 
and physicians were aware of JHS status, potentially influencing the diagnostic 
label they were eventually given. Hence there was a need to perform a large 
unbiased study to determine if there was a true association between JHS and 
FGID.  
 
4.2 Aims 
The aim of the study was to determine if there was an association between JHS 
and GI disorders in a secondary care setting. The primary aims were 1) to 
determine if there is an increased prevalence of JHS in patients with FGID, 
compared to both patients with organic GI disorders (positive controls) and to 
patients without GI disorders (negative controls); 2) to determine if there is an 
increased prevalence of JHS in any organic GI disorders; (3) to determine if 
there is an association between JHS and particular ROME III categories of 
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FGID. The secondary aims were (1) to determine whether autonomic and 
somatic hypersensitivity factors are involved in the association between JHS 
and GI disorders, just as they are with GI symptoms in patients with established 
JHS; (2) to determine whether the presence of JHS in FGID was associated 
with increased comorbidity, and decreased quality of life and was therefore 
clinically relevant. 
 
4.3 Hypothesis 
We anticipated an increased prevalence of JHS in patients with FGID compared 
to patients with organic GI disorders, and to patients without GI disorders. In 
view of the specific GI symptoms found to be associated with JHS in Chapter 2, 
we hypothesized that the association with FGID would specifically be with 
functional dyspepsia and IBS-M. We expected patients with FGID and JHS to 
have more autonomic and somatic symptoms, more psychopathology and 
opiate use compared to FGID patients without JHS, and therefore expected 
them to have increased comorbidity and worse quality of life. In line with 
previous patient studies (Chapter 2) demonstrating that autonomic and somatic 
hypersensitivity factors were involved in the association between JHS and GI 
symptoms, we also expected those factors to be involved in the association of 
JHS with FGID.  
 
4.4 Materials and Methods 
4.4.1 Study design 
A nested case control study in secondary care gastroenterology clinics at Barts 
and the London NHS Trust and Mile End Hospital was undertaken. Consecutive 
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‘new’ patients attending general gastroenterology clinics for their first visit 
between April 2010 and April 2012 completed a set of validated questionnaires, 
and were assessed for JHS and fibromyalgia (see below) before their initial 
clinical consult with the attending gastroenterologist who was blinded to their 
hypermobility status. Throughout their gastroenterology consultations, patients 
underwent routine investigations as deemed appropriate by their 
gastroenterologist and were eventually given a diagnosis, which was either 
functional or organic. A negative control group consisting of patients who were 
referred by their GP’s to secondary care for non-gastroenterology problems 
underwent the same protocol, except that they were not seen by a 
gastroenterologist. The prevalence of JHS and other associated factors was 
compared in patients with functional GI disorders, organic GI disorders and in 
non-GI controls. 
 
4.4.2 Subjects 
4.4.2.1 Recruitment 
GI patients 
New referrals to the GI clinic were identified by searching the hospital 
computerized booking system. These were all sent a study pack consisting of 
an invitation letter, an information sheet, a consent form and a questionnaire 
booklet. A few days prior to their appointment, they were contacted by the 
research team to ensure that they had received the invite, to clarify what the 
study would involve, and to answer any questions they may have had. Those 
that were interested in taking part were asked to attend their clinic appointment 
with sufficient time to be assessed by the research team prior to their clinical 
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consult, and they were asked to complete the questionnaires prior to their 
hospital visit.  
 
Non-GI patients 
Non-GI controls were recruited from 3 GP practices within the catchment area 
of Barts and the London and Mile End Hospital. Controls were identified by 
using the eligibility criteria to run a search on the EMIS-based GP practice 
registries.  Suitable patients were sent an information sheet and an invitation 
letter. Contact details of the research tem were provided. Upon contact, 
eligibility criteria were assessed again to ensure that they were suitable for the 
study and a meeting was arranged. 
 
4.4.2.2 Eligibility criteria 
GI group 
Patients aged 18-70, who had GI symptoms and were newly referred to 
secondary care gastroenterology clinics at Barts and the London NHS Trust 
and Mile End Hospital were eligible to take part. Patients who were illiterate or 
who could not speak English were excluded as the study relied heavily on 
questionnaires. Patients who were pregnant, or attending for bowel cancer 
screening or hepatology problems or those with a known diagnosis of JHS were 
also excluded.  
 
Non-GI control group 
Patients aged between 18-70 who had been referred by their GP to secondary 
care in the past 5 years for non-GI related problems were eligible to take part. 
Patients with known GI diagnoses or ongoing GI symptoms, diabetes, 
inflammatory arthritides (e.g. rheumatoid arthritis, psoriatic arthritis), a 
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generalized neuropathy or myopathy, severe psychiatric disorders requiring 
treatment and those who were pregnant were excluded, as those factors are 
known to be associated with GI symptoms and pathology. Patients who were 
illiterate or who did not have a sufficient understanding of written English were 
also excluded. 
All subjects were recruited after informed written consent. The study was 
approved by the East London and City Research Ethics Committee: REC Ref: 
09/H0704/72. 
 
4.4.3 Questionnaires 
Subjects completed validated questionnaires to systematically assess GI 
symptoms, somatic symptoms, psychopathology, autonomic symptoms, 
personality and quality of life. Demographic information and medication 
histories were also collected via standardized case report forms.  
 
GI symptom assessment:  
The Bowel Disease Questionnaire (BDQ) (Talley, Phillips et al. 1990) was used 
to elicit GI symptoms as described in Chapter 2. It consists of the questions 
used for the ROME III classification of FGID and therefore additionally enables 
the categorisation of FGID patients into a particular ROME III category.  
 
Autonomic symptom assessment:  
The COMPASS questionnaire was used to determine the presence and type of 
autonomic symptoms, as described in Chapter 2 (Suarez, Opfer-Gehrking et al. 
1999). Scores are provided for various autonomic domains; for this study, 
scores relating to constipation, gastrointestinal, diarrhoea, urinary, vasomotor 
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and syncope domains were used. Scores range from 0 to 100, with higher 
scores representing more severe symptoms.  
 
Psychological assessment:  
Raw scores for anxiety and depression were obtained using the validated SCL-
90 questionnaire as described in Chapter 2 (Derogatis, Rickels et al. 1976).  
 
Somatic symptoms: 
The validated PHQ15 assesses for the range of somatic symptoms and the 
severity of somatosensory amplification and was used as described in Chapter 
2 (Kroenke, Spitzer et al. 2002). In addition to the total PHQ15 score (0-30), 
and adjusted score which was calculated without the GI symptom scores 
(PHQ15 adj, range: 0-24) was used. 	  
Quality of life assessment:  
Health-related QOL was evaluated using the SF-36, as described in Chapter 2 
(McHorney, Ware et al. 1993). 
 
4.4.4 Examination and structured interview 
Structured interviews and examinations were performed by myself. All 
assessments were conducted blind to the results of questionnaires. 
Examination was used to assess for JHS and fibromyalgia as described in 
Chapter 2. Fibromyalgia was considered to be present if the 1990 or 2010 
American College of Rheumatology diagnostic criteria for fibromyalgia were 
satisfied (Wolfe, Smythe et al. 1990; Wolfe 2010). 
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4.4.5 GI diagnosis 
As part of their routine gastroenterology workup, GI patients were assessed by 
a gastroenterologist who was not part of the study. After clinical assessment 
and relevant investigations, organised by the attending gastroenterologist, they 
were eventually given a diagnosis for their GI symptoms. This was obtained 
from the patients’ notes after recruitment of all patients was complete. In certain 
instances, no diagnosis was specified, but organic conditions had been 
excluded and the patient was discharged back to the general practitioner. In 
such cases, the diagnosis was considered to be functional. Gastro-oesophageal 
reflux in the absence of any other diagnosis was considered a separate 
category and not included as either organic or functional. Further categorisation 
of FGID was possible using the ROME III classification and the questions from 
the BDQ.  
 
4.4.6 Blinding 
Patients were not informed of their hypermobility status until after the 
questionnaires had been collected, thus ensuring that they were blinded to their 
JHS status when they were completing the questionnaires. Questionnaires 
were collected and placed in a sealed envelope to ensure blinding of the 
researchers to questionnaire responses when the assessment of JHS and FM 
was being performed.  Physicians consulting the patients were not involved in 
the study and would not have been aware of the patients’ hypermobility status, 
so the GI diagnosis reached would have been independent of the presence or 
absence of JHS. 	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4.4.7 Sample size and statistical calculations: 
The study was powered to detect a 10% difference in the prevalence of JHS 
between the groups. According to our hypothesis, JHS is associated with FGID 
and not organic GI disease. Hence the prevalence of JHS in the organic GI 
disease group should be the same as that in the general population  - 15% 
(Garcia Campayo, Asso et al. 2010). Assuming a difference in prevalence of 
10% (i.e. 25% JHS in patients with FGID), one would need a sample size of 270 
to achieve a power of 80% at a significance level of 0.05. In general, 40% of 
patients attending a general gastroenterology end up with a functional GI 
diagnosis, therefore we would need to assess 675 new patients to ensure that 
270 patients end up in the FGID group. 270 non-GI controls would also be 
needed - Figure 4.1. 
 
 
Figure 4.1: Flowchart of study design in Chapter 4 
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4.4.8 Data analysis and Statistics 
Data were described in terms of means and standard errors (normal ordinal 
data), medians and IQR (non-normal ordinal data) and proportions and 
confidence intervals (categorical data).  
 
Prevalence of JHS in GI disorders 
The GI and Non-GI groups were first compared in terms of age (t-test), gender 
(chi-squared) and ethnicity (chi-squared) to ensure they were comparable. The 
prevalence of JHS was measured in patients with functional disorders, other GI 
disorders and in non-GI controls. Comparisons of the prevalence of JHS were 
made with the non-GI group (negative controls), and with the organic group 
(positive control), and were adjusted for age and gender. In line with external 
statistical advice this was performed as a two-stage analysis to resemble 
derivation and validation cohorts, with the first cohort analysed after half the 
patients had been recruited. As the data were similar in the two cohorts a 
pooled analysis is presented in this thesis to increase the statistical power and 
significance of the association.   
 
To determine the prevalence of JHS across the range of primary diagnoses the 
patients were given, the prevalence of JHS was measured in the individual 
organic disorders, reflux disorders and in FGID and were compared to the 
prevalence of JHS in the non-GI control group, using Pearson’s chi-squared 
test. 
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Prevalence of JHS in ROME III classes and subcategories 
Patients with FGID and who had a complete set of questionnaires could be 
further subdivided into a ROME III class (e.g. functional oesophageal disorders) 
and subcategory (e.g. functional dysphagia). The prevalence of JHS was first 
measured in each ROME III class. Due to the fact that patients could fulfill 
criteria for more than one class, a stepwise logistic regression analysis was 
performed, which assessed for an association between JHS and each of the 
classes, independent of all the other classes.  
 
The classes were then further subdivided into subcategories, to enable a 
comparison of the prevalence of JHS within individual ROME III categories. In 
many cases, this did result in small numbers of patients within the groups, and 
so this comparison was largely observational. However, in addition, a stepwise 
logistic regression analysis was performed as with the ROME III classes, to 
explore whether any subcategories did show a significant independent 
association with JHS.  
 
Influence of extra-intestinal factors on the association between JHS and 
GI disorders 
The next part of the analysis aimed to determine the effect of potential 
confounders on the association between JHS and GI disorders. We were 
particularly interested to find out if autonomic, somatosensory and fibromyalgia 
factors, which were involved in the association between JHS and GI symptoms 
in Chapter 2, were also involved in the association between JHS and GI 
disorders.  The first stage involved the comparison of all these factors between 
the JHS and non-JHS patients to determine which factors were associated with 
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this group of JHS patients. Those factors that were associated with JHS and 
known to be associated with GI disorders were considered possible 
confounding factors. They were added to a multivariate logistic regression 
model which contained the GI diagnosis as the dependent variable, JHS as the 
independent variable and the other confounding factors, including age and 
gender, as the covariates. This produced an adjusted odds ratio which was a 
measure of the strength of the association between JHS and each GI diagnosis, 
after adjusting for all the confounding factors. A significant adjusted ratio 
(p<0.05) suggested that the association between JHS and the relevant GI 
diagnosis was independent of all the confounding factors. A non-significant 
adjusted odds ratio (p>0.05) suggested that the association between JHS and 
the GI disorder was dependent on one or more of the covariates. To determine 
which of the covariates (confounding factors) was important, each factor was 
added individually to the multiple logistic regression model, and the effect of the 
addition on the adjusted odds ratio for the GI-JHS association was observed. 
Factors which reduced the odds ratios considerably were interpreted as being 
involved in the association between JHS and the GI disorder. 
 
Comorbidity and quality of life in FGID patients with and without JHS 
The final analysis involved the comparison of FGID patients with and without 
JHS, with respect to GI symptoms, non-GI symptoms and quality of life, to 
determine if the presence of JHS was clinically relevant. Comparisons were 
performed using the t-test (normal ordinal data), Mann Whitney U-test (non-
normal ordinal data), Pearson’s chi squared test (categorical data), or Fisher’s 
exact test (categorical data, and small proportions (<5%)). For all comparisons, 
a p value of less than 0.05 was considered significant. 
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4.5 Results 
4.5.1 Subjects  
GI patients - Figure 4.2 
As described in Chapter 2, 2445 new patients scheduled to attend GI clinics 
were invited to take part in the study and 778 of these consented. Of these, 15 
were excluded because they were hepatology patients or were undergoing 
bowel screening and 21 did not undergo a complete physical examination. 54 
had an established diagnosis of JHS (JHS-Rh) and were included in the study 
in Chapter 2, but excluded from this study analysis. This left 688 patients who 
were finally included in the study. Of these, 341 (49.6%) had a functional 
diagnosis, 254 (36.9%) had an organic diagnosis and 53 (7.7%) had a reflux 
diagnosis. As the reflux group was large, and did not clearly belong to either the 
organic or functional group, this remained as a separate category. The 
remaining 40 patients (5.8%) were not assigned a diagnosis, either because 
they did not attend for investigations or for follow-up. These patients were 
excluded from the analysis, leaving 648 patients in the final analysis. 
 
Non-GI controls - Figure 4.2 
The computer search identified 3160 patients who met the inclusion criteria for 
the study and these were all invited to take part. 107 (3%) of these made 
contact with the research team and eligibility was re-assessed. A total of 92 
were eligible and they were included in the study.  
 
Hence a total of 740 patients in 4 groups were included in the analysis: 341 
patients with FGID, 254 patients with organic GI disorders, 53 patients with 
reflux disease and 92 non-GI controls. Out of the 740 patients, only 604 had 
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complete questionnaires, and so comparisons which required the use of 
questionnaire data (in the final stages of analysis) were only performed in this 
subgroup. 
 
 
 
Figure 4.2: Flowchart of subjects included in the study in Chapter 4 
 
 
4.5.2 Demographics 
Gender distribution 
There were 65.1% females in the FGID group, 54.7% in the organic group, 
39.6% in the reflux group and 67.4% in the non-GI group. There was a 
significant difference in the proportion of females across the groups, (p<0.001). 
The proportion of females in the reflux group was significantly lower than in the 
FGID group (p<0.001), organic group (p=0.04), and in the non-GI group 
(p=0.001) (Fig 4.2). 
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Age distribution 
The mean age of the patients was highest in the reflux group (46.3 ± 1.9), 
followed by the organic group (43.5 ± 0.93), non-GI group (42.9 ± 1.51) and 
FGID group (40.1 ± 0.71). There was a significant difference in the mean ages 
across the groups (p=0.003). The reflux patients were significantly older than 
both the FGID patients (p=0.002) and the organic patients (p=0.04) - Figure 4.3. 
 
 
 
Figure 4.3: Gender and age distribution in each of the 4 groups.  
Patients were older and less likely to be female in the reflux group 
compared to the other GI and non-GI groups. 	  
 
Ethnicity - Figure 4.4 	  
The ethnic distribution of the patients in each of the 4 groups was comparable: 
most patients were White, followed by Asians and Afro-Caribbeans (Figure 4.4). 
There were no patients of Chinese or Mixed ethnicity in the Reflux group. There 
was no difference in the proportion of White patients in each group (p=0.7).  
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Figure 4.4: Ethnic distribution of patients in the 4 groups. 
 
 
4.5.3 Prevalence of JHS in GI and Non-GI groups 
JHS was present in 33.5% of GI patients: 38.4% in FGID, 25.6% in organic GI 
disorders and 39.6% in reflux. The prevalence of JHS in non-GI patients was 
26.1%  - Figure 4.5.  
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Figure 4.5: Prevalence of JHS in FGID, organic disorders, reflux disorders 
and non-GI patients.  
The prevalence of JHS was highest in reflux and FGID. The prevalence of 
JHS in organic GI disorders was the same as the prevalence in the non-GI 
patients. 
 
Comparisons between the groups were adjusted for age and gender using 
logistic regression analysis. When compared to non-GI patients, there was a 
significant association of JHS with both FGID (ORadj: 1.71, CI: 1.02-2.88, 
p=0.04), and with reflux (ORadj: 2.24, CI: 1.07-4.68, p=0.03), but not between 
JHS and organic GI disorders (ORadj: 1.03, CI: 0.59-1.79, p=0.92). The FGID 
and reflux groups were then compared to the organic group, to determine if 
there were significant differences within the GI groups.  Compared to the 
organic group, there was a significantly higher prevalence of JHS in FGID 
(ORadj: 1.67, CI: 1.16-2.39, p=0.006) and in reflux disorders (ORadj: 2.18, CI: 
1.16-4.08, p=0.015). 
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4.5.4 Prevalence of JHS by primary diagnoses 
The primary GI diagnoses were grouped into various categories as shown in 
Figure 4.6. ‘Other colitis’ included microscopic, ischaemic and infectious colitis. 
‘Dysmotility’ included achalasia and other oesophageal dysmotilities, 
gastroparesis and small bowel dysmotility. ‘Panc-bil’ diagnoses included bile 
salt malabsorption, gallstones and cholecystitis and pancreatitis. ‘Perianal 
problems’ included haemorrhoids, abscesses, non-IBD fistulae and anal 
fissures. 
 
 
 
Figure 4.6: Prevalence of JHS by primary diagnosis.  
Numbers in brackets represent the number of patients in that group. The 
dotted line represents the prevalence in non-GI controls. The shaded grey 
column represents the mean prevalence in GI patients. PI-IBS: Post 
infectious IBS, GERD: Erosive reflux disease, NERD: non-erosive reflux 
disease, UC: ulcerative colitis 
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The prevalence of JHS was highest in NERD (46%), post-infectious IBS (43%), 
erosive reflux disease (GERD) (41%) and FGID (38%) and lowest in dysmotility 
(8.7%), ulcerative colitis (18.9%), patients with gastritis, duodenitits or peptic 
ulcer disease (21.4%) and patients with perianal problems (23.1%) - Figure 4.6. 
Within the organic group, the prevalence of JHS in disorders such as Crohn’s 
disease (32%), Coeliac disease (30%) and pancreatico-biliary problems (33%) 
was higher than that in other organic conditions such as ulcerative colitis (19%) 
organic gastroduodenal problems e.g. gastritis and peptic ulcers (21%), and 
higher than in non-GI controls (26%) but these comparisons were not 
significant.  Compared to non-GI patients the only disorders where the 
prevalence of JHS was significantly increased was in patients with FGID 
(p=0.03), and in patients with NERD (p=0.04).  
 
4.5.5 Prevalence of JHS in ROME III classes of FGID 
The FGID group in Figure 4.6 was very large, and consisted of a variety of 
functional disorders. Although the categorisation of FGID was not consistently 
performed by the physician, it was possible, using the BDQ, to do this for the 
patients with completed questionnaires. This enabled the comparison of JHS 
prevalence in the different ROME III classes and subcategories. 
 
Out of the 258 FGID patients with fully completed questionnaires, 47 (18%) had 
a functional oesophageal disorder, 113 (44%) had a functional gastro-duodenal 
disorder, 198 (77%) had a functional bowel disorder, 3 (1%) had functional 
abdominal pain syndrome, 18 (7%) had a functional gallbladder or sphincter of 
oddi disorder, and 57 (22%) had a functional anorectal disorder. 34% of 
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patients fulfilled criteria for more than ROME III category, with functional gastro-
duodenal and functional bowel disorders frequently overlapping. 
 
The prevalence of JHS in the different ROME III classes is shown in Figure 4.7. 
Functional abdominal pain was not included as there were only 3 patients in 
that group. The prevalence of JHS was highest in functional gallbladder and 
SOD disorders (44%) followed by functional gastroduodenal disorders (43%) 
and functional anorectal disorders (42%).  
 
 
 
Figure 4.7: Prevalence of JHS in ROME III functional GI categories.  
Proportions and 95% confidence intervals of JHS in each category are 
displayed. The dotted line represents the prevalence of JHS in non-GI 
controls.  
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In view of the overlap between the different classes, a step-wise logistic 
regression was performed to determine if any of the ROME III classes were 
independently associated with JHS. Only functional gastroduodenal disorders 
were independently associated with JHS (OR: 1.83, CI: 1.15-2.91, p=0.01).  
 
4.5.6 Prevalence of JHS in ROME III subcategories  
The prevalence of JHS was further compared in the individual ROME III 
subcategories - Figure 4.8. Categories that included 5 patients or fewer – 
functional defecation disorder (4), aerophagia (5), functional heartburn (2), 
unspecified excessive belching (3), cyclical vomiting (0), rumination (0), 
functional bloating  (0) and functional abdominal pain (3) -  were not included as 
there were too few patients to make meaningful comparisons.  
 
The prevalence of JHS in chronic proctalgia (50%), PI-IBS (50%), functional 
vomiting (46.2%), idiopathic nausea (50%), postprandial distress (51%) and 
functional chest pain (47.1%) was higher than the mean prevalence of JHS in 
FGID but this was not significant. Using stepwise logistic regression analyses 
only postprandial distress showed a significant and independent association 
with JHS (OR: 2.24, CI: 1.18-2.24, p=0.01). 
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Figure 4.8:Prevalence of JHS in ROME III subcategories.  
Numbers in brackets represent the number of patients in each of the 
subcategories. The dotted line represents the prevalence of JHS in Non-GI 
controls. The shaded grey column represents the 95% confidence 
intervals for prevalence of JHS in FGID. SOD: Sphincter of Oddi. F: 
Functional. 
 
 
4.5.7 Identification of factors involved in the association between JHS 
and GI disorders 
We demonstrated earlier that there exists an association between JHS and 
FGID, and between JHS and reflux disorders, when compared to both non-GI 
patients and to patients with organic disorders. To explore what factors may 
have been contributing to this association, and to determine specifically if 
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autonomic and somatic factors were involved, a multiple logistic regression 
analysis was carried out.  
 
4.5.7.1 Identification of factors associated with JHS (i.e. potential 
confounding factors) – Table 4.1 and Table 4.2 
JHS patients were more likely to be female (66% vs 57%, p=0.02) and they 
were significantly younger (39.3 ± 0.88 vs 43.4 ± 0.63, p<0.001). JHS patients 
had more chronic widespread pain, insomnia, memory problems, and positive 
tender points, compared to patients without JHS. In line with this, JHS patients 
were more likely to have fibromyalgia (p=0.001) - Table 4.1. There was no 
difference in the use of opiates (6.2 vs 6.6, p=0.8), antispasmodics (6.5 vs 6.1, 
p=0.5), PPIs (21.9 vs 27.7, p=0.09) or prokinetics (8.8 vs 7.8, p=0.4) in subjects 
with and without JHS.  
 
Autonomic scores were very skewed towards 0 on all domains which made 
statistical comparisons difficult using the Mann-Whitney U test. In order to 
enable more meaningful comparisons the autonomic scores were converted 
into categories using a cut-off score of 25. The proportion of patients with a 
score > 25 was then compared for each domain using the Pearson’s Chi 
squared test.  JHS patients were more likely to have significantly higher 
autonomic symptom scores for the urinary and gastrointestinal domain (p=0.03, 
p=0.02 respectively). They were also more likely to have higher orthostatic 
symptom scores but this was not significant (51% vs 41%, p=0.06) - Table 4.2.  
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Total PHQ15 scores were significantly higher in JHS both with and without the 
inclusion of the GI questions (p<0.001). Patients with JHS also had higher 
anxiety (p<0.001) and depression (p=0.03) scores.  
 
Table 4.1: Comparison of fibromyalgia and chronic pain features in 
subjects with and without JHS 	  
 
 
 
No JHS 
(n=499) 
 
JHS 
(n=241) 
 
p 
 
Chronic widespread pain 
(CI) 
 
9.6 
(7.2-12.6) 
 
 
21.2 
(16.2-26.9) 
 
<0.001 
Positive tender points 
(CI) 
 
35.6 
(31.5-40.0) 
56.0 
(49.5-62.4) 
<0.001 
Memory problems 
(CI) 
 
8.0 
(5.8-10.8) 
15.3 
(11.0-20.5) 
0.009 
Insomnia 
(CI) 
 
15.4 
(12.4-18.9) 
24.5 
(19.2-30.4) 
0.01 
Fibromyalgia 
(CI) 
 
4.4 
(2.8-6.6) 
11.6 
(7.9-16.4) 
<0.001 
Opiate use 
(CI) 
 
6.6 
(4.6-9.2) 
6.2 
(3.5-10.1) 
0.8 
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Table 4.2: Comparison of autonomic scores, somatic sensitivity scores 
and psychopathology in subjects with and without JHS 	  
Questionnaire data No JHS 
(n=411) 
JHS 
(n=193) 
 
 
SOMATIC SENSITIVITY SCORES 
 
Median PHQ15  
(IQR) 
 
8 
(4-13) 
10 
(6-15) 
<0.001 
Median PHQ15 adj  
(IQR) 
 
5 
(3-8) 
6 
(4-9) 
<0.001 
PSYCHOPATHOLOGY 
 
Anxiety score 0.305 
(0.005-0.705) 
0.405 
(0.105-1.06) 
<0.001 
Depression score 0.58 
(0.24-1.2) 
0.76 
(0.31-1.5) 
0.03 
 
AUTONOMICS: proportion with scores>25 
 
Urinary 16.6 
(13.1-20.5) 
 
23.8 
(18.0-30.5) 
0.03 
Orthostatic 43.1 
(38.2-48.0) 
 
51.3 
(44.0-58.5) 
0.06 
Syncope 1.5 
(0.5-3.2) 
 
1.6 
(0.3-4.4) 
0.93 
Vasomotor 17.5 
(14.0-21.5) 
 
22.8 
(17.1-29.4) 
0.12 
Diarrhoea 37.2 
(32.5-42.1) 
 
42.5 
(35.4-49.8) 
0.22 
Constipation 31.6 
(27.2-36.3) 
 
35.2 
(28.6-42.4) 
0.38 
Gastrointestinal 30.7 
(26.2-35.4)  
39.9 
(32.9-47.2) 
 
0.02 
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4.5.8 Influence of extra-intestinal factors on the association between JHS 
and GI disorders 
Fibromyalgia features, anxiety, depression, autonomic symptoms, somatic 
sensitivity, younger age and female gender are all factors known to be 
associated with FGID and they were also associated with the JHS patients in 
this study (Table 4.1 and Table 4.2). Hence these were all considered as 
potential confounders. There was no association between medication use and 
JHS (Table 4.1), and thus it was not considered a confounding factor. 
 
To determine if the high prevalence of JHS in FGID and in reflux, but not in 
organic disease, was due to the co-existence of these extra-intestinal factors, 
all these possible confounding factors were entered into a logistic regression 
model. This was done for both FGID and for reflux, and compared to patients 
with organic GI disease. For FGID, the association with JHS lost its significance 
after adjusting for all those factors, (ORadj: 1.43, CI: 0.94-2.17) suggesting that 
some or all of those factors were responsible for the association seen between 
FGID and JHS. For reflux, the association remained significant even with the 
addition of all the other factors, (ORadj: 2.58, CI: 1.27-5.24), suggesting that 
psychopathology, fibromyalgia, somatic and autonomic symptoms were not 
confounders in the case of reflux. 
 
 
 
 
 
 
	   182	  
4.5.9 Influence of autonomic, psychological, fibromyalgia and 
somatosensory factors on the association between JHS and FGID 
The individual effect of psychological, fibromyalgia, autonomic and 
somatosensory factors on the association between JHS and FGID was 
determined using a multiple logistic regression model as described in the 
methods section. A similar analysis was also performed to determine the effect 
of those factors on the specific association between JHS and postprandial 
distress syndrome. The effect of the addition of each of those factors on the 
strength of the association (adjusted odds ratio) between JHS and either FGID 
or postprandial distress syndrome is shown in Table 4.3.  
 
In the case of FGID, none of the factors had a very large effect on the adjusted 
odds ratio. The addition of autonomic symptoms seemed to have the largest 
effect on reducing the adjusted odds ratio.  
 
The effect of the individual factors was seen more clearly in the case of PDS. 
Apart from somatosensory scores, the addition of each of the other factors, 
particularly the autonomic symptoms, reduced the odds ratio between JHS and 
PDS. Of all the extra-intestinal factors, only orthostatic symptom scores were 
independently associated with PDS - the odds of having PDS increased by 1.03 
(CI: 1.01-1.04) for every 1-point increase in orthostatic scores. 
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Table 4.3 :  Effect of psychopathology, fibromyalgia, somatic sensitivity,  
autonomic factors and the combination of all 4 on the association 
between JHS and FGID and between JHS and PDS 
 
 FGID PDS 
 
ORadj (age, gender) 
 
 
1.48 
(0.99-2.22) 
 
 
2.31 
(1.27-4.22) 
 
ORadj (age, gender, FM) 
 
 
1.45 
(0.96-2.18) 
 
 
2.13 
(1.15-3.93) 
 
ORadj (age, gender, auton) 
 
 
 
1.40 
(0.92-2.11) 
 
1.88 
(0.97-3.65) 
 
ORadj (age, gender, PHQ15adj) 
 
 
1.51 
(1.0-2.27) 
 
 
2.39 
(1.30-4.38) 
 
ORadj (age, gender, psych) 
 
 
1.44 
(0.96-2.19) 
 
 
2.06 
(1.10-3.83) 
 
ORadj (all) 
 
 
1.43 
(0.94-2.17) 
 
1.90 
(0.98-3.74) 
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4.5.10 Comparison of intestinal and extra-intestinal factors in FGID 
patients with and without JHS  
To find out if the presence of JHS in patients with FGID was clinically relevant, 
comorbidity and quality of life was compared in the JHS and non-JHS patients 
who were diagnosed with FGID and shown in Table 4.4. 
 
There were no differences in age or gender in the 2 groups. Patients with JHS 
were more likely to have chronic widespread pain (23.2% vs 11.7%, p=0.01), 
positive tender points (60% vs 41.1%, p=0.003) and more likely to fulfil criteria 
for fibromyalgia (12.6% vs 4.9%, p=0.02). They were also more likely to have a 
higher number of somatic symptoms as measured by the PHQ15 (13 vs 
10,p=0.001), but not if the GI questions were excluded i.e. PHQ15adj scores (6 
vs 6, p=0.6). Anxiety scores were higher in JHS (0.5 vs 0.36, p=0.02), but 
depression scores did not differ. JHS patients were more likely to have high 
urinary autonomic scores (30.5% vs 19.6%, p=0.047). There was no difference 
in the proportion of patients with high scores on any of the other autonomic 
domains. 
 
Compared to FGID patients without JHS, those with JHS had worse quality of 
life scores for the SF36 pain domain (45 vs 63.5, p=0.007), and role-limiting 
emotional domain (66 vs 100, p=0.01) - Table 4.5. No differences were 
observed in any of the other domains. 
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Table 4.4: Comparison of extra-intestinal features in FGID patients with 
and without JHS 
 NO JHS 
(n=163) 
JHS 
(n=95) 
p 
 
DEMOGRAPHICS 
 
% Female  
(CI) 
 
62.6 73.7 0.07 
Mean age  
(SE) 
 
42.0  
(1.02) 
39.3  
(1.4) 
0.11 
CHRONIC PAIN AND FIBROMYALGIA 
 
Fibromyalgia 
(CI) 
 
4.9 
(1.6-8.2) 
12.6 
(5.8-19.4) 
0.02 
Chronic widespread pain 
(CI) 
 
11.7 
(6.7-16.6) 
23.2 
(14.5-31.8) 
0.01 
%  positive tender points 
(CI) 
 
41.1 
(33.5-48.7) 
60.0 
(50.0-70.0) 
0.003 
SOMATIC SENSITIVITY 
 
PHQ15 
(IQR) 
 
10 
(6-14) 
13 
(9-17) 
0.001 
PHQ15 – no GI 
(IQR) 
 
6 
(3-9) 
6 
(3-10) 
0.67 
PSYCHOPATHOLOGY 
 
Anxiety 
(IQR) 
 
0.36  
(0.005-0.80) 
0.5  
(0.205-1.1) 
0.02 
Depression 
(IQR) 
 
0.62 
 (0.24-1.4) 
0.85  
(0.31-1.5) 
0.1 
AUTONOMICS: % with score>25 
 
Urinary 
(CI) 
 
19.6 
(13.5-25.8) 
30.5 
(21.1-39.9) 
0.047 
Orthostatic 
(CI) 
 
48.5 
(40.7-56.2) 
57.9 
(47.8-68.0) 
0.14 
Syncope 
(CI) 
 
2.5 
(0.0-4.8) 
1.1 
(0.0-3.1) 
0.3 
Vasomotor 
(CI) 
 
20.2 
(14.0-26.5) 
21.1 
(12.7-29.4) 
0.9 
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Table 4.5: Comparison of quality of life in FGID patients with and without 
JHS 
SF36 domain NO JHS 
(n=163) 
JHS 
(n=95) 
p 
 
Physical function 
(IQR) 
 
 
85  
(50-95) 
 
82.5  
(47.5-95) 
 
0.5 
Role limiting physical 
(IQR) 
 
75  
(0-100) 
50  
(0-100) 
0.1 
Emotional well being 
(IQR) 
 
68  
(52-80) 
68  
(52-80) 
0.9 
Role limiting emotional 
(IQR) 
 
100  
(33-100) 
66  
(0-100) 
0.01 
Energy fatigue 
(IQR) 
 
45  
(30-60) 
45 
 (27.5-60) 
0.6 
Pain 
(IQR) 
 
63.5  
(32-80) 
45  
(22-67) 
0.007 
Social function 
(IQR) 
 
62  
(37-87) 
62  
(25-87) 
0.4 
General health 
(IQR) 
 
 
50  
(30-65) 
45  
(25-60) 
0.4 
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4.6 Discussion 
4.6.1 Summary of results 
In this nested case-control study we aimed to determine if there was an 
association between JHS and GI disorders i.e. if there existed a high 
prevalence of JHS in general GI clinics and if there was an association between 
JHS and particular GI disorders. We demonstrated that 33% of patients 
attending a general gastroenterology clinic in secondary care fulfil criteria for 
JHS, and this was especially high in patients with FGID (38%) and patients with 
reflux (39%).  
 
FGID was significantly associated with JHS, compared to patients with no GI 
disease, and to patients with organic GI disease. The association between JHS 
and FGID appeared to be dependent on autonomic factors, and appeared to 
mostly relate to postprandial distress syndrome, although the prevalence of 
JHS in PI-IBS and chronic proctalgia were also high. Within the FGID group, 
patients with and without JHS differed with respect to extra-intestinal symptoms. 
Those with JHS had more chronic pain, fibromyalgia, positive tender points, 
somatic symptoms, anxiety and urinary autonomic symptoms.  
 
Unexpectedly, reflux was also significantly associated with JHS compared to 
non-GI controls and to patients with organic GI disorders. Interestingly, the 
association between JHS and reflux was independent of all measured factors, 
and appeared to mostly relate to NERD.  
 
There was no significant association between JHS and organic GI disorders, 
but there was variability in the prevalence of JHS in different organic disorders. 
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The prevalence of JHS was high in Crohn’s disease, Coeliac disease and 
pancreatico-biliary disorders, and low in ulcerative colitis and organic 
gastroduodenal disorders.  
 
Hence JHS appears to be associated with FGID and reflux, but not with organic 
GI disorders.  
 
4.6.2 Comparison with previous studies 
This is the first epidemiology study of JHS in a secondary care gastroenterology 
setting, and it was surprising to find that a third of all-comers to general 
gastroenterology clinics had previously undiagnosed JHS. The prevalence of 
JHS in the non-GI controls (26%) may also appear high but it is in fact 
comparable to previous studies in a healthy population (Baeza-Velasco, Gely-
Nargeot et al. ; Bulbena, Gago et al. 2011). The lack of previous diagnosis of 
JHS in both GI and non-GI patients is compatible with previous studies which 
suggest that JHS is a grossly undiagnosed condition (Adib, Davies et al. 2005). 
 
4.6.3 Association between JHS and FGID 
38% of patients with FGID attending non-specialist GI clinics satisfied the 
Brighton criteria for JHS. This is the first time that the prevalence of JHS has 
been measured in such a GI setting, and so a comparison with other studies is 
not possible. The only other GI study which measured the prevalence of 
hypermobility, did so in a specialist neurogastroenterology setting and did not 
have a control group for comparison (Zarate, Farmer et al. 2009). In that study, 
GJH (not JHS) was assessed using the 5-point hypermobility questionnaire and 
it was found that 49% of patients with FGID attending these specialist clinics 
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had GJH. However, due to the different setting and different methods of 
assessment, these studies are not directly comparable. 
 
Although previous studies suggest an association between JHS and FGID, 
(Ross and Grahame; Castori 2012), this is the only study which conclusively 
demonstrates this on a large scale. Although reports of an association between 
JHS and IBS have been published, our study did not find such an association. 
Instead the association was with postprandial distress syndrome (PDS), a 
subtype of functional dyspepsia. To our knowledge, this has never been 
previously reported, although one study of JHS patients attending a genetics 
clinic did report a high prevalence of ‘gastritis’ in their patients (Castori, 
Camerota et al. 2010). It is unknown whether those patients actually had 
endoscopic evidence of gastritis, which is an organic cause of dyspepsia, or 
whether they had a normal endoscopy and dyspeptic symptoms, in which case 
they would have fulfilled criteria for functional dyspepsia. 
 
The association between JHS and PDS is not surprising in view of the 
association between JHS and postprandial symptoms in the literature (Castori, 
Camerota et al. 2010) and in this thesis (Chapter 2 and 3). The association 
between JHS and symptoms of postprandial fullness and early satiety were 
present in both patients with established JHS (Chapter 2), and in healthy 
students with JHS (Chapter 3). Furthermore, published studies in JHS patients 
document a high prevalence of nausea, vomiting, dyspepsia and 
bloating,(Hakim and Grahame 2004; Rombaut, Malfait et al. 2011) all of which 
are features of functional dyspepsia, and more compatible with the PDS 
subtype than the epigastric pain syndrome subtype. 
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Within the FGID group, although it was only PDS which showed a significant 
association with JHS, it deserves mention that the highest prevalence of JHS 
was seen in both PI-IBS and chronic proctalgia, each of which will be discussed 
in turn. 
 
 The lack of an independent association between IBS and JHS is surprising, not 
only because of the presence of small series in the literature which document 
such an association, but also because published literature and data from our 
study in JHS patients (Chapter 2) both demonstrate an association between 
JHS and symptoms of abdominal pain, alternating bowel habit and bloating, all 
of which are core features of IBS. There are three possible explanations for this. 
The first is that IBS-C, IBS-D and IBS-M are differentially associated with JHS, 
and therefore by combining them, any association that would have been seen 
with the subtypes would be obliterated. This notion is supported by the fact that 
when the IBS subtypes were separated, the highest prevalence was seen in 
IBS-C, lowest in IBS-D, and intermediate in IBS-M. However despite the 
separation of the subtypes, the prevalence of JHS in IBS-C was still not 
significant. This may be because of the resultant small number of patients in 
each group and therefore a lack of power to detect a difference, especially as 
the study was only powered to detect a difference in the large diagnostic groups 
but not the small subcategories. Thus lack of power is the second possible 
explanation for why the prevalence of JHS was not significantly increased in 
IBS. The third explanation is that IBS and functional dyspepsia frequently 
overlap in up to two thirds of patients (Cremonini and Talley 2004; Ford, 
Marwaha et al. 2010). Using step-wise logistic regression, we demonstrated 
that IBS was not independently associated with JHS i.e. there was no 
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association between JHS and IBS in the absence of PDS. However this does 
not exclude the fact that patients with JHS and PDS may have coexistent IBS 
and this is what is reported in the literature.  In fact, in this study, 58% of the 
patients with JHS and PDS also had IBS, and the majority of this was IBS-M. 
 
Interestingly the prevalence of JHS was very high in PI-IBS. This suggests that 
JHS individuals are more predisposed to developing IBS following an infection 
compared to individuals without JHS. In the Walkerton study, it was found that 
the susceptibility to PI-IBS following an outbreak of gastroenteritis is associated 
with the presence of genes that encode proteins involved in epithelial cell 
barrier function and the innate immune response to enteric bacteria (Villani, 
Lemire et al. 2010). However before embarking on speculation that individuals 
with JHS have abnormal intestinal permeability or host immunity, it should be 
noted that the association between JHS and PI-IBS in our study was not 
significant but simply showed a trend in a small number of patients, and would 
need to be replicated in a larger study before any conclusions can be drawn. 
Furthermore, meta-analyses and systematic reviews demonstrate that younger 
age, female gender and associated anxiety and depression are risk factors for 
development of PI-IBS (Thabane, Kottachchi et al. 2007), and in fact these are 
all factors which are present in the JHS group. Therefore an alternative 
explanation for this seeming association between JHS and PI-IBS is simply due 
to the fact that the JHS individuals had the relevant demographic and 
psychological risk factors, and that it is not related to intrinsic differences in JHS 
per se.  
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In our study, 1 in 2 patients who satisfied the ROME III criteria for chronic 
proctalgia had JHS; this was not the case for proctalgia fugax where only a third 
of patients had JHS. This is a novel observation not previously described in the 
literature.  In our study of university students (Chapter 3) twice as many 
students with JHS complained of proctalgia compared to students without JHS 
(14% vs 7%), suggesting that there is a basis for the observation in this study. 
In a recent study to investigate possible mechanisms for chronic proctalgia, it 
was found that 59% of patients with chronic proctalgia had a high grade internal 
rectal prolapse and this was associated with obstructive defecation, suggesting 
that rectal prolapse underlies chronic proctalgia (Hompes, Jones et al. 2011), 
particularly in patients with obstructed defecation. In our study we had only 3 
patients with functional defecation disorders, and so it was impossible to draw 
any conclusions relating to this. However, rectal prolapse is associated with 
JHS and in fact, forms part of the diagnostic Brighton criteria (Table 1.5). 
Furthermore JHS has been shown to be associated with obstructive defecation, 
particularly in patients with lower urinary tract symptoms (Manning, Korda et al. 
2003).  Hence JHS patients are more likely to have obstructive defecation and 
rectal prolapses, both of which are associated with chronic proctalgia, and may 
therefore explain the high prevalence of JHS in chronic proctalgia. Future 
studies in a lower GI physiology setting may help shine more light on the 
matter.  
 
4.6.4 Association between JHS and reflux disorders 
39% of patients in general GI clinics with a reflux diagnosis (either Barretts, 
GERD or NERD, but not functional heartburn) satisfied the Brighton criteria for 
JHS, and this association was independent of anxiety, chronic pain, somatic 
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and autonomic factors. Furthermore, of the different reflux disorders, it was 
NERD which was most strongly associated. Although this was contrary to our 
expectations, it should not have come as a complete surprise. Firstly, other 
studies based on small numbers of JHS patients attending genetics clinics have 
documented a high prevalence of gastro-oesophageal reflux in JHS (Castori, 
Camerota et al. 2010). Secondly, our study of GI symptoms in JHS (Chapter 2) 
showed a significantly increased prevalence of regurgitation compared to GI 
patients without JHS. Thirdly, there exists literature to suggest that there is an 
overlap between reflux disease, IBS and functional dyspepsia, and furthermore, 
that IBS and functional dyspepsia symptoms are most common in NERD, 
compared to GERD and Barretts (Stanghellini, Tosetti et al. 1999; Neumann, 
Monkemuller et al. 2008). In our analysis using logistic regression we found the 
association between JHS and reflux to be independent of FGID, and therefore 
the explanation could not lie in the fact that patients with NERD were the 
patients with functional dyspepsia. Another explanation is that the same 
underlying pathophysiological mechanism is responsible for both NERD and 
functional dyspepsia (Talley 2006) and that this is present in JHS. One 
possibility is anxiety – this is known to be associated with JHS and is an 
independent predictor for overlap between NERD and functional dyspepsia in 
population studies (Lee, Lee et al. 2009). However, in our study, anxiety was 
not significantly involved in the association between JHS and FGID or reflux. 
Another common aetiological possibility is altered sensorimotor function which 
can lead to visceral hypersensitivity, dysmotility, and altered compliance, all of 
which have been implicated in both NERD (Thoua, Khoo et al. 2008; Kwiatek, 
Pandolfino et al. 2010; Porter, Kumar et al. 2012) and functional dyspepsia 
(Oustamanolakis and Tack 2012). This notion is supported by a study which 
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confirmed that gastroparesis was present in patients with reflux disease and 
with functional dyspepsia, and in patients with an overlap of both disorders 
(Gonlachanvit, Maurer et al. 2006). Furthermore, reflux disease was associated 
with more proximal gastric retention, and this pattern of gastroparesis was 
associated with symptoms of early satiety, regurgitation, bloating, and nausea, 
all symptoms that were confirmed to be increased in JHS (Chapter 2). A 
systematic study of proximal and distal gastroparesis in JHS patients with GI 
symptoms has never been performed, and will need to be addressed in the 
future. 
 
4.6.5 Association between JHS and organic GI disorders 
In our study 26% of patients with organic GI disorders satisfied the Brighton 
criteria for JHS and this was no different to non-GI controls, thus excluding an 
association between JHS and organic disorders in general. However, in view of 
the literature proposing an association between JHS and gastritis (Castori, 
Camerota et al. 2010), Coeliac disease (Danese, Castori et al. 2011) and 
between hypermobility and Crohn’s disease (Vounotrypidis, Efremidou et al. 
2009), we were keen to explore this further, and so divided the organic group 
into individual diagnoses. The prevalence of JHS in gastritis and duodenitis in 
our study was low (19%), which is in contrast to the proposition by Castori 
(Castori, Camerota et al. 2010; Castori, Sperduti et al. 2012) that JHS patients 
have a high prevalence of gastritis. As described earlier, it is unclear what 
‘gastritis’ referred to in the Castori study – it may have referred to dyspeptic 
symptoms in the absence of endoscopic evidence of gastritis, in which case it 
might really have referred to functional dyspepsia, which would be consistent 
with our findings in PDS. Furthermore, Castori’s study was very small with only 
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21 selected patients in genetics clinics, thus introducing a lot of selection bias. 
Hence it is more likely that our larger study of unselected patients is more 
representative of JHS patients in general.  
 
Although we did not demonstrate a significant association between JHS and 
either Coeliac disease or Crohn’s disease, the prevalence of JHS in these 
disorders (32% and 30% respectively) was much higher than the prevalence in 
other organic GI disorders suggesting that a trend did exist. Both Coeliac 
disease and Crohn’s Disease (CD) have features which overlap with FGID, 
particularly IBS, and this may explain this relatively high prevalence. IBS 
symptoms are significantly higher in Crohn’s disease than in non-IBD controls 
and in patients with UC (Halpin and Ford 2012). Furthermore, Crohn’s disease 
and IBS have many other features in common including decreased variability of 
gut microbiota, increased gut permeability, altered immune activation 
particularly in response to stress, and upregulation of Toll-like receptors 
(especially TLR-4) (Spiller and Lam 2011). Moreover, all these observations are 
supported by the fact that both Crohn’s disease and IBS share common 
susceptibility genes (Zucchelli, Camilleri et al. 2011), particularly relating to 
neural, mast cell or barrier function, and these are also associated with slow 
transit (Camilleri, Carlson et al. 2011) suggesting that the overlap is between 
CD and IBS-C. Interestingly, out of all the IBS subtypes, it was IBS-C which was 
most strongly associated with JHS.  
 
In the case of coeliac disease, published studies have suggested an 
association with IBS (Sanders, Carter et al. 2001). Furthermore, patients with 
IBS can develop non-coeliac gluten sensitivity (Pietzak 2012; Sanders and Aziz 
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2012) suggesting again that IBS and coeliac disease share features in 
common.  
 
All this suggests that similar mechanisms may underlie symptoms in Crohn’s 
disease and IBS, and in Coeliac disease and IBS and some of these 
mechanisms may exist in JHS thus explaining the trends with both organic 
disorders. However, in view of the small numbers of patients in each organic 
group, no meaningful or significant conclusions could be drawn. To further 
address this, much larger studies will be required, and inferences should be 
postponed until robust associations are established in much larger samples. 
 
 
4.6.6 Influence of autonomic and somatic factors on the association 
between JHS and FGID 
Anxiety, depression, fibromyalgia, somatic sensitivity (PHQ15) autonomic 
symptoms, younger age and female gender are all factors known to be 
associated with FGID, and these were all increased in patients with JHS, 
suggesting they were possible confounders. From chapter 2 it was evident that 
fibromyalgia, somatic sensitivity and autonomic symptoms were important in 
mediating the association between JHS and gastro-oesophageal symptoms, 
and so we performed a multiple logistic regression analysis to determine if they 
were also involved in the association with FGID. 
 
None of the extra-intestinal factors had a large effect on the observed 
association between JHS and FGID, which was contrary to our expectations. 
This may have been because the FGID group was large and heterogeneous, 
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and included several different functional GI diagnoses, many of which were not 
associated with JHS - Figure 4.8. Thus any individual differences between the 
groups ROME III subcategories would not be observed. To overcome this 
problem, the effect of the extra-intestinal factors was further explored in patients 
with PDS, a diagnosis we had shown to be independently associated with JHS.  
In the case of PDS, the presence of fibromyalgia, anxiety and depression 
reduced the strength of the association between JHS and PDS, but did not 
abolish it, suggesting that these factors were partly, but not substantially, 
involved in the association. Autonomic factors were the strongest confounders, 
and the addition of the autonomic symptom scores to the regression model, 
completely abolished the association between JHS and PDS, suggesting that 
the association of JHS and PDS was only present in those patients with high 
autonomic symptom scores. Furthermore, of all the autonomic domains it was 
the orthostatic domain that was responsible for this confounding effect and in 
fact it was independently associated with PDS. This supports our results in 
Chapter 2, where it was found that orthostatic symptoms are particularly 
important in mediating the postprandial symptoms. It also suggests that PDS 
occurs in patients with orthostatic dysfunction, or POTS. Preliminary support for 
this concept comes from the fact that POTS patients have postprandial 
symptoms (Mathias, Low et al. 2011) and this is associated with increased 
variability of the gastric pacemaker postprandially (Seligman, Low et al. 2012). 
These are early observations and will require further study in larger groups of 
patients. 
 
Interestingly, somatic sensitivity (PHQ15adj scores) did not confound the 
association between JHS and either FGID or PDS. This is compatible with our 
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study in university students, where somatisation did not influence the 
association between JHS and GI symptoms. However it contrasts with the study 
of JHS patients in Chapter 2 where somatic factors were very important in 
mediating the association between JHS and GI symptoms. One possible 
explanation is that somatic symptoms are not that important in determining GI 
symptoms early on, but become more important later in the progression of 
disease, when musculoskeletal and chronic pain symptoms become prominent, 
possibly as a result of peripheral and central sensitisation. This is supported by 
the fact that patients without musculoskeletal symptoms do not have many 
other symptoms (De Wandele, Rombaut et al. 2013), and that published studies 
demonstrating an association between JHS and functional somatic syndromes 
have all been performed in patients with musculoskeletal symptoms and an 
established diagnosis of JHS (Hakim and Grahame 2004; Castori, Celletti et al. 
2011).  
 
4.6.7 Influence of autonomic and somatic factors on the association 
between JHS and reflux disorders 
Although we did not initially aim to perform a detailed investigation of reflux 
disorders, the association of JHS with reflux was interesting and unexpected. 
To preliminarily explore whether this association was due to autonomic, 
psychological, pain and somatic factors, the multiple logistic regression analysis 
was also performed to investigate the effect of these extra-intestinal factors in 
patients with reflux. Interestingly, the association between JHS and reflux 
appeared to be independent of all these factors, suggesting that some other 
factor intrinsic to JHS is responsible for the development of reflux disorders. 
This requires further study and replication in a larger number of reflux patients. 
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4.6.8 Differential presentations of JHS and non-JHS patients with FGID 
It was interesting that JHS patients and non-JHS patients with the same type of 
GI disorder (FGID) differed with respect to several extra-intestinal factors and 
the JHS patients had more chronic pain, fibromyalgia, positive tender points, 
somatic symptoms, anxiety and urinary autonomic symptoms. Furthermore, 
their quality of life scores were worse for pain. This is all consistent with the 
data on JHS, as presented in the introduction. What is surprising is that in 
contrast to other studies which have compared JHS patients to healthy controls, 
our study compared JHS patients who were previously undiagnosed, to patients 
without JHS who had exactly the same kind of GI disorder. This makes it very 
unlikely that the differences seen are due to recall bias, and more likely that the 
association with these extra-intestinal symptoms is due to a true association 
with JHS.  It also highlights the importance of identifying JHS in patients with a 
combination of FGID and associated fibromyalgia, autonomic symptoms and 
widespread somatic symptoms. These are the classical ‘heart-sink’ patients 
who have multiple unexplained symptoms and respond poorly to conventional 
treatment. Identifying JHS may enable other therapeutic options to be explored, 
including cognitive behavioural therapy, which appears to be most effective for 
JHS patients with multiple symptoms (Daniel 2010). 
 
4.6.9 Future research implications 
The over-representation of JHS in PDS and NERD suggests that some 
underlying aetiology, which is present in JHS, predisposes these patients to 
these subtypes of GI disorders, as well as to FM, and chronic pain. Possibilities 
include autonomic dysfunction, somatic and visceral hypersensitivity, and 
abnormal biomechanical properties of the stomach and gastro-oesophageal 
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junction, all of which will need to be assessed in JHS to further our 
understanding of why these patients are prone to GI dysfunction. 
Understanding the mechanism of development of GI symptoms may also help 
explain why these patients are predisposed to developing other functional 
somatic syndromes. 
 
In addition, the high prevalence of JHS in NERD and PDS provides an 
opportunity to categorise these conditions by JHS phenotype. This may be 
more meaningful than an arbitrary symptom-based classification and may 
enable more meaningful genetic, physiological or molecular conclusions to be 
drawn.  
 
4.6.10 Limitations 
In this large blinded nested case-control study in GI clinics, where we compared 
patients with no prior knowledge of their JHS status, to a non-GI control group, 
we managed to overcome several of the limitations of previous studies. 
However, we were left with a few new limitations. Firstly, our study was 
powered to detect a 10% difference in the prevalence of JHS in FGID vs 
organic patients, and was not designed to detect differences in the individual 
diagnostic subcategories. Thus any association, or lack of, with the smaller 
groups of patients should be interpreted with caution. This also applies to the 
reflux group which is much smaller than the FGID and organic GI group. 
However, our significant findings in the smaller groups are consistent with 
previous literature and so are unlikely to be simply due to chance. Secondly, 
our GP control group (92 patients) was much smaller than we had planned for 
(270 patients). This was due to an extremely poor response rate despite the 
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involvement of multiple large GP practices. The consequence of this small 
control group is that the variability in this group was high, making it less 
generaliseable to the population. Thirdly, in line with this, our control group 
consisted of patients who had been referred to secondary care, rather than 
healthy controls, as we had wanted them to be as comparable to the GI patients 
as possible. Thus, our findings should be interpreted as being relative to a non-
GI patient group, rather than to a healthy population. Lastly, in the absence of a 
biomarker for the diagnosis of JHS, assessment was purely clinical and relied 
on the fulfilment on several major and minor criteria. Although some of these 
were objective (e.g. scoliosis, Marfanoid habitus, papyraceous scarring, 
Beighton score) others were fairly subjective and could have easily been 
affected by recall and response bias on the part of the patient. For example, 
particularly enthusiastic and hypervigilant patients with pain and anxiety issues 
may answer ‘yes’ to the ‘presence of arthralgia in more than 4 joints’,‘back pain’ 
and ‘multiple soft tissue injuries’. Thus there was a bias towards a positive 
diagnosis in patients with anxiety and chronic pain. However, this bias would 
have been expected to occur in all the different groups, thus although it might 
account for the very high absolute prevalence of JHS seen, it cannot explain the 
differential prevalence in the different GI categories. 
 
Conclusions 
JHS is present in a third of patients attending GI clinics. It is a risk factor for 
FGID and reflux disorders, specifically NERD and PDS, but not organic GI 
disorders. Autonomic and pain factors, but not somatic factors seem to be 
important in the association with FGID, but not with reflux. 
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Chapter 5 Preliminary Observations of Gastro-oesophageal Sensori-motor Function in patients with the Joint Hypermobility Syndrome and Symptoms of Dysphagia and Reflux 
Observations of Gastro-oesophageal Sensori-Motor 
Function in patients with the Joint Hypermobility 
Syndrome and Symptoms of Dysphagia, Reflux and 
Dyspepsia 
5.1 Introduction 
It is evident from the Chapter 2 that patients with JHS have, in addition to their 
musculoskeletal symptoms, an excess of upper GI symptoms particularly reflux, 
dysphagia and dyspepsia which adversely affects their quality of life. Effective 
treatment requires an understanding of the mechanisms underlying these upper 
GI symptoms, and this is so far lacking. Data presented in Chapter 4 of this 
thesis suggests that JHS is associated with FGID and gastro-oesophageal 
reflux disease (GORD), but not organic GI disorders (Chapter 4), so it is 
possible that mechanisms that are implicated in the pathophysiology of 
functional GI disorders and GORD may also be relevant to patients with JHS 
and GI symptoms.  
 
Mechanisms underlying functional disorders include abnormalities in sensitivity 
(centrally and peripherally), motility and biomechanics, and this is certainly true 
for gastro-oesophageal symptoms. For example, visceral hypersensitivity of the 
oesophagus is implicated in GORD (Thoua, Khoo et al. 2008), and abnormal 
gastric sensitivity is associated with functional dyspepsia (Tack, Caenepeel et 
al. 2001; Oustamanolakis and Tack 2012). Decreased compliance of the 
oesophageal body is associated with dysphagia in eosinophilic oesophagitis 
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(Kwiatek, Pandolfino et al. 2010) and impaired gastric accommodation is 
associated with functional dyspepsia (Tack, Piessevaux et al. 1998; 
Oustamanolakis and Tack 2012). Dysmotility of the oesophagus is associated 
with dysphagia (Clouse 2003; Roman, Lin et al. 2011), and gastroparesis is 
associated with early satiety and postprandial fullness, both features of 
Postprandial Distress Syndrome (Sarnelli, Caenepeel et al. 2003). Hence it is 
clear that symptoms of GORD, dysphagia and dyspepsia can arise secondary 
to sensori-motor and biomechanical abnormalities. 
 
Reflux symptoms can be due to pathological acid reflux, oesophageal 
hypersensitivity to physiological reflux or to functional heartburn. The latter 
refers to the presence of reflux symptoms in the absence of pathological or 
physiological reflux and it is incompletely understood compared to the other 
reflux subtypes. Oesophageal hypersensitivity is thought to be secondary to 
sensorineural processes occurring either peripherally or centrally (Sarkar, Aziz 
et al. 2000; Lottrup, Olesen et al. 2011). Pathological acid reflux is due to either 
an increase in the number of reflux episodes or an increase in the exposure of 
the oesophagus to acid. It is associated with anatomical changes in the gastro-
oesophageal junction (e.g. hypotensive lower oeosphageal sphincter and hiatus 
hernias), as well as with more physiological abnormalities such as increased 
compliance of the gastro-oesophageal junction (Kwiatek, Pandolfino et al. 
2010), and  dysmotility of the stomach and oesophagus (Galindo, Vassalle et al. 
2012).  
 
A study of upper GI physiology in patients with JHS and upper GI symptoms 
has never been performed and so it is unknown whether there are 
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demonstrable physiological abnormalities that can account for GI symptoms in 
these patients, or whether symptoms are truly unexplained and may possibly be 
related to psychosomatic factors. One published case series demonstrated that 
upper GI dysmotility, including gastroparesis and oesophageal hypomotility, 
was present in some symptomatic JHS patients attending a tertiary 
neurogastroenterology clinic (Zarate, Farmer et al. 2009), suggesting that GI 
dysmotility has been documented in a small proportion of symptomatic JHS 
patients. However, it is difficult to draw any firm conclusions from this, as it was 
simply an observation in a small number of selected patients. Furthermore, it 
did not include a control group and so it remains unknown how upper GI 
physiology in symptomatic JHS patients compares to that in non-hypermobile 
patients with similar symptoms. 
 
Whereas a detailed study of visceral sensori-motor function in JHS patients has 
not yet been undertaken, several studies of the skin and skeletal muscle of JHS 
patients demonstrate that biomechanical and sensori-motor abnormalities are 
present in musculoskeletal tissue in JHS, and these are thought to underlie 
several somatic symptoms. For example, patients with JHS have increased 
compliance of their skin (Henry, Goffin et al. 1996; Hakim and Sahota 2006; 
Grahame and Hakim 2008), increased somatic hypersensitivity associated with 
fibromyalgia (Castori 2012), and myopathic features in skeletal muscle which 
are associated with decreased muscle strength and tone, and with myalgia and 
fatigue (Voermans, van Alfen et al. 2009; Rombaut, Malfait et al. 2012; 
Rombaut, Malfait et al. 2012). Thus, sensori-motor and biomechanical 
abnormalities do underlie other symptoms in JHS, and it is not inconceivable 
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that they may also be present in the upper GI tract and be associated with 
symptoms.  
 
5.2 Aims 
The aims of this study were (1) to determine if physiological abnormalities in the 
stomach and oesophagus are present in JHS patients with symptoms of 
dysphagia, and reflux; (2) to determine how GI physiology findings compare to 
those observed in non-hypermobile patients with similar symptoms; and (3) to 
determine if compliance is increased in the GOJ in patients with JHS and reflux 
symptoms.  
 
5.3 Hypothesis 
We hypothesised that the connective tissue abnormality in JHS is not localised 
to the musculoskeletal system but also present in the GI tract where it affects 
the biomechanics of the gut, leading to altered physiology including dysmotility, 
and therefore symptoms. Hence, we expected symptoms in JHS patients to be 
associated with physiological and compliance abnormalities. 
 
5.4 Materials and methods 
5.4.1 Study design 
A prospective characterisation of upper GI physiology findings was carried out 
in consecutive patients with established JHS attending the upper GI physiology 
unit between June 2011 and December 2012. JHS patients completed a set of 
validated questionnaires to assess for upper GI symptoms, and then underwent 
a combination of high-resolution manometry (HRM) and 24-hour combined 
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ambulatory pH-impedance testing (MII). The study design was ‘pragmatic’ and 
therefore other tests, including gastric emptying testing using 13C Octanoic Acid 
breath tests, were only performed if requested by the physician. Results of 
physiological testing were compared to that in a group of age-matched controls 
without hypermobility who were attending the GI physiology department for 
investigation of similar symptoms.  
 
Halfway through the study an endoflip tool, which is used for the assessment of 
GOJ distensibility, was acquired by the department. As part of the department 
policy, JHS patients who had reflux disease and who were attending the unit for 
investigation after this time also underwent Endoflip testing.  Data from the 
endoflip was compared to healthy control data obtained from a previously 
published study. 
 
5.4.2 Subjects 
JHS patients 
Adult patients (>18 years) who had a confirmed diagnosis of JHS, and who 
were attending the GI physiology unit for investigation of dysphagia or reflux 
were included.  
 
Non-hypermobile controls  
Control data was obtained from a database of all patients who had attended the 
GI physiology unit between Jan 2010 and December 2011 for investigation of 
upper GI symptoms. This database contained demographic information, 
symptom profiles, responses to the hypermobility screening questionnaire and 
the results of physiology testing. All patients who were between the ages of 18 
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and 65, who had fully completed and screened negatively on the hypermobility 
questionnaire, and who had symptoms of dysphagia and/or reflux were selected 
as controls. Patients with diabetes, connective tissue disorders or vasculitides 
were excluded, as were patients with incomplete tests and those with faulty test 
results secondary to technical problems.  
 
Exclusion criteria 
Both JHS patients and non-hypermobile controls were excluded if they had 
undergone previous surgery to the stomach or oesophagus, or therapeutic 
endoscopic procedures e.g. oesophageal dilation, Botox injection, or if they 
were on PPI or prokinetics at the time of HRM or MII testing.  
 
5.4.3 Questionnaires 
JHS patients completed a detailed set of validated questionnaires to assess for 
reflux and dysphagia symptoms.  
 
Reflux disease questionnaire (RDQ) 
This is a self-administered questionnaire that has been validated to identify 
patients with gastro-oesophageal reflux disease in primary care (Ofman, Shaw 
et al. 2002). It scores 12 individual items relating to the frequency and severity 
of reflux, using a Likert scale, where 0 represents the most positive option and 5 
the most negative one. A raw score is calculated for domains of heartburn 
(score: 0-20) and regurgitation (score: 0-20), both of which can be combined to 
give a total GERD score (0-40). A cut-off of 9 for the GERD domain has 83% 
sensitivity and 83% specificity for identifying the presence of gastro-
oesophageal reflux symptoms (Ofman, Shaw et al. 2002).  
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Dysphagia Odynophagia Questionnaire 
This is a validated 10-item questionnaire that assesses the frequency of 
dysphagia, food impaction and odynophagia. Items are scored from 0-5, using a 
Likert scale where higher scores represent worse symptoms. A total score out 
of 50 is calculated - higher scores represent more severe dysphagia. A score ≥ 
6 has 86% sensitivity and 97% specificity for identifying the presence of 
dysphagia (Escobar, Pandolfino et al. 2011).  
 
Dyspepsia questionnaire 
This consists of 9 dyspeptic symptoms and 1 heartburn symptom, each of which 
is scored from 0-3 to indicate the severity and relevance of the symptoms over 
the past 3 months. A maximum score out of 30 was obtained, with higher 
scores indicating greater severity of dyspepsia (Tack, Caenepeel et al. 2001). 
 
5.4.4 Physiology assessment 
All subjects were studied having been fasted for at least 6 hours, and 
medication that could affect oesophageal motor function or the presence of 
reflux (e.g. prokinetics, smooth muscle relaxants, proton pump inhibitors, 
antacids) were discontinued for at least 5 days prior to the study. 
 
5.4.4.1 High Resolution Manometry (HRM)  
A solid-state HRM assembly with 36 solid-state sensors spaced at 1-cm 
intervals was used (Sierra Scientific Instruments Inc., Los Angeles, CA). Each 
sensor is circumferentially sensitive, accurate to within 1 mmHg, and capable of 
recording transient pressure changes in excess of 6,000 mmHg/s - Figure 5.1. 
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The catheter was calibrated and zeroed to atmospheric pressure, prior to each 
study.  
 
 
 
Figure 5.1: HRM catheter. 
The HRM catheter consists of 36 solid-state sensors spaced 1cm apart. 
 
Studies were performed with the patient in a semi-recumbent position. The 
catheter was passed transnasally and positioned until both the upper 
oesophageal sphincter (UOS) and lower oesophageal sphincter (LOS) could be 
visualized in the recording frame, with at least 3 intragastric sensors visible. The 
catheter was fixed in place by taping it to the side of the face. The patient was 
given 5 minutes to settle, before a 30 second swallow-free period (landmark 
frame) was recorded. This was used to assess the oesophageal landmarks  - 
Figure 5.2 - and to obtain the resting (basal) UOS and LOS pressures. 
Following this, recordings of 10 water swallows  (5ml of water spaced at least 
30 seconds apart), and 2-3 multiple rapid swallows (MRS) (five 2 mL water 
swallows 2-3s apart) were obtained. The latter was used to assess the 
neuromuscular integrity of the oesophagus and has been found to be useful in 
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the assessment of patients with hypomotility (Fornari 2009 NGM). Pressure 
data were acquired using a computerized HRM acquisition, display and analysis 
system (Manoscan, Manoview; Sierra Scientific Instruments/Given Imaging). 
 
	  
Figure 5.2: High-resolution manometry tracing of a water swallow.  
A normal swallow is associated with relaxation of the upper and lower 
oesophageal sphincters, and peristaltic contraction of the oesophageal 
body. The black solid line surrounding the peristaltic contraction is the 
isobaric contour, which can be set at any pressure. Breaks larger than 
2cm in the 20mm Hg isobaric contour are indicative of hypomotility. 
 
Analysis of manometry studies was performed using Sierra ManoView software 
version 2 (Sierra Scientific Instruments). UOS basal and residual pressure, LOS 
basal and residual pressure, and the distal contractile integral (DCI) were 
calculated. The 20mm Hg isobaric contour was used to detect the presence of 
breaks in the peristaltic waves. In this way, the number of swallows with small 
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breaks (2-5cm), large breaks (>5cm) and the number of failed swallows was 
counted for each of the patients, and used to determine the motility pattern, as 
per the Chicago classification (Bredenoord, Fox et al. 2012). Furthermore, the 
presence of a hiatus hernia, and the response to MRS was noted.   
 
5.4.4.2 Multichannel Intraluminal Impedance Monitoring (MII)  
Combined oesophageal impedance-pH monitoring was performed using a 
Sleuth® Multi-channel Intraluminal Impedance ambulatory system (Sandhill 
Scientific, Inc.; Highland Ranch, CO). The system includes a portable data 
logger with impedance-pH amplifiers and a catheter containing one antimony 
pH electrode and eight impedance electrodes at 2, 4, 6, 8, 10, 14, 16, and 18 
cm from the tip of the catheter. Each pair of adjacent electrodes represents an 
impedance-measuring segment, 2 cm in length, corresponding to one recording 
channel. The impedance amplifier delivers AC voltage in a range of 1–2 kHz 
with resulting current flow variations in response to intraluminal impedance 
changes. The six impedance and pH signals were recorded at 50 Hz on a 128 
MB CompactFlash card for further analysis. The studies were performed ‘off’ 
PPIs, following the HRM protocol. Before the start of the recordings, the pH 
recorder was calibrated using pH 4.0 and 7.0 buffer solutions. 
 
After LOS location by HRM, the impedance-pH catheter was passed 
transnasally and positioned in the esophageal body to record pH at 5 cm and 
impedance at 3, 5, 7, 9, 15, and 17 cm proximal to the LOS. Subjects were 
encouraged to maintain normal activities, sleep schedule, and eat their usual 
meals at their normal times. Event markers on the data-logger recorded 
symptoms, meal times, and posture changes. 
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Analysis of the MII-pH tracings was performed by computer with software from 
Sandhill Scientific (BioView Analysis version 5.6.0). The tracings were revised 
visually and manually for bolus and symptom events and for bolus–symptom 
correlation. The final reports included the number of acid and non-acid reflux 
episodes  - Figure 5.3 - (both total and those with proximal extent), the total acid 
exposure, split into the upright and the recumbent components, the number of 
symptoms, and 2 measures of the reflux-symptom correlation: the symptom 
index (SI), and the symptom association profile (SAP).  
 
 
Figure 5.3: MII tracings of acid and non-acid reflux events.  
In both events the drop in impedance (dashed arrow) starts distally and 
travels proximally, confirming reflux. In acid reflux (A) the reflux event is 
accompanied by a drop in pH. In non-acid reflux (B) there is no 
accompanying drop in pH. 
 
5.4.4.3 Gastric emptying testing  
Gastric emptying was measured using the previously validated breath test.  
Briefly, all studies were performed after a 6-hour fast. Baseline end alveolar 
breath samples were taken followed by a test meal, which was either solid or 
	   213	  
semi-solid. The solid meal consisted of scrambled egg labeled with 100mg 13C 
octanoic acid, and 2 slices of toast. The semi-solid meal consisted of plain oats 
and milk mixed and labeled with 100mg 13C acetic acid. Following the meal, 
end-alveolar breath samples were taken every 15 minutes for 2 hours and then 
every 30 minutes for a further 2 hours. Gastric half emptying time (T1/2) was 
calculated by measuring the presence of exhaled 13CO2 by isotope-selective 
nondispersive	   infrared spectrometry (IRIS; Wagner/Analysen Technik). Gastric 
emptying was considered delayed when the T1⁄2 exceeded 135 minutes in 
solids, and 80 in semi-solids (Schadewaldt, Schommartz et al. 1997).  
 
5.4.4.4 Endoflip assessment  
Distensibility of the GOJ was determined using the commercially available 
EndoFLIP system (McMahon, Frokjaer et al. 2007) - Figure 5.4. In this 
technique, a probe is inserted into the oesophagus and placed at the level of 
the GOJ. The probe consists of a 240-cm catheter with a 14-cm bag attached to 
its distal end, which is compliant to a maximal diameter of 25 mm. Within the 
inflatable bag, 17 electrodes are placed at 4-mm intervals. An excitation current 
of 100 µA is generated between 2 adjacent electrodes at a frequency of 5 kHz. 
Using impedance planimetry, cross-sectional areas (CSAs) are determined for 
the 16 balloon cross-sections during volume-controlled distensions. 
Additionally, 2 pressure sensors are located on the probe to determine intrabag 
pressure, allowing assessment of GOJ distensibility. The distention probe and 
the pressure transducers were calibrated by the manufacturer.  
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Figure 5.4: Endoflip assembly. A pre-filled syringe containing conducting 
solution is attached to the recording unit, and to the endoflip catheter, 
which has its end an inflatable balloon which contains the impedance 
electrodes and the pressure sensors. Inflation and deflation of the bag 
with the conducting solution is operated using the touchscreen display. 
 
The pressure sensor was zeroed before insertion of the catheter, and 
subsequently the deflated catheter was inserted through an anesthetized 
nostril. HRM readings were used to position the balloon at the level of the GOJ. 
The catheter was manually held in place by anchoring it at the nostril, as the 
inflations frequently resulted in peristaltic contractions and a caudal migration of 
the catheter. The balloon was inflated from 10ml to a maximum of 50ml in 5 ml 
increments, as tolerated by the patient. Pressures and CSAs were collected at a 
rate of 10Hz. Median values of intrabag pressure and minimum CSA at each of 
the above volumes was assessed by analyzing peristalsis-free intervals. 
Distensibility was calculated at each of the time frames over the peristalsis-free 
period, by dividing the minimum CSA by the intrabag pressure. The 
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distensibility calculated at each of the distending volumes was the median 
distensibility over that time frame.  
 
5.4.5 Terminology and parameters 
The terms used in this chapter are defined in Table 5.1 and Table 5.2. The 
motility patterns in Table 5.1 are taken from the Chicago classification of motility 
disorders (Bredenoord, Fox et al. 2012). Patients were considered to have 
pathological acid reflux if they had an increase number of reflux events i.e. > 45 
reflux events, or >35 acid reflux events (Zerbib, Roman et al. 2012); or if they 
had increased acid exposure i.e. >4.2% total acid exposure, >6.3% upright acid 
exposure or >1.2% recumbent acid exposure (Zerbib, Des Varannes et al. 
2005).  
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Table 5.1: Terms and definitions used for the HRM studies. 	  
Term Definition 
 
LOS basal pressure 
 
 
Mean of the minimum pressures at the LOS during 
respiration. Hypotensive if less than 4.8 mmHg 
 
 
Integrated relaxation pressure 
(IRP) 
 
 
Represents LOS relaxation during a swallow. 
IRP>15 indicates incomplete LOS relaxation 
 
Distal contractile integral (DCI) 
 
 
Represents the force of oesophageal contraction 
during a swallow. DCI<450 indicates hypomotility. 
DCI>5000 indicates hypertensive contractions. 
 
 
Weak peristalsis with small 
breaks 
 
Small breaks (2-5cm) in the 20 mmHg isobaric 
contour in more than 3 wet swallows 
 
 
Weak peristalsis with large 
breaks 
 
Large breaks (>5cm) in the 20 mmHg isobaric 
contour in 3 or more wet swallows 
 
 
Frequent failed peristalsis 
 
Failure of oesophageal contractions in more than 
3 out of 10 swallows. 
 
 
Absent peristalsis 
 
Absence of oesophageal contractions on all wet 
swallows in the presence of a normal IRP 
 
 
Oesophageal hypomotility 
 
Collective term to describe weak peristalsis, 
frequent failed peristalsis and absent peristalsis 
 
 
Achalasia 
 
Incompletely relaxing LOS (high IRP) and failure of 
normal peristalsis 
 
 
Oesophageal spasm 
 
Rapid oesophageal contractions 
 
 
Hypertensive peristalsis 
 
Oesophageal contractions with DCI>5000 
 
 
Functional GOJ obstruction 
 
Incompletely relaxing LOS in the presence of 
preserved peristaltic contractions 
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Table 5.2: Terms and definitions used for the reflux studies. 	  
Terms Definitions 
 
Symptom Index (SI) 
 
Measure of the association between reflux 
episodes and symptoms. Positive if SI>50 
 
Symptom Association Probability 
(SAP) 
Another measure of the association 
between reflux episodes and symptoms. 
Positive if SAP>95 
 
Erosive reflux disease (GERD) Presence of oesophagitis or Barrett’s 
oesophagus on endoscopy 
 
Non-erosive reflux disease (NERD) Reflux in the absence of positive 
endoscopic findings. Includes both Non-
erosive pathological GOR and 
Hypersensitive oesophagus 
 
Pathological GOR – Non erosive Increased acid exposure or increased reflux 
episodes on 24-hour reflux testing in the 
absence of a positive endoscopy 
 
Hypersensitive oesophagus Normal acid exposure with a positive 
association between reflux episodes and 
symptoms  
 
Functional heartburn Reflux symptoms in the absence of 
pathological acid reflux episodes or 
pathological acid exposure and the 
absence of a positive reflux-symptom 
correlation.  
 
Acid reflux Reflux episodes accompanied by a drop in 
pH<4.5 
 
Non-acid reflux Reflux episodes not accompanied by a 
drop in pH<4.5 
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5.4.6 Data analysis and statistics 
Data were described in terms of means and standard errors (normal ordinal 
data), medians and IQR (non-normal ordinal data) and proportions and 
confidence intervals (categorical data). Comparisons between JHS patients and 
controls were performed using the t-test (normal ordinal data), Mann Whitney U-
test (non-normal ordinal data), chi squared test (categorical data) or Fisher’s 
exact test (categorical data with values of less than 5%). For all comparisons, p 
values <0.05 were considered statistically significant.  
 
5.5 Results 
5.5.1 Subjects 
JHS patients 
30 JHS patients (28 female, age range: 18-62) attended the GI physiology unit 
between June 2011 and December 2012. HRM and MII were performed as 
basic tests on all subjects. 16 of the 30 had additional gastric emptying tests, 
and 8 of the 30 had endoflip testing - Figure 5.5. Symptom characteristics, and 
results of motility, reflux and gastric emptying testing for each of the 30 patients 
is shown in Table 5.3, Table 5.4 and Table 5.5. 
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Figure 5.5: Flowchart of JHS patients undergoing GI physiology testing 	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Table 5.3: Characteristics of each of the 30 JHS patients Sx:	  symptoms,	  POTS:	  Presence	  of	  postural	  orthostatic	  tachycardia	  syndrome	  Dysphagia	  symptoms	  based	  on	  dysphagia	  score:	  -­‐	  :	  0-­‐6;	  +:	  6-­‐25;	  ++:	  26-­‐50	  Reflux	  symptoms	  based	  on	  RDQ	  GERD	  score:	  -­‐:	  0-­‐9;	  +:	  10-­‐25;	  ++:	  26-­‐40	  Dyspepsia,	  based	  on	  dyspepsia	  score:	  -­‐	  :	  0-­‐10;	  +:	  11-­‐20;	  ++:	  	  21-­‐30	  OGD	  findings:	  HH:	  Hiatus	  hernia;	  NA:	  OGD	  not	  done;	  	  N:	  Normal;	  HP:	  H	  Pylori;	  G:	  Gastritis;	  D:	  Duodenitis	  	  
Patient 
 
Age 
 
Sex 
 
POTS 
 
Dysphagia 
Sx 
Reflux 
sx 
Dyspepsia 
Sx 
OGD findings 
 
1 35 F - ++ + ++ NA 
2 25 F + + + + NA 
3 26 M - + + + HH 
4 40 F + ++ ++ ++ Gastric polyps 
5 27 F + ++ + + N 
6 31 F - - - + N 
7 20 F - - ++ + N 
8 30 F + + ++ - N 
9 24 F + ++ ++ ++ NA 
10 38 F - + - ++ N 
11 20 F + ++ ++ ++ N 
12 32 F - + ++ ++ HH 
13 25 F + + + + NA 
14 48 F - + - + HP Gastritis 
15 34 F + ++ ++ ++ NA 
16 46 F + + + + N 
17 40 F + + + + NA 
18 18 F + - + + NA 
19 45 F - + + + HH 
20 28 M - - + + NA 
21 29 F - - ++ + NA 
22 62 F - + + + Gastric polyps, HH 
23 30 F + + + + NA 
24 32 F + ++ ++ ++ NA 
25 24 F + + ++ ++ NA 
26 28 F - + + + NA 
27 23 F + + - + NA 
28 48 F + + ++ + NA 
29 26 F + + + + Food residue 
30 21 F + ++ ++ ++ Food residue, G, D 
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Table 5.4: Oesophageal motility and gastric emptying in JHS patients LOS	  basal	  pressure:	  L:	  Low,	  N:	  Normal,	  H:High	  ;	  LOS	  relaxation:	  Y:	  complete	  relaxation	  (IRP<15),	  N:	  incomplete	  relaxation;	  DCI:	  Distal	  contractile	  integral:	  L:	  Hypotensive	  	  (DCI<450),	  N:	  Normal	  (DCI:	  450-­‐5000);	  HH:	  hiatus	  hernia,	  -­‐:	  No	  hiatus	  hernia;	  Motility	  pattern:	  N:Normal,	  FF:	  Frequent	  failed	  peristalsis,	  LD:	  Weak	  peristalsis	  with	  large	  defects,	  SD:	  Weak	  peristalsis	  with	  small	  defects;	  MRS	  pattern:N:	  Normal;	  Weak:	  Weak	  after-­‐contraction,	  Inc	  Inh:	  Incomplete	  inhibition	  of	  contractions	  ;	  Gastric	  emptying:	  NA:	  Not	  performed,	  N:	  Normal,	  D:	  Delayed,	  SD:	  Severely	  delayed	  	  
Patient 
 
LOS 
Basal P 
LOS 
relaxation 
DCI HH Motility MRS Gastric 
emptying 
1 N Y N - N N NA 
2 N Y N 3cm FF N D 
3 N Y N - LD N NA 
4 N Y N - N Inc Inh NA 
5 L Y L 1cm LD N NA 
6 L Y L - LD Weak NA 
7 N Y N - N Inc Inh D 
8 N Y N - N N D 
9 N Y N - N N D 
10 N Y N - LD N D 
11 L Y L - LD Weak SD 
12 N Y L <1cm SD Weak NA 
13 N Y L - SD N D 
14 H N N - N Inc Inh D 
15 N N N - LD Weak NA 
16 N Y N <1cm N N NA 
17 N Y N - SD N D 
18 L Y L - FF N NA 
19 N Y N <1cm LD Weak NA 
20 L Y N - N Weak NA 
21 L Y N  <1cm N N D 
22 L Y N - N N NA 
23 L Y L - FF N SD 
24 N Y L - LD Weak D 
25 N Y L - FF N N 
26 N Y L - N N N 
27 N Y N <1cm N N NA 
28 N Y N - N N SD 
29 N Y N - N N D 
30 N Y L - FF Weak NA 
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Table 5.5: Reflux findings in JHS patients Ep:	  Episodes;	  Exp:	  Exposure;	  Sx	  :	  Symptom;	  Dx:	  Diagnosis	  ;	  NA:	  Not	  measured;	  Total	  reflux	  episodes:	  N:	  Normal	  (<45),	  +:	  High	  (>45),	  ++:	  very	  high	  (>80);	  Acid	  reflux	  ep:	  N:	  Normal	  (<35),	  +:	  High	  (≥35);	  Non-­‐acid	  reflux	  ep:	  N:	  Normal	  (<12),	  +:	  High	  (>12);	  Total	  acid	  exp	  :	  N:	  Normal	  (<4.2),	  +:	  High	  (>4.2),	  ++:	  Very	  high	  (>	  10);	  Upright	  acid	  exp	  :	  N:	  Normal	  (<6.3),	  +:	  High	  (>6.3),	  ++:	  Very	  high	  (>12);	  Recumbent	  acid	  exp:	  N:	  Normal	  (<1.2),	  +:	  High	  (1.2-­‐10),	  ++:	  Very	  high	  (10.1-­‐20),	  +++:	  Extremely	  high	  (>20);	  Symptom	  correln:	  -­‐:	  No	  correln	  H:	  positive	  correln	  with	  heartburn,	  R:	  positive	  correln	  with	  regurgitation;	  Diagnosis:	  AR:	  Pathological	  acid	  reflux,	  HO:	  hypersensitive	  oesophagus,	  F:	  Functional	  reflux	  symptoms	  
Patient 
 
 
Total 
reflux  
ep 
Acid  
reflux  
ep 
Non-ac 
reflux  
ep 
Total  
acid exp 
Upright  
acid exp 
Recumb 
acid exp 
Sx 
correln 
Dx 
1 + + H N N + R HO 
2 N N N N N N - F 
3 N N H N N N - F 
4 + N H + ++ N H AR 
5 + N H N N N H,R HO 
6 N N N N N N - F 
7 N N H N N N - F 
8 + + H + + N H,R AR 
9 NA NA NA NA NA N - NA 
10 NA NA NA NA NA N - NA 
11 N N N N N N - AR 
12 N N H ++ N ++ R AR 
13 ++ + H N N N H,R AR 
14 N N N N N N - F 
15 N N N N N N - F 
16 N N N + ++ N R AR 
17 + N H N N + R AR 
18 + + N ++ N +++ - AR 
19 + N H N N + - AR 
20 N N N ++ ++ +++ H AR 
21 + N H N N N R HO 
22 + + H ++ N +++ - AR 
23 + + H + N + H AR 
24 N N N + N ++ H AR 
25 + N H N N N H,R HO 
26 + N H N N N R HO 
27 N N N N N N - F 
28 N N N N N N R HO 
29 ++ NA NA N + + R AR 
30 N N H + + N R AR 
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Non-hypermobile control patients 
1108 patients underwent GI physiology testing between Jan 2010 and 
December 2011. 382 scored 0 out of 5 on the screening hypermobility 
questionnaire, and therefore screened negative for JHS. Of these, 311 were 
between the ages of 18 and 65, and 259 were eligible for inclusion into the 
study - Figure 5.6. 98 patients had dysphagia and complete HRM data (56 
female, age range 20-65), and 108 had reflux symptoms and had complete 
HRM and MII testing off PPI (61 female, age range 18-65). 	  	  	  
 
 
Figure 5.6: Selection of non-hypermobile controls 	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To understand the individual symptoms and enable appropriate comparisons 
with the control group, both JHS and non-hypermobile patients were divided 
into those with predominant symptom of dysphagia (25 JHS, 98 controls) and 
those with predominant symptoms of reflux (26 JHS, 108 controls) and the 
physiology findings were compared in patients with the same symptom. Hence 
the results will be split into three parts. The first part relates to dysphagia, the 
second part to reflux and the third part to GOJ compliance.  For each part, GI 
physiology in JHS will be characterised and will then be compared to the control 
group. 
 
5.5.2 Dysphagia in JHS 
25 of the JHS patients (93% female, age range 18-62) had symptoms of 
dysphagia, and their dysphagia scores ranged from 6 to 45 out of 50 - Figure 
5.7. None of the JHS patients had an obstructive cause for dysphagia on 
endoscopy or barium swallow. To investigate for other possible mechanisms for 
dysphagia, the characteristics of the gastro-oesophageal junction and the 
motility patterns were analysed on the HRM tracings. 
 
	  
Figure 5.7: Dysphagia scores in JHS patients.  
The dotted line represents the cut-off score of 6 which is used to identify 
the presence of dysphagia. 25 of the 30 patients had scores > 6. 
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5.5.2.1 HRM findings in JHS patients with dysphagia 
Gastro-oesophageal junction 
2 out of the 25 patients had a high IRP (incompletely relaxing LOS), and both 
these patients had high or borderline high basal LOS pressures - Figure 5.8. In 
both these patients, peristalsis was present thus excluding the diagnosis of 
achalasia. Subsequent barium swallows in these patients revealed clear 
passage of contrast into the stomach with no hold-up in the oesophagus, 
thereby suggesting that the high IRP was no responsible for the dysphagia.  
 
 
Figure 5.8: Characteristics of GOJ in JHS patients with dysphagia.  
Most patients had normal basal LOS pressures and a completely relaxing 
LOS. 2 patients had a high IRP i.e. an incompletely relaxing LOS. One of 
these patients had a high basal LOS pressure and the other had a 
borderline high basal LOS pressure. 
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Oesophageal motility  
Although 2 patients had a high IRP and should have been classified as GOJ 
outflow obstruction (Table 5.1), it was clear from the barium swallow that there 
was no obstruction and hence they were categorised as per their motility 
pattern - Table 5.1. 
 
Of the 25 patients with JHS and dysphagia, 11 had normal oesophageal 
motility, 3 had weak peristalsis with small defects, 7 had weak peristalsis with 
large defects and 4 had frequent failed peristalsis - Figure 5.9. Thus, a total of 
14 patients (56%) had oesophageal hypomotility. 
 
 
Figure 5.9: HRM motility patterns in JHS patients with dysphagia.  
a- Normal motility (44%), b- weak peristalsis with small breaks (12%),  
c-weak peristalsis with large breaks (28%), d- frequent failed peristalsis 
(16%). Oesophageal hypomotility was present in 56%.  
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Consistent with the high prevalence of fragmented or failed swallows, the mean 
DCI, a measure of total contractile force, was low in 10 patients (40%), and in 
the remaining patients it was in the lower end of the normal range  - Figure 
5.10.  
 
 
 
Figure 5.10:  Mean DCI in patients with JHS and dysphagia.  
Dotted lines represent the upper and lower limit of normal. None of the 
JHS patients had a high DCI, or hypertensive oesophageal contractions. 
10 of the 25 patients had a very low DCI, consistent with oesophageal 
hypomotility.  
 
To further characterise the oesophageal hypomotility the multiple rapid swallow 
(MRS) traces were examined. A normal MRS involves the complete relaxation 
of the LOS, inhibition of oesophageal contractions during the MRS and a high 
amplitude after-MRS contraction (Figure 5.11a). All patients with normal motility 
had a normal MRS response. Out of the 14 patients with hypomotility, 6 (43%) 
had an abnormal MRS response, with weak, fragmented after-contractions 
(Figure 5.11b). This suggested that in 43% of the patients with oesophageal 
hypomotility, there was a problem with the neuromuscular apparatus. 
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Figure 5.11: MRS responses in JHS patients with oesophageal 
hypomotility.  
a- Normal MRS present in 8 (57%) patients, b- abnormal MRS with weak or 
fragmented after-MRS contractions in 6 (43%). 	  	  
5.5.2.2 Comparison of motility patterns in JHS and non-hypermobile 
controls with dysphagia 
In the 98 control patients with dysphagia, 47 had normal motility, 18 had 
hypomotility, 5 had absent peristalsis, 15 had achalasia, 10 had diffuse 
oesophageal spasm, 2 had hypertensive contractions and 1 had functional GOJ 
obstruction – Figure 5.12. The prevalence of normal oesophageal motility was 
similar in both groups, but the controls had a much larger range of motility 
patterns. Oesophageal hypomotility was significantly more common in the JHS 
patients (56% vs 18%, p<0.001). None of the JHS patients had achalasia and 
this was significant compared to the controls (0% vs 15%, p=0.04).  
 
Of the 23 control patients with oesophageal hypomotility, 9 (39%) had an 
abnormal MRS response, which was no different to the prevalence in the JHS 
patients (43%, p=1.0). 
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Figure 5.12: Comparison of HRM motility patterns in JHS and control 
patients with dysphagia.  
There was significantly more hypomotility, and significantly less achalasia 
in JHS patients. 	  	  
5.5.3 Reflux in JHS 
The JHS patients had a range of reflux symptom scores - Figure 5.13. In 
general scores for regurgitation (12.3 ± 1.0) were higher than those for 
heartburn (9.1 ± 1.2). 26 patients had reflux symptoms (score>9), 1 of these did 
not have MII testing because of a latex allergy. Hence 25 patients were 
included in the analysis (92% female, age range: 18-62). 
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Figure 5.13: Symptom scores for heartburn, regurgitation and overall 
reflux (GORD) in JHS patients.  
Bar represents the median score. The dotted line represents the cut-off 
score of 9 which is sensitive and specific for identifying the presence of 
reflux symptoms. 	  	  
5.5.3.1 Reflux diagnoses in JHS and control patients  
None of the 25 JHS patients had erosive reflux disease. 21 (84%) had NERD: 
15 (60%) with high acid exposure, and 6 (24%) with hypersensitive 
oesophagus. The remaining 4 (16%) patients had functional heartburn. JHS 
patients with pathological reflux were more likely to have to have increased 
number of non-acid reflux episodes (53%) compared to acid reflux episodes 
(27%). In those with increased acid exposure, this was more likely to occur in 
the recumbent position (67%) compared to the upright position (40%).  
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Of the 108 control patients with reflux symptoms, 11 (10.2%) had erosive 
disease on endoscopy, 55 (50.9%) had increased acid exposure with no 
erosions (non erosive pathological GOR), 5 (4.6%) had hypersensitive 
oesophagus, and 37 (34.3%) had functional heartburn.  
 
The prevalence of non-erosive pathological GOR was comparable in both 
groups (60% vs 51%, p=0.4). The prevalence of hypersensitive oesophagus 
was significantly increased in JHS (24% vs 5%, p=0.006). The prevalence of 
functional heartburn in JHS was low but this was not significant (12% vs 34%, 
p=0.07) - Figure 5.14. 
 
9 (60%) JHS patients had isolated nocturnal reflux compared to 19 (35%) 
control patients but this was not significant (p=0.1). 
 
HRM parameters in patients with non-erosive pathological GOR 
To determine if there were differences in anatomical factors predisposing to 
reflux in JHS compared to the control patients, the presence of hiatus hernias, 
hypotensive LOS and hypomotility was compared in patients with non-erosive 
pathological reflux. 
 
Only 3 (20%) JHS patients had a hiatus hernia compared to 25 (45%) control 
patients (p=0.08). 2 (13%) of JHS patients had a hypotensive LOS and this was 
no different to controls (29%, p=0.3). Although there was a higher prevalence of 
hypomotility in the JHS group compared to the controls  (60% vs 34%, p=0.07) 
this only showed a trend.  
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Figure 5.14: Reflux diagnoses in JHS and control patients.  
JHS patients had significantly more hypersensitive oesophagus. The 
prevalence of NERD was high (>50%) in both groups. HO: Hypersensitive 
oesophagus, FH: Functional heartburn 
 
5.5.4 Gastric emptying in JHS patients  
16 JHS patients had gastric emptying testing as requested by their physician. 
The range of dyspepsia scores in these patients is shown in Figure 5.15. 2 
patients (12.5%) had normal gastric emptying, and 14 patients (87.5%) had 
delayed gastric emptying.  
 
Figure 5.15: Dyspepsia scores in JHS patients undergoing gastric 
emptying testing. 
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In view of the association between orthostatic symptoms and postprandial 
distress syndrome demonstrated in Chapter 5, the prevalence of PoTS was 
compared in JHS patients with and without gastroparesis. PoTS was present in 
10 (71%) of the JHS patients with delayed gastric emptying and 1 (50%) of the 
JHS patients with normal gastric emptying (p=0.5). 
 
Gastric emptying in JHS patients with NERD 
The prevalence of gastroparesis was also assessed in the subgroup of JHS 
patients with reflux. Of the 15 JHS patients with non-erosive pathological reflux, 
7 had gastric emptying testing and all had delayed gastric emptying. 
 
5.5.5 Distensibility testing of the GOJ 
8 patients with reflux symptoms and NERD (7 female, age range 18-44) 
underwent endoflip testing of the GOJ - Figure 5.16. CSA - Pressure curves 
were plotted for each patient - Figure 5.17 - the slope of the curves represents 
GOJ distensibility. Control data from healthy subjects was obtained from 
another study as described in the methods section. This was plotted as a 
reference (Rohof, Hirsch et al. 2012).  
 
GOJ distensibility appeared to be lower in JHS compared to healthy controls. 
Only 5 patients tolerated the full distension protocol to 50ml, so values of CSA, 
pressure and distensibility were compared at the 40ml distension volume.  
There was no difference in the CSA of the GOJ in JHS or controls (114.4 ± 
15.71 vs 124.8 ± 26.5, p=0.5). However patients with JHS had higher 
intraballoon pressures (34.8 ± 2.4 vs 26.5 ± 1.3, p=0.01) and lower GOJ 
distensibility (3.5 ± 0.6 vs 5.0 ± 0.6, p=0.048). 
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Figure 5.16: Appearances of endoflip testing of GOJ in a patient with JHS. 
Left: distension with 30ml water. Right: distension with 50ml water. 
 
 
 
Figure 5.17: CSA Pressure curves representing GOJ distensibility for each 
patient.  
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The dotted line represents the CSA-Pressure curve for healthy subjects. 
JHS patients have lower GOJ distensibility compared to healthy subjects. 
5.6 Discussion 
The aim of this pilot study was to determine if physiological abnormalities were 
present in the stomach and oesophagus of JHS patients with symptoms of 
dysphagia and reflux. We discovered that (1) there was a high prevalence of 
oesophageal and gastric dysmotility in symptomatic patients, (2) most patients 
had true non-erosive reflux (NERD), as opposed to functional heartburn, and (3) 
there was no evidence of increased GOJ compliance in patients with JHS and 
reflux.  
 
5.6.1 Dysphagia in JHS 
Dysphagia in the JHS patients referred to the GI physiology unit was non-
obstructive and none of the patients had radiographic or endoscopic evidence 
of obstruction. 2 patients had an incompletely relaxing LOS but even they had 
no evidence of true or functional obstruction on barium swallow.  
 
56% of JHS patients with dysphagia had oesophageal hypomotility, and the 
prevalence of this motility pattern was significantly increased compared to the 
non-hypermobile controls with dysphagia in our study. It was also increased 
compared to a published study of 113 patients with dysphagia attending a GI 
physiology unit (Roman, Lin et al. 2011). In that study, 14% of the patients had 
weak peristalsis with large breaks, whereas in our JHS patients 7 of the 25 
patients (28%) had this motility pattern (section 5.5.2.1).   This suggests that the 
JHS patients with dysphagia do indeed have relatively more hypomotility 
compared to other patients with dysphagia.  
	   236	  
 
Weak peristalsis, particularly in the presence of large breaks, and frequent 
failed peristalsis, as well as DCI values of less than 450 are associated with 
incomplete bolus clearance (Bulsiewicz, Kahrilas et al. 2009; Xiao, Kahrilas et 
al. 2012). In our study, 44% of patients had weak peristalsis with large breaks or 
frequent failed peristalsis, and 36% had DCI values less than 450mmHg-cm-s. 
Thus it is likely that incomplete bolus clearance may be present in about 40% of 
JHS patients with dysphagia, and may account for symptoms.  
 
The cause of the oesophageal hypomotility in the JHS patients is unknown. The 
presence of hypomotility is known to be associated with erosive reflux disease, 
particularly Barrett’s oesophagus (Porter, Kumar et al. 2012). However, none of 
the JHS patients in our study had erosive reflux disease and therefore this is 
not a potential explanation for the dysmotility. Another potential explanation 
comes from studies of the peripheral neuromusculature in JHS patients. These 
demonstrate that myopathic features of skeletal muscle can be present in JHS 
patients with myalgia and muscle weakness (Voermans, van Alfen et al. 2009). 
It is therefore possible that the oesophageal dysmotility is secondary to a 
primary myopathy or neuropathy of the smooth muscle of the oesophagus. 
From our study, it is not possible to determine if this is indeed the case. The 
presence of a normal MRS response on HRM in the majority of patients with 
oesophageal hypomotility would suggest that most patients have an intact 
neuromuscular apparatus (Fornari, Bravi et al. 2009). Future studies in those 
patients with abnormal MRS may help shed further light on the matter. 
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11 JHS patients with dysphagia had normal motility, and no manometric cause 
of dysphagia was found, thus in these patients the dysphagia was unexplained. 
As shown in Figure 5.14 hypersensitive oesophagus was relatively more 
common in JHS patients compared to controls. The presence of oesophageal 
hypersensitivity may provide an explanation for the dysphagia in a proportion of 
patients with normal oesophageal motility. Another possibility is that the 
dysphagia is more proximal and arises secondary to problems in the proximal 
striated muscle of the oesophagus or in the transition zone. In one study these 
type of abnormalities were present in 6% of patients undergoing HRM and in 
half of these patients it was associated with unexplained dysphagia (Ghosh, 
Janiak et al. 2008). This was not investigated in our study, but pharyngeal 
dysphagia in JHS, requiring referral to ENT specialists, has been documented 
in the literature (Rombaut, Malfait et al. 2011). 
 
Thus it would appear that majority of JHS patients with dysphagia have 
associated oesophageal hypomotility, and that other factors such as 
oesophageal hypersensitivity or oropharyngeal dysphagia, may be important in 
the patients with normal HRM motility patterns, and these deserve further study.   
 
5.6.2 Reflux in JHS 
The majority of JHS patients with reflux symptoms had true reflux (NERD) and 
this is consistent with the association between JHS and NERD demonstrated in 
Chapter 4. Only 4 (16%) patients had functional heartburn, suggesting that 
most JHS patients with reflux symptoms do have physiological abnormalities 
which can account for symptoms. The majority of patients with NERD had 
increased acid exposure, and this was more likely to occur when patients were 
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recumbent (67% of patients) compared to when they were upright (40%).  
Furthermore, in those with pathological acid exposure, only 27% had a high 
number of reflux episodes, suggesting that most episodes were long lasting to 
account for the high acid exposure. In terms of possible mechanisms for the 
reflux, a small hiatus hernia and a hypotensive LOS were only present in a 
small proportion of patients (3 and 2 patients out of 15 respectively). 
Oesophageal hypomotility was present in 60% of these patients and 
gastroparesis in 7 out of the 7 patients studied, and these may have contributed 
to decreased clearance of acid from the oesophagus, and increased volume of 
potential refluxate respectively. Putting this all together it would appear that in a 
significant proportion of JHS patients, pathological reflux may be due to long-
lasting nocturnal episodes, exacerbated by incomplete acid clearance 
secondary to oesophageal hypomotility, and by the presence of gastroparesis, 
particularly in the presence of a hypotensive LOS.   
 
Compared to non-hypermobile controls, JHS patients were significantly more 
likely to have hypersensitive oesophagus (24% vs 5%, p=0.006), though this 
finding may be a consequence of the surprisingly low prevalence of 
hypersensitive oesophagus in our control patients. In a published study of 200 
patients with endoscopy negative reflux, 32% had hypersensitive oesophagus 
(Savarino, Pohl et al. 2009), which suggests that the prevalence of 
hypersensitive oesophagus seen in the JHS patients is no different to that in 
other patients with reflux symptoms.  
 
The prevalence of hiatus hernias in JHS patients was surprisingly low, being 
present in only 6 out of the 25 JHS patients with reflux symptoms. Most of these 
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hernias were very small, and often disappeared halfway through the HRM 
study. This low prevalence was contrary to our expectations, partly because the 
presence of hernias form part of the Brighton criteria for diagnosis of JHS, and 
because an association between hypermobility and hiatus hernias has 
previously been demonstrated (Al-Rawi, Al-Dubaikel et al. 2004). However in 
that study, the diagnosis of hiatus hernias was made on endoscopy and not 
manometry, and the term ‘hypermobility’ referred to a high beighton score, 
which is simply a measure of joint hyperflexibility and not necessarily 
synonymous with JHS.  
 
The last section of the results included preliminary pilot data relating to GOJ 
distensibility in the JHS patients. This was simply an observation in a very small 
sample using a newly acquired tool, and was designed to assess for any gross 
differences in visceral compliance in the JHS patients compared to healthy 
controls.  GOJ distensibility at a 40ml distension volume was significantly lower 
than that in healthy controls and more comparable to the GOJ distensibility 
observed in successfully treated achalasics (Rohof, Hirsch et al. 2012). This 
was a surprising finding and contrary to our assumed hypothesis, and suggests 
that pathological GOR in JHS is not due to increased GOJ distensibility.  
 
5.6.3 Limitations 
The main limitation of the study was the small size of the JHS group, which 
made comparisons difficult, particularly for the endoflip testing. However, the 
study was designed to be pragmatic and to simply provide initial observations 
that may help tailor future studies in a larger number of patients.  
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6.1.1 Clinical implications. 
The findings in his study have implications for the clinical management of JHS 
patients with dysphagia and reflux symptoms. In the absence of obstructive 
causes for dysphagia, the need for oesophageal dilatation in these patients can 
be excluded, leaving treatment to pharmacological agents.  In view of the 
hypomotility, prokinetics such as domperidone may be useful, particularly for 
those patients with a normal MRS response.  
 
For the patients with reflux, the absence of large hiatus hernias and the high 
prevalence of hypomotility make anti-reflux surgery a less attractive option than 
pharmacological measures, particularly in patients with poor MRS response. A 
combination of prokinetics for the dysmotility, neuromodulators for the 
hypersensitivity, and lifestyle changes, is likely to be more efficacious.  
 
6.1.2 Patho-aetiological implications 
The high prevalence of GI dysmotility in these patients has implications for the 
underlying aetiology of JHS, which is as yet unknown. The dysmotility, in the 
absence of gross differences in compliance, would suggest an underlying 
myopathy or neuropathy. As described before, such features have been 
observed in skeletal muscle and it is possible that a similar process is taking 
place in the smooth muscle.  In view of our observations in Chapter 2 that upper 
GI symptoms are mediated by autonomic and somatic factors, it is possible that 
the mechanism for the dysmotility involves abnormalities in autonomic nerves or 
in sensory afferents. The possibility of autonomic involvement is supported by 
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the fact that 10/14 (70%) patients with oesophageal dysmotility and with 
gastroparesis had POTS. This requires future study. 
6.2 Conclusion 
It is thus clear, that the majority of patients with JHS and upper GI symptoms do 
have abnormal GI physiology, particularly dysmotility in the stomach and 
oesophagus, and that this is not too dissimilar to the physiological patterns 
found in other connective tissue disorders such as scleroderma and Sjogren’s 
syndrome. Future studies will need to explore the possible mechanisms for this, 
focussing on autonomic and sensorimotor aetiologies.  In this small group of 
patients, compliance of the GOJ did not seem to be increased. However, 
compliance of visceral tissue at other locations will need to be assessed before 
the possibility of biomechanical abnormalities in these patients can be 
discounted. 	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Chapter 6 General Discussion 
General Discussion 
Research to discover the aetiology of FGID has so far not been fruitful, and this 
is thought to be due to the heterogeneous nature of the condition and that 
attempts to divide FGIDs into symptom-based ROME subcategories may not 
have resulted in aetiologically meaningful subgroups. Preliminary observations 
from previous studies suggest an overlap between JHS, a non-inflammatory 
connective tissue disorder, and FGID.  Confirmation of this overlap would 
provide an identifiable and homogenous phenotype of patients who are 
predisposed to FGID, and will thus facilitate progress in understanding the 
aetiology of FGID, at least in a subgroup of patients.  
 
My aim in this thesis was to determine if an association exists between JHS and 
FGID. Furthermore, I aimed to fully characterise the range and prevalence of GI 
symptoms in JHS in health and in disease, to determine the influence of various 
aetiological factors on these symptoms, and to determine if physiological 
abnormalities were associated with GI symptoms in these patients.  
 
I have addressed all these aims through a systematic series of epidemiology 
studies in 3 groups of JHS patients: patients with established JHS which 
represented a forme fruste of the condition (JHS-Rh); healthy students who 
were previously unaware that they had JHS (a blinded non-patient sample); and 
new patients attending GI clinics who were previously unaware that they had 
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JHS (JHS-G: blinded unselected patient sample). For each of these JHS 
groups, an appropriately matched control group without JHS was selected. 
 
6.1 JHS and GI symptoms 
6.1.1 JHS and Dyspepsia 
The most conclusive finding was an association between postprandial dyspeptic 
symptoms and JHS. In Chapter 2, I demonstrated that in tertiary care patients 
with established JHS and GI symptoms, the prevalence of postprandial distress 
symptoms (i.e. early satiety and postprandial fullness) is significantly increased 
compared to that in other patients with GI symptoms, but without JHS. In 
Chapter 3 I further demonstrated that these dyspeptic symptoms are also 
significantly increased in healthy students with JHS compared to those without 
JHS, suggesting that the association is related to JHS and not to factors 
associated with being a tertiary care patient. Furthermore, in Chapter 4 I have 
shown in a large case control study of over 600 new patients attending GI 
clinics that JHS is associated with postprandial distress syndrome (PDS). The 
validity of these findings is strengthened by the fact that they have been 
reproduced in different groups of patients as well as in non-patients. Moreover, 
as most studies have been performed in subjects unaware of their JHS status, 
these results are less likely to be influenced by response bias. Furthermore they 
are consistent with the preliminary observations in the literature in patients 
attending non-GI clinics, adding further support to the validity of these findings.  
 
6.1.2 JHS and Gastro-Oesophageal Reflux Disease 
Other GI associations that were demonstrated for JHS were not as clear-cut. 
There appears to be an association between JHS and reflux disease, 
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particularly with non-erosive reflux disease (NERD). In Chapter 2, I 
demonstrated that patients with established JHS have significantly increased 
regurgitation compared to other GI patients, and in Chapter 4 I demonstrated 
that in patients newly referred to GI clinics there was a significant and 
independent association between JHS and NERD. This association was not 
however demonstrated in healthy students so it is difficult to conclude whether 
the association between JHS and gastro-oesophageal reflux is to do with all 
JHS groups, or only to those individuals who become patients. 
 
6.1.3 JHS and IBS symptoms 
Lastly, I demonstrated in Chapter 2 that patients with established JHS also had 
significantly increased IBS-type symptoms with increased abdominal pain, 
bloating and alternating bowel habit compared to other GI patients. However no 
such association between JHS and these symptoms was demonstrated in the 
non-patient sample in Chapter 3, nor was an association between JHS and IBS 
disorders demonstrated in Chapter 4.  This suggests that either this association 
is only relevant to those JHS patients who have previously consulted a 
rheumatologist i.e. those with severe symptoms and musculoskeletal 
involvement, or that the association of JHS with these symptoms is due to 
another confounding factor. However, in Chapter 2 I demonstrated that the 
association between JHS and alternating bowel habit, abdominal pain and 
bloating was independent of all other measured factors including medication 
use, psychopathology, autonomic and somatosensory factors, suggesting that 
these factors were not confounding the association. A final explanation is that 
the association with IBS symptoms is only present in tertiary JHS patients, and 
indeed the presence of IBS-type symptoms has been reported in several 
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tertiary JHS patient groups including those attending rheumatology, urology and 
genetics clinics (Manning, Korda et al. 2003; Hakim and Grahame 2004; 
Castori, Camerota et al. 2010; Rombaut, Malfait et al. 2011). Hence it would 
seem that these IBS symptoms are only relevant in a subgroup of JHS patients, 
possibly those with a more severe presentation with musculoskeletal 
involvement, and attending tertiary care. 
 
6.2 Factors mediating the association between JHS and GI 
symptoms 
One of the aims of the research was to explore, using epidemiology techniques, 
what factors might be involved in the association between JHS and GI 
dysfunction. Previous studies have postulated that GI and extra-articular 
symptoms in JHS are due to either medication use, deconditioning, genetic 
factors or autonomic factors (De Wandele, Rombaut et al. 2013). In addition, 
somatisation and psychopathology are strongly linked to both JHS and to FGID 
(Table 1.6) and therefore also have to be considered as a possible explanation 
for the GI symptom association in JHS. By demonstrating excess GI symptoms 
in JHS students, none of whom were on opiates and all of whom were active 
and healthy, medication and deconditioning can be excluded as main reasons 
for the association between JHS and GI symptoms. Using multiple logistic 
regression analysis in the epidemiology studies in Chapters 2-4, it was evident 
that anxiety was not involved in the association between JHS and GI symptoms 
in any of the JHS groups. This suggests that despite the fact that anxiety is 
strongly linked to JHS (Bulbena, Gago et al. 2011) and that anxiety is known to 
be associated with several FGID, anxiety is not the explanation for the GI 
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manifestations in JHS. This leaves the possibility of autonomic, genetic or 
somatisation factors.  
 
It was clearly demonstrated that autonomic symptom scores, number of positive 
tender points and somatisation scores (PHQ15) were significantly increased in 
the JHS subjects in all the different groups, including the healthy students, 
confirming previous observations that these symptoms are inherently 
associated with JHS (Gazit, Nahir et al. 2003; Baeza-Velasco, Gely-Nargeot et 
al. 2011; Castori 2012), and suggesting that they were potentially responsible 
for the GI association seen. This was explored further using multiple logistic 
regression analyses which demonstrated that autonomic factors, and to a lesser 
extent somatisation factors were involved in the association between JHS and 
postprandial symptoms. The degree of involvement varied depending on the 
JHS group. In the rheumatology patients with established JHS, the presence of 
autonomic and somatic symptoms completely accounted for the association 
seen with postprandial symptoms. In the unselected GI patient group (Chapter 
4), autonomic factors completely accounted for the association between JHS 
and PDS, but somatic factors did not. In the student study in Chapter 3, the 
presence of postprandial satiety was partly accounted for by autonomic factors 
(particularly orthostatic factors) but somatic factors were not involved (Table 
3.6). 
 
6.2.1 Autonomic factors and GI symptoms in JHS 
Putting this all together, it would appear that autonomic factors are consistently 
involved in the association between JHS and postprandial symptoms, and that 
this involvement is very significant in established JHS patients with severe 
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disease, and that it is less important in healthy students who have milder 
disease and who are non-patients. Interestingly, out of all the autonomic 
domains it was the orthostatic domains which were most important in mediating 
the postprandial symptoms in all three studies (Chapter 2-4). Evidence from the 
literature on PoTS supports this finding. Orthostatic symptoms are the hallmark 
of PoTS and in these patients, postprandial symptoms are common (Mathias, 
Low et al. 2011), regardless of whether or not they have coexistent JHS. 
Furthermore, it has been demonstrated that PoTS is associated with increased 
variability of the gastric pacemaker rhythm pre and post-prandially, and that in 
patients with GI symptoms, the postprandial changes are more marked 
(Seligman, Low et al. 2012). In view of the fact that gastric pacemaker activity is 
integral to the coordinated motor activity of the stomach, it is possible that the 
presence of this altered pacemaker variability leads to gastric dysmotility, 
particularly postprandially. Indeed, as demonstrated in Chapter 5, gastroparesis 
is present in a large proportion of JHS patients with postprandial symptoms and 
that the majority of patients with gastroparesis had PoTS.  
 
Therefore it is possible that as JHS severity increases and the presence of 
PoTS increases, this will be associated with altered pacemaker activity, 
gastroparesis and therefore postprandial symptoms, and eventually a diagnosis 
of postprandial distress syndrome. This is simply a hypothesis and will need to 
be tested in much larger studies of JHS patients and suitable control groups. 
 
6.2.2 Somatic factors and GI symptoms in JHS 
The partial involvement of somatic sensitivity factors (somatisation) in the 
association between JHS and GI symptoms was interesting, as it was much 
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less important than initially expected to be. Although the definition of 
somatisation is vague, there is consensus that it refers to the presence of 
multiple somatic symptoms, and that this can be measured by various 
questionnaires such as the PHQ15 questionnaire which was used in our study.  
It is clear from our study and previous studies (Baeza-Velasco, Gely-Nargeot et 
al. 2011) that the presence of JHS is associated with higher levels of 
‘somatisation’ or higher somatic symptom scores than in non-JHS patients, and 
that it is associated with several functional somatic syndromes, such as 
fibromyalgia, chronic fatigue syndrome and FGID. What is less clear, and 
perhaps more interesting, is what somatisation really refers to. In fact, the 
definition of somatisation is currently undergoing dramatic change. 
Somatisation was initially considered a psychiatric condition, characterised by 
the presence of multiple clinically significant complaints about gastrointestinal, 
sexual, pseudoneurological and pain symptoms in the absence of clear organic 
pathology, and it was considered a manifestation of emotional distress. 
According to this psychological definition of ‘somatisation’, it was thought that 
the presence of multiple somatic symptoms, and functional somatic disorders 
e.g. FGID, were ‘psychosomatic’. That is, they were simply psychological with 
no physiological basis.  
 
Applying this psychological explanation of somatisation to the association 
between JHS and FGID would suggest that the presence of FGID in JHS would 
be strongly associated with psychopathology and not with demonstrable 
physiological abnormalities on testing. This is clearly not the case. Firstly, it is 
evident that the association between JHS and GI symptoms are present even in 
healthy students, who do not have anxiety and depression. Secondly, in patient 
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studies (Chapter 2 and 4) the association between JHS and GI symptoms and 
disorders was independent of psychopathology. Thirdly, physiological 
abnormalities were in fact demonstrated in the majority of symptomatic JHS 
patients in our physiology study (Chapter 5). Hence, the psychosomatic 
explanation for the higher somatic symptom scores and for increased 
prevalence of functional somatic syndromes does not appear to hold true, at 
least for FGID.  
 
More recent explanations for ‘somatisation’ suggest that these disorders are not 
all ‘in the mind’, but rather that some yet undiscovered common aetiology 
underlies them all (White 2012). Various factors had been put forward, and 
these include pain hypersensitivity and changes in autonomic processing, both 
of which have been documented in association with symptoms in patients with 
functional somatic syndromes. As an example, patients with FM have abnormal 
autonomic responses to exercise (da Cunha Ribeiro, Roschel et al. 2011) and 
that in both patients with IBS and those with FM, these abnormal autonomic 
responses are associated with somatic hyperalgesia (Chalaye, Goffaux et al. 
2012). Thus an alternative explanation for the presence of multiple somatic 
symptoms in JHS may be that these patients have abnormal or altered pain 
processing and that this itself may be secondary to autonomic dysfunction. This 
proposed explanation for the high prevalence of functional somatic syndromes 
in JHS has been put forward by other authors (Castori, Celletti et al. 2011), but 
has not yet been proven. Investigating this further, and exploring the link 
between pain processing, dysautonomia and functional somatic syndromes in 
JHS may further our understanding of the mechanisms underlying FGID in the 
subgroup of patients who suffer with multiple unexplained syndromes. 
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6.2.3 Biomechanics and altered sensori-motor function 
In the case of functional dyspepsia, somatic and autonomic factors seem to be 
important, and may be working via a shared pathway. In contrast, these factors 
do not seem to be responsible for the association seen with NERD and with 
IBS-type symptoms. In the case of NERD, one possibility includes altered 
compliance of the gastro-oesophageal junction, which has previously been 
shown to be associated with reflux (Kwiatek, Pandolfino et al. 2010). However 
in our limited study of 8 patients, we did not find this to be the case. This study 
will need to be repeated in a larger number of patients and at other locations in 
the GI tract before the biomechanical theory can be discounted. For the IBS-
type symptoms, one possible mechanism is altered sensori-motor function. This 
was clearly associated with upper GI symptoms in the JHS patients in Chapter 
5, but has not been studied in relation to the lower GI tract.  
 
6.3 Schematic for mechanism of GI symptoms in JHS 
It would appear therefore that the aetiology of GI symptoms in JHS is 
multifactorial, and involves at least the following 3 underlying processes: 
autonomic dysfunction, altered pain sensitivity, and altered biomechanics, either 
working alone or in combination with each other. It would also appear that the 
relative contribution of each of these factors varies depending on the type of 
symptoms, severity of disease and patient type. All these factors are assumed 
to result in altered sensori-motor function and therefore a functional, as 
opposed to organic, GI disorder. It can be postulated that altered sensori-motor 
function results in the symptoms of heartburn and regurgitation in NERD, 
nausea and postprandial satiety in PDS and bloating, altered bowel habit and 
abdominal pain in IBS. A hypothetical mechanism by which these factors lead 
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to these FGID subtypes is illustrated in Figure 6.1. The individual processes are 
described below. 
 
Figure 6.1: Schematic for mechanism of GI symptoms and aetiology of 
FGID in JHS 
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6.4 Processes underlying FGID in JHS 
6.4.1 Autonomic dysfunction and dysmotility 
Autonomic dysfunction would appear to be integral to the whole schema, as it 
was most important in all the regression analyses presented in this thesis, and 
appears to be strongly associated with JHS, both in health and disease. The 
autonomic dysfunction in JHS is likely to be of two types – pure orthostatic 
dysfunction (PoTS), and generalized autonomic dysfunction. The latter would 
result in GI dysmotility and would lead to various symptoms depending on 
which part of the GI tract was involved. Oesophageal dysmotility would result in 
impaired clearance of acid reflux and predispose JHS individuals to gastro-
oesophageal reflux disorders, such as NERD, particularly at night, when 
swallowing is reduced. Gastroparesis, is implicated in both NERD and PDS, 
and would result in postprandial symptoms. Small bowel dysmotility 
predisposes to small bowel bacterial overgrowth, which leads to symptoms of 
bloating, diarrhoea and abdominal pain, all features of IBS.  
 
In Chapter 5 I demonstrated that oesophageal hypomotility and gastroparesis 
were common in symptomatic JHS patients, particularly in those with autonomic 
dysfunction. Although my work did not investigate small bowel motility, there is 
literature to suggest that small bowel dysmotility is indeed present in patients 
with JHS and abdominal pain and bloating (Zarate, Farmer et al. 2009). Future 
work can focus on reproducing and refining these motility findings in larger 
numbers of patients, and correlating this with autonomic function.  
 
PoTS is associated with increased variability of the gastric pacemaker rhythm 
(Seligman, Low et al. 2012), and this in turn may lead to gastroparesis which 
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may consequently explain the postprandial and regurgitation symptoms in JHS. 
Whereas dyspepsia is associated with delayed gastric emptying in the antrum, 
regurgitation and NERD is thought to be associated with delayed gastric 
emptying in the fundus (Karamanolis, Caenepeel et al. 2007). Thus the location 
of the gastric dysmotility may explain the various upper GI symptoms. To 
confirm this and to further our understanding of the consequence of the gastric 
myoelectric changes in PoTS, motility testing in both the proximal and distal 
stomach, and with both solids and liquids independently, would need to be 
assessed.   
 
6.4.2 Altered sensory processing and visceral hypersensitivity 
It is clear that both patients and healthy individuals with JHS have a higher 
prevalence of somatic symptoms and chronic pain than their non-JHS 
counterparts (Chapter 2 and 3); (Baeza-Velasco, Gely-Nargeot et al. 2011; 
Castori, Morlino et al. 2012). As described earlier, this is suggestive of an 
underlying hypersensitivity or pain-sensing problem. If this sensory abnormality 
is generalized, then it would be expected to cause both somatic and visceral 
hypersensitivity. The latter could explain reflux symptoms (oesophageal 
hypersensitivity), dyspeptic symptoms (gastric hypersensitivity) and abdominal 
pain and bloating (visceral hypersensitivity of the bowel). 
 
Hypersensitivity in JHS is likely to arise due to sensitization at both a peripheral 
and central level. At a peripheral level, alterations in the biomechanical 
properties of tissue can potentially cause undue stretch and strain, leading to 
sensitization of the nerves peripherally. Central sensitization can arise 
secondary to anxiety and hyperarousal states, which themselves can be a 
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consequence of dysautonomia, which is known to be present in JHS. It is also 
possible that in JHS, alterations in connective tissue surrounding nerve 
plexuses, lead to altered neural processing, potentially leading to altered pain 
sensing or increased pain. These underlying processes are not specific to FGID 
but can also be implicated in the other functional somatic syndromes 
characterized by hypersensitivity, such as chronic pelvic pain and fibromyalgia. 
This common underlying process occurring in various somatic and visceral 
tissues may represent the common mechanism that links the many functional 
somatic syndromes, and may explain why individuals can have multiple pain 
syndromes. 
 
Clearly these are simply hypotheses at present, and will need to be tested in 
future studies, focusing on sensitivity testing of different parts of the GI tract, 
and correlating this with sensitivity testing of somatic sites e.g. skin and muscle, 
and with autonomic function.  
 
6.4.3 Altered biomechanics 
It is clear from the regression analysis in Chapter 3 that some GI symptoms 
(particularly abdominal pain, bloating and alternating bowel habit) are not 
significantly affected by autonomic or somatic factors. This suggests that some 
other mechanism may be more important for these symptoms. One possibility 
relates to altered biomechanics. It has been consistently demonstrated that 
patients with JHS have altered biomechanics of their skin and joints, and it is 
not inconceivable that a similar process could occur in the viscera.  
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It is clear from patients with scleroderma, that alterations in the connective 
tissue structure of the GI tract leads to alterations in the biomechanical 
properties of the gut (Gao, Liao et al. 2009), and that this in turn has a direct 
effect on motility and tone of the gut (Gregersen, Villadsen et al. 2011; Frokjaer, 
Brock et al. 2012). Furthermore, it is known that in patients with functional 
dyspepsia, abnormal gastric accommodation is associated with hypersensitivity. 
Thus there is evidence that biomechanical abnormalities in the GI tract are 
associated with alterations in both sensation and motility of the gut. Therefore it 
is possible that if the underlying connective tissue disorder in JHS does indeed 
affect the biomechanics of the GI tract, then this would provide another 
explanation for some of the functional GI symptoms in JHS.   
 
Although no such biomechanical abnormalities were detected on preliminary 
testing of a very small number of subjects in Chapter 5, this would need to be 
repeated in larger numbers of patients in different parts of the GI tract and in 
relation to both upper and lower GI symptoms, before it can be completely 
discounted.  
 
6.5 Investigating the aetiology of FGID in JHS 
Now that an association between JHS and FGID has been demonstrated, the 
focus can shift to elucidating the exact mechanisms by which this occurs at a 
physiological, biomechanical, molecular and genetic level, and to test the 
hypothetical mechanisms illustrated in Figure 6.1. This would need to be done 
systematically, using a translational approach with both human and animal 
studies.   
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Firstly, one would need to confirm using physiological studies that GI 
dysmotility, visceral hypersensitivity and visceral biomechanical abnormalities 
do indeed exist in individuals with JHS. In addition to the standardised historical 
techniques that have been developed to test for all these, recent advances in 
radiology and physiological testing means that less invasive techniques such as 
functional magnetic resonance imaging for motility, and the use of the smartpill 
capsule for motility testing, can also be used, thus increasing the willingness of 
the patients to comply with these tests. It would also be useful to characterise 
the GI symptoms, FGID subtypes and non-GI characteristics that are 
associated with the above abnormalities, as this will enable categorisation of a 
very heterogenous group of JHS individuals into more homogenous 
phenotypes, which will be useful when doing genetic or molecular studies later 
on.  
 
Secondly, one would need to demonstrate that the above-mentioned 
physiological abnormalities are responsible for the symptoms. That is, that they 
are present in symptomatic JHS individuals and not asymptomatic ones, and 
that by treating the underlying process, the symptoms improve. To do this 
would require interventional studies, involving symptomatic JHS patients and 
asymptomatic JHS controls, all of whom undergo motility, sensitivity and 
distensibility testing, and then are randomised to treatment or no treatment for 
the underlying abnormality, all the while making a detailed assessment of 
symptom severity.  
 
Thirdly, it would be useful to assess the temporal order by which symptoms and 
physiological abnormalities develop and also to identify risk factors which 
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predict the development of FGID in JHS individuals. This would require 
longitudinal cohort studies.  It would be important that the cohort be followed up 
from a very young age, as it is evident from the literature that some of the 
complications associated with JHS occur very early on in life. 
 
The final step would be the investigation of the aetiology of the above 
processes. This is perhaps the most difficult step, particularly in view of the fact 
that the aetiology of JHS itself has not yet been determined. This may, in part, 
be due to the fact that JHS is heterogeneous in aetiology, that connective tissue 
biology is extremely complicated and that abnormalities in a whole variety of 
connective tissue enzymes and proteins can lead to the same endpoint i.e. 
abnormal connective tissue.  This is where stratifying JHS individuals into very 
homogenous groups may enable more meaningful conclusions to be drawn. 
This is particularly important for genetic studies, particularly as genome wide 
association studies have so far failed to find candidate genes which are 
responsible for JHS. Newer techniques such as exome-sequencing can be 
used for ‘JHS families’, however once again, it is important that the affected 
family members have a similar phenotype, which is generally not the case.  
 
It is important to bear in mind that even if a candidate gene were to be found, 
this is not necessarily meaningful. Epigenetics suggests that the environment 
has a huge effect on the expression of genes, and that this is a fairly dynamic 
process. Thus it may be more useful to look at abnormalities in expressed 
proteins, as opposed to abnormalities in the genes. This is where translational 
studies will be very informative.  
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Animal models of JHS exist, and these can be used to develop our 
understanding of the macroscopic and microscopic connective tissue and 
biomechanical abnormalities present in the GI tract in JHS. To ensure that the 
animal models are sufficiently comparable to humans, motility and autonomic 
function should be tested first in these animal models to ensure they are similar 
to findings in humans. Provided that this is the case, in vivo, ex vivo and in vitro 
biomechanical studies of different parts of the GI tract can be assessed. Using 
immunohistochemistry, a quantitative and qualitative assessment of the 
structure of different connective tissue components can be assessed, and their 
relationship to various neuronal components in the bowel can be determined. 
3D electron microscopy can yield further information at an ultrastructural level. 
Single nerve recordings can be used to determine how the nerves function in 
response to biomechanical stimuli.  These findings can then be compared to 
that in GI tissue obtained from JHS patients undergoing bowel resections or 
endoscopic biopsies to enable a fully translational model to be built. 
 
Understanding all this will not only result in a better understanding of the 
pathological processes underlying GI dysfunction in JHS patients, but more 
importantly, will further our understanding of the role of connective tissue in the 
GI tract in health and in disease, something which for many years has remained 
a relative enigma. This will have implications on our understanding and 
treatment of the GI aspects of a variety of connective tissue disorders, both 
inflammatory and non-inflammatory, and hopefully have the potential to lead to 
the development of new pharmacological agents in the future.  
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6.6 Clinical implications of the association between JHS and 
FGID 
Aside from the exciting research implications described above, the novel 
findings in my PhD have several clinical implications.  
 
It is evident from the studies in Chapters 3 and 4 that quality of life in JHS 
individuals who have not yet seen a rheumatologist and have not had a formal 
diagnosis of JHS was relatively preserved, even in the presence of GI 
symptoms. In comparison, patients with an established diagnosis of JHS had 
very poor general health, and physical and social functioning, compared not 
only to GI patients without JHS but also to other JHS patients seen at tertiary 
care centres (Rombaut, Malfait et al. 2010). This suggests that earlier 
recognition and management of JHS and its associated complications may 
enable intervention at an earlier stage before the patient becomes moribund 
from a physical, social and emotional point of view.  
 
The presence of JHS in GI clinics provides gastroenterologists with an ideal 
opportunity to diagnose this condition early and initiate multidisciplinary 
management at this early stage. In view of the fact that the prevalence of JHS is 
very high in PDS and in NERD, the diagnosis of JHS should be considered in 
patients with these GI disorders, particularly if they have rheumatological 
symptoms with or without other functional somatic syndromes such as 
fibromyalgia and chronic fatigue syndrome. If autonomic factors are indeed 
involved in the aetiology of PDS in JHS patients, then treating the autonomic 
problem may also help treat the PDS. Although anecdotal evidence suggests 
that this may be the case, it has not been formally studied. In any case, it is 
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worth enquiring about the presence of autonomic symptoms in JHS patients 
with upper GI symptoms, and referring patients to an autonomic specialist if 
these symptoms are present.  
 
The discovery of this novel link between JHS and FGID is extremely exciting. It 
is hoped that this will lead to a paradigm shift in our approach to FGID and 
other medically unexplained disorders. This is absolutely critical if we are to 
tackle the false preconceptions surrounding the medically unexplained 
disorders, remove the stigma associated with them and improve lives for the 
millions of patients who suffer unnecessarily with these.  
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